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Chapter 1 
 
 
 
 
 
General introduction and outline of this thesis 
 
 
 
 
 
 
 
 
‘The attack on disease must not be meddlesome; the desire to do something must be guided 
by sure argument that good will come of it’ 
Gibson AG. The Physician’s Art. Oxford: The Clarendon Press, 1933 
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General Introduction 
 
 
1.1 Cervical carcinoma 
 
Cervical carcinoma is an important health problem throughout the world. Each year an 
estimated 493,000 new cases are diagnosed of which more than 80 % occur in the 
developing countries. Consequently, cervical carcinoma is the second most common 
cancer among women globally 1,2 . Moreover, in many regions in developing countries it is 
the leading cancer, accounting for 15 % of the female cancers with a cumulative risk of 1.5 
%. Eastern and South Africa, Melanesia, Latin America and the Caribbean show the highest 
incidence rates with incidence rates up to 43 per 100,000 (figure 1) 3. The incidence in 
developed countries is much lower with age-standardized rates less than 14.5 per 100,000 
women. However, this low incidence has been accomplished only after the introduction of 
screening programs in the 1960s and 1970s 4-11, resulting in substantial declines in cervical 
cancer incidence. Before this time, the incidence in Western countries was similar to 
developing countries today 2.  
 
Figure 1: Incidence of cervical cancer worldwide, Globocan IARC 2002 3
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Major geographical variations in incidence are observed not only in developing areas of the 
world and between developed and developing countries, but also within Europe. In the 
1990s, cervical cancer incidence varied by over factor 3, with the highest incidence rates in 
Poland and the former DDR (over 20 per 100,000) and the lowest rates in Italy, Switzerland, 
Spain and The Netherlands (less than 7 per 100,000) 12,13.  
 
The mortality rate of cervical cancer is substantially lower as compared to the incidence. 
Worldwide, the mortality to incidence rate ratio varies between    0.47 – 0.55. Though survival 
rates differ between regions, even in developing countries the survival is rather good 2. 
Nevertheless, an estimated 274,000 women die every year of cervical cancer, globally.  
 
In The Netherlands, the incidence of and mortality from cervical cancer is among the lowest 
in Europe 11,13. Cervical screening programs were gradually introduced in the early 1970s. 
However, it was not until 1988 that nationwide screening was performed.  As shown in figure 
2, the incidence and mortality started to decrease in the late 1960s and early 1970s 14. This 
decrease continued in the following years and is attributed for a large part to treatment of 
screen-detected  premalignant cervical lesions. 
 
 
The majority of cervical cancers are squamous cell carcinomas. However, the proportion of 
adenocarcinomas is generally higher in low incidence areas. In some western countries 
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adenocarcinoma even contribute up to 25% of cervical cancers. This is a consequence of 
cervical screening which is successful in the reduction of squamous cell carcinomas but has 
only marginal effect on adenocarcinomas. This has been explained by the localization of 
most cervical adenocarcinomas high in the endocervical canal, which is not easily sampled. 
In several countries an increased frequency of endocervical adenocarcinomas is found, 
especially in women of 35 years and younger 15-17.  
 
 
1.2 Etiology of cervical cancer 
 
Since the late 1970s, epidemiological studies recognized cervical cancer as being suggestive 
of a sexually transmitted process. A causal role was imputed to several infectious organisms, 
among which syphilis, gonorrhea and type 2 herpes simplex virus (HSV-2) 18. However, during 
the 1990s strong evidence was found on the role of HPV in the carcinogenesis of cervical 
cancer, as already pointed out by Zur Hausen in the late 1970s 19. HPV is a double-stranded 8 
kb large DNA virus. Over 130 different genotypes of HPV have been identified of which 18 are 
associated with cervical carcinogenesis. These so called high-risk HPV (hrHPV) types include 
HPV 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and 82. Infections with high-risk 
HPV is a necessary cause in the development of (pre-)cancerous cervical lesions. Cervical 
cancer is considered as a rare consequence of an infection with hrHPV 18. HrHPV DNA can be 
found in virtually all cervical carcinomas, were HPV types 16, 18, 31 and 45 are the most 
common types 1,18,20-22. Low-risk HPV (lrHVP) types such as HPV 6 and HPV 11 are associated 
with benign genital warts (condylomata accuminata). 
 
HPV infection is a very common sexually transmitted disease with a life time risk estimated to 
be up to 80% 18,23,24. Estimates of the prevalence of HPV infections range from 2 % to 44% 
depending on the age range of the population studied and the sensitivity of the DNA assay 
used 25. The cross-sectional prevalence of HPV is highest among young women and 
decreases spontaneously to a background level of 2 % to 8 % in most populations in women 
aged 35 years and above 1. Risk factors for HPV infection are the lifetime number of sexual 
partners, promiscuity (also of the male partners), age at first intercourse, male circumcision 
status, smoking and oral contraceptive use 1,25.  
 
Most HPV infections are transient and 80 % has been cleared after 12 to 18 months. However, 
some infections can become latent or persistent and these women are at increased risk for 
HPV associated disease. Persistence of HPV infection is among others associated with host 
immune factors 25,26. 
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1.3 Natural history of cervical cancer 
 
Until recently it was thought that de natural history of a HPV-infection towards cervical 
carcinoma occurred via a continuum of long-lasting, consecutive stages of premalignant 
cervical intraepithelial lesions: CIN 1, CIN 2 and CIN 3. Currently an alternative concept is 
increasingly supported, in which clinically relevant high-grade lesions as CIN 2 and CIN 3 are 
induced rapidly within 2 to 3 years after infection with hrHPV. This first stage is then followed by 
a second stage of 10 to 12 years during which invasive cervical cancer develops 21. Low-
grade (CIN 1) lesions are generally more associated with transient, productive viral infections, 
whereas high-grade lesions (CIN 2 and CIN 3) occur when replicating immature, basal stem 
cells are infected with hrHPV subtypes which 
leads to continued replication of immature 
cells and accumulation of genetic 
abnormalities and instability 25. Most low-grade 
lesions should therefore not be considered as a 
true precursor lesion of cervical cancer, but 
rather as a cytopathological effect of 
productive viral infection which is reflected in 
a high regression rate of these lesions 26-28. 
High-grade lesions on the other hand will, 
when left untreated, ultimately progress to 
cancer in one-third to half of the cases 25,29. 
The area of the squamocolumnar junction 
(SCJ), which is the border between 
ectocervical squamous and endocervical 
columnar epithelium, is especially susceptible 
for HVP-induced infection and transformation 
(Figure 3). Consequently most cervical lesions 
originate in this so called transformation zone. This is the area where the original columnar 
endocervical epithelium has been replaced by squamous epithelium via proliferation of 
reserve cells, a process termed squamous metaplasia. Primary HPV infections targeting 
proliferating basal cells of the squamous epithelium and multi-potent stem cells of the SCJ 
can result in viral persistence and CIN development whereas primary infection of 
differentiated, more superficial cells give rise to transient, productive viral infections, where 
the viral DNA will be lost with the shedding of infected cells and virions during the terminal 
differentiation process 24,,30-32. In infected proliferating basal cells, HPV gene products such as 
E6 and E7 are responsible for deregulation of normal cell cycle mechanisms, ultimately 
leading to genomic instability and hyperproliferation. In benign and low-grade cervical 
Original SCJ
a
Figure 3: Squamocolumnar junction and transformation zone
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lesions, the HPV genome is generally present in an episomal state. Progression to more severe 
CIN is associated with integration of the HPV genome in the genome of the host cell 33. 
However it is still unclear whether integration represents the cause or just the consequence of 
genomic instability, leading to malignant transformation of CIN 21,24,30-34.  
 
 
1.4 Terminology and classification of cervical lesions 
 
The concept of precursor lesion of cervical carcinoma dates back to the nineteenth century, 
where Williams (1888) found areas of non-invasive epithelial changes adjacent to invasive 
cervical carcinoma 35. Carcinoma in situ (CIS) was introduced as an entity by Broders in 1932 
36. CIS was defined as undifferentiated carcinomatous cells, involving the full thickness of the 
cervical epithelium, however without disruption of the basal membrane.  
 
One decade later, Papanicolaou and Traut 37 found that exfoliated cells in vaginal smears 
could be used for the diagnosis of CIS and cervical carcinoma in 1941 and introduced the 
cytological PAP classification system. The term dysplasia was introduced by Reagan in the 
1950s as an intermediate between normal epithelium and CIS 38. Dysplasia was categorized in 
three groups - mild, moderate and severe - which form a continuum with CIS and cervical 
carcinoma. Subsequently, Richart introduced the concept of cervical intraepithelial 
carcinoma (CIN) in the late 1960s 39.  CIN was subdivided into grades 1,2 and 3, where CIN 1 
corresponds to mild dysplasia, CIN 2 to moderate dysplasia and CIN 3 to severe dysplasia 
and CIS.  
 
Simultaneously, the National Cancer Institute organized a workshop in Bethesda, USA, on 
reporting of cervical cytology results. The cytological reporting system resulting from this 
workshop became known as the 1988 Bethesda system (TBS) 40. The system was revised in 1991 
and 2001 41,42. The introduction of the term squamous intraepithelial lesion (SIL) was the most 
important feature of TBS. It uses a two-tiered classification scheme consisting of LSIL (low-
grade squamous intraepithelial lesion) and HSIL (high-grade squamous intraepithelial lesion). 
Condylomatous changes are categorized with low-grade CIN into LSIL. HSIL includes CIN 2 
and CIN 3. Furthermore, the terms atypical squamous cells of undetermined significance 
(ASCUS) and atypical glandular cells of undetermined significance (AGUS) were introduced. 
These categories were replaced in TBS 2001 by ASC-US (atypical squamous cells of 
undetermined significance), ASC-H (atypical squamous cells cannot exclude HSIL) and AGC 
(atypical glandular cells). 
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In the Netherlands the KOPACB classification system is in use nationally since 1996 44,45. This 
cytological system classifies the composition of the smear (K), inflammation (O), squamous 
abnormalities (P), other and endometrial abnormalities (A) and cylindrical abnormalities (C). 
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The adequacy is scored in the three tiered category B. KOPACB is more detailled than the 
PAP classification system but can be easily translated into PAP or Bethesda classification.  
 
The British Society for Clinical Cytology (BSCC) adopted an alternative terminology in 1986. 
This BSCC terminology was revised in 2002. An overview of the various cytological and 
histological terminology is provided in table 1. Invasive cervical tumours are divided in three 
general categories: squamous, glandular and ‘other’ epithelial tumours.  
 
 
1.5 Methods for screening and diagnosis of CIN and cervical cancer 
 
There are several techniques for diagnosing CIN and cervical cancer. The method of choice 
is depending on the availability of resources and qualified and trained personnel but also on 
the test accuracy and expected follow-up compliance. 
 
1.5.1 Visual inspection (VI, VIA, VILI, VIAM) 
 
Visual inspection (VI) of the uterine cervix is used most often in low-resource settings. This 
technique of looking at the uterine cervix with the naked eye can be performed unaided by 
simple clinical examination of the cervix with a speculum and light source.  The sensitivity of VI 
is too low for use as a primary screening test 49. During the last decade a combination of 
visual inspection after application of diluted (3 % – 5 %) acetic acid to the cervix with a 
cotton swab is frequently used (VIA or Visual Inspection with Acetic acid). Test positivity is 
based on the appearance of acetowhite areas in or near the transformation zone. Sensitivity 
of VIA has been reported similar to  cervical cytology, but with a lower specificity 50. Visual 
inspection using Lugol’s iodine (VILI) is a technique originally developed by Schiller in 1933. It 
was recognized that non-staining areas after application of Lugol’s iodine were easier to 
interpret than acetowhite areas. In the only published report on performance of VILI 49 the 
sensitivity of VILI was higher than VIA with an equal specificity.  The use of a low-level 
magnification (2-4x) for inspection of the cervix after application of acetic acid is called 
VIAM (visual inspection using acetic acid with low-level magnification). No differences in test 
performance has been found between VIAM and VIA 51. 
 
1.5.2 Cytology 
 
The concept of cytologic examination of exfoliated cervical cells was introduced by George 
Papanicoloau in the 1940s 52. The Pap test is the most widely used cancer screening test in 
developed countries 53. The test involves microscopic examination of fixed and stained 
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cervical cells which are scraped from the surface of the cervical transformation zone by 
special sampling devices. The cells are subsequently examined for abnormal morphologic 
cell changes.  
 
A critical  step in the preparation of a cytological specimen is proper sample collection, as 
one half to two thirds of false negative cervical cytology has been attributed to sampling 
errors 54. Therefore, dedicated sampling devices such as the wooden or plastic spatula, with 
or without an extended tip and the Rovers® Cervex-Brush® have been designed. The 
Cytobrush is a sampling device, focusing on direct sampling of the endocervical canal. 
Recently, collection devices have been developed that sample the ecto- and endocervix 
simultaneously, such as the Rovers® Cervex-Brush® Combi. In order to prevent sampling 
errors, it is of utmost importance to obtain a sample of the complete transformation zone, 
since this is the region where the majority of  CIN lesions occur.  
 
Screening of a cervical  smear is a complex procedure which is prone to screening and 
interpretation errors. These errors are highly correlated with the quality of the smear. The 
quality of a smear depends on adequate sampling but also on the presence of interpretation 
obscuring elements. Sampling adequacy is described in terms of cellularity as well as the 
presence of transformation zone indicators (endocervical or metaplastic cells) whereas 
obscuring elements concern excess of blood or inflammatory cells or bad fixation of the cells. 
Judgement of the quality of the slide is an important part of the diagnostic report. 
 
1.5.2.1 Conventional cytology 
 
In conventional cytology, the cervical cells are smeared onto a glass slide immediately after 
sampling. Cell fixation must be performed within a few seconds to prevent air-drying artifacts 
which hampers the cytological interpretation seriously and can lead to false diagnoses.  
Studies have shown that more than half of the sampled material remains on the sampling 
device, which is discarded and lost for analysis 55.  
Nevertheless, though never proven in randomized clinical trials, there is convincing evidence 
from observational studies that screening with conventional cytology is effective in reducing 
the incidence of squamous cervical cancer 1,56. However, the accuracy of conventional 
cervical cytology has been questioned the last decades. Accuracy of a test is defined by 
two aspects. One is the test specificity and the other the test sensitivity for detecting a given 
condition. Several meta-analyses showed that the cross-sectional test-validity (test-validity of 
a single test at one point in time to detect a defined end-point) of conventional cytology for 
CIN is rather limited 57-60. The test sensitivity and specificity of conventional cytology is not 
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known precisely but estimates range from 50 % – 85 % and 60 %  – 98 % respectively, 
depending on characteristics of the study group and study design 1,61.  
 
 
1.5.2.2 Liquid-based cytology 
 
Liquid-based cytology (LBC) is a new preparation technique that was introduced in the mid-
1990s to improve the performance of the Pap test.  The main difference with conventional 
cytology is the technique for transferring the exfoliated cervical cells from the sampling 
device to the microscope slide. The cells are not spread onto a glass slide by the sample 
taker as with conventional cytology but immersed into a vial by thoroughly rinsing the 
sampling device within a special liquid preservation fluid. The vial is transported to a specially 
equipped laboratory, where the microscopic slide is prepared. The result is that almost all 
sampled cells are transferred into the liquid. Next, a representative sample is transferred to a 
well defined circular area containing a limited number of cells which are evenly spread in a 
thin-layer. Though the various LBC systems differ in preparation technique, they all result in a 
thin, monolayer-like sample of well-preserved cells without obscuring blood, mucus and 
inflammatory cells. Advantages of the LBC technique are the availability of residual material 
for preparation of multiple smears or additional  molecular testing, being a more proper 
target for automated screening and a possible increased detection of cervical lesions. 
Worldwide, various LBC systems are used. Most widely used systems are the ThinPrep system 
(Hologic Corporation, Marlborough, MA) and the AutoCytePrep system (currently known as 
SurePath; TriPath Imaging, Burlington, NC) 43. 
 
The comparative performance of LBC and conventional cytology has been evaluated in 
numerous studies. Although there is reasonable agreement that LBC improves specimen 
adequacy and reduces screening time as compared to conventional cytology, controversy 
remains on the diagnostic performance of LBC, largely due to a lack of adequately designed 
studies 1,62-64. 
 
1.5.3 Computer-assisted screening 
 
Computer-assisted screening specifically aims on increasing the sensitivity of the Pap test by 
reducing false-negative results due to screening errors and better productivity by decreased 
screening time. This is thought to result in a reduction of the costs of screening programs and 
ultimately in a decreased incidence and mortality of cervical cancer. Automated screening 
devices help cytotechnologists to focus on abnormal cells on the slide, thus facilitating a 
correct diagnosis. On the other hand it should increase productivity by excluding normal 
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parts of the slides from manual screening by selecting only the most abnormal cells for 
interpretation by the cytotechnologist.  
 
Computer-assisted screening is thought to perform at least as well as conventional screening 
and may be valuable in a sub-optimal screening environment by improving the sensitivity. On 
the other hand it may have no advantage in a high-quality setting other than a higher 
productivity 1,53,61. First studies evaluating the ThinPrep Imager show an increased detection of 
computer-assisted screening as compared with conventional cytology 65. 
 
1.5.4 Colposcopy 
 
Colposcopy is a procedure, first described by Hinselmann in 1925, that allows observation of 
the uterine cervix under illumination and magnification (6x – 40x) after the application of 
normal saline for removing excess cervical mucous, 3% – 5% acetic acid and Lugol’s iodine 
respectively.  The cervical epithelium is examined for acetowhiteness, abnormal blood vessels 
and iodine uptake, identifying (pre-)malignant disease of the cervix.  
 
Meta-analytical examination of 9 studies showed that the estimated sensitivity and specificity 
of colposcopy for detection of CIN 2+ was 96 % and 48 % respectively 62,66. Colposcopy is not 
recommended for screening, because of its low specificity. However, colposcopy is an 
essential triage method for the management of women with abnormal cytology 61. 
 
1.5.5 HPV  testing 
 
Recognition of the causal role of HPV infection in the development of cervical cancer has 
led to the development of several HPV testing systems. Most are based on hrHPV DNA testing. 
Hybrid Capture 2 (HC2; Digene Corp., Gaithersburg, Maryland, USA) is a commercially 
available test for the detection of 13  hrHVP types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 
59, 68) that is approved by the FDA for cervical cancer screening in combination with 
cytology for women over 30 years of age.  Most other HPV tests are generally PCR tests such 
as the GP5+/6+ assay, PGMY09/11, SPF10 and Amplicor Human Papillomavirus Test (Roche 
Molecular Diagnostics). HPV-genotyping can be performed after PCR amplification with 
SPF10 or PGMY09-11 using for instance LiPA HPV typing systems. Furthermore there are the 
DNA micro-array detection system (Biomedlab Company, Seoul, South-Korea) and a viral 
mRNA detection systems such as NASBA and a commercially available test kit (PreTect HPV-
Proover, NorChip AS, Kokkastua, Norway) 61. The applicability of the different tests for use in 
clinical practice rather varies. This is because analytical sensitivity (minimum amount of DNA 
detectable) should be distinguished from clinical sensitivity (ability to detect clinical relevant 
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lesions). There is strong evidence that a high clinical sensitivity and specificity is not directly 
synonymous with presence or absence of hrHPV in a cervical sample. When the analytical 
sensitivity is too high this will result in decreased clinical specificity, since a low viral load is not 
associated with increased risk for CIN. When considering HPV tests for screening, a distinction 
between clinical relevant and irrelevant hrHPV infections should be made 67,68.  
 
Roughly three applicable strategies for HPV testing in cervical cancer prevention can be 
defined. Firstly, it can be used as primary screening test, alone or in combination with a Pap 
smear, for the detection of cervical cancer precursor lesions. In general the sensitivity of HPV 
screening is higher as compared to cytology but at the same time it is significantly less 
specific 63,69. Combining HPV testing with cytology results in only slight improvement of 
sensitivity but at the expense of further loss in specificity. Several strategies are suggested to 
improve the specificity of HPV testing for primary screening. One of them is restriction of HPV 
screening to age-groups of 35 years or older 60. Another is simply repeating the HPV test to 
identify persistent infections 61. Beside that, HPV viral load 70-74, HPV genotyping 75 and 
cytology triage 73,76 have been proposed. Finally, the use of molecular markers such as mRNA 
testing for E6 or E7 oncogenes 77,78, immunostaining  of overexpressed cell-cycle regulating 
proteins (e.g. p16) are promising methods for triage of HPV-positive women at increased risk 
for progressive CIN and cervical cancer 79. The higher sensitivity of primary HPV screening as 
compared to cytological screening is a clear advantage. However, several potential 
disadvantages have been put forward. First there is the high unit cost and lower specificity of 
the HPV test as compared to cytology-based screening. This might result in unfavorable cost-
efficacy since a relatively small decrease in specificity can have dramatic consequences on 
costs 61. Besides that, there are some major negative psychosocial aspects of HPV testing. 
Public awareness on HPV and its role in cervical cancer is limited. Confusion and anxiety 
about the association with sexually transmitted infections as well as issues of fidelity and trust 
in relationships after communicating a positive HPV test results is common and may 
compromise screening participation 80. On the other hand, HPV testing is suitable for self-
sampling and has been propose as an alternative to cell collection by a clinician. Self-
sampling is especially appealing for women who are reluctant to attend cervical screening 
for social or religious reasons and it is likely to improve compliance in these populations. 
 
Another strategy for HPV detection in cervical cancer screening is the use of HPV testing for 
triage of women with equivocal (ASCUS) or LSIL cytological results. This strategy is allowed in 
follow-up of low-grade abnormalities in the Netherlands recently. Liquid-based cytology is 
especially suitable for this triage purpose since HPV testing can be easily performed on the 
residual material, avoiding a second visit for a HPV triage test. ASCUS triage using HC2 is 
significantly more sensitive for the detection of HSIL as compared to repeat cytology and 
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equally specific. HPV triage of LSIL lacks specificity and is not considered a useful 
management option in these cases. Up to now repeat cytology is considered still the best 
triage management option for LSIL 81,82. Triage with other potential candidate molecular 
surrogate progression markers, such as cell cycle regulation proteins, viral integration markers 
and viral mRNA are under evaluation.  
 
Finally, there is a potential role for HPV testing in the follow-up after treatment of CIN. This so 
called post-treatment testing procedure is based on the assumption that HPV DNA is 
commonly cleared after effective treatment of CIN. Persistence of HPV DNA is related with 
residual of recurrent CIN lesions and thus with treatment failure. Post-treatment HPV testing 
has been found a more sensitive and more rapid procedure for detection of residual or 
recurrent CIN during follow-up as compared to follow-up cytology with equal specificity 82.  
 
1.5.6 Molecular markers 
 
Several molecular markers are proposed for triage purposes and may potentially predict 
progressive behavior. However, research has been restricted to correlation studies so far and 
is not representative for applications in actual screening settings. Two widely used 
oncoproteins are Ki-67 and p16INK4a. The proteins are up-regulated in dysplastic cervical 
epithelial cells through the hrHPV infection. Ki-67 (recognized by the monoclonal antibody 
Mib1) is expressed in dividing or proliferating cells. Normally, Mib1 positivity is only found in 
basal or suprabasal cell-layers. In dysplastic epithelium Mib1-positive cells are found 
throughout the whole thickness of the abnormal epithelium. p16INK4a overexpression is, just as 
overexpression of Mib1 considered to be a sensitive marker for CIN 43. Potential applications 
are in the field of triage of women with minor or low-grade abnormalities, improving the 
accuracy and reproducibility of histological verification and prognostic prediction purposes. 
 
 
1.6 Histological diagnosis and treatment of cervical (pre) invasive disease 
 
Women with abnormal findings on cytology or HPV testing are referred to the gynaecologist 
for colposcopic evaluation. The referral criteria vary from country to country. Colposcopy is a 
procedure where the uterine cervix is viewed with a stereoscopic microscope with a 
magnification between 6 and 40 times. After application of  3% acetic acid and Lugol’s 
iodine (Schiller test) the transformation zone is visualized and inspected for abnormalities. 
When such abnormal areas are found, they are graded according to morphological 
features, such as acetowhiteness, margins, blood vessels and iodine uptake 1. The role of 
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colposcopy is to identify the most abnormal area’s for histological confirmation with a 
colposcopy directed biopsy or direct treatment. 
 
In histology, intraepithelial squamous lesions are characterized by an abnormal cellular 
proliferation and maturation together with nuclear atypia. The morphologic epithelial 
alterations are classified in three categories: CIN 1 to CIN 3, which are mutually prone to a 
high intra- and interobserver variability 46. In CIN 1 atypical basaloid cells and mitotic figures 
are found in the lower third part of the epithelium. HPV-induced cellular effects, such as 
koilocytotic changes are frequently found in these lesions. In CIN 2 lesions, atypical basaloid 
cells and mitotic figures occupy the lower two thirds of the epithelium. CIN 3 lesions show 
neoplastic changes or dysplastic cells and mitoses in two thirds to full thickness of the 
abnormal epithelium. The nuclear-to-cytoplasmatic ratio of the cells is increased substantially 
and the abnormal nuclei contain dense, hyperchromatic coarse chromatine. A schematic 
representation of the morphological changes in the consecutive CIN lesions is provided in 
figure 4. Invasive cervical epithelial tumours are subdivided in three categories: squamous, 
glandular and ‘other’ epithelial tumours. 
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In general there are two techniques available for the treatment of CIN: destructive and 
excisional techniques. Destructive treatment can be only applied when pre-treatment biopsy 
has been performed and invasive cervical cancer has been ruled out. These techniques 
include CO2-vaporation, cryotherapy, electro-cauterization and cold coagulation. Excisional 
techniques, in general followed by histological examination includes CO2 laser excision, cold 
knife technique (including cone biopsy), Loop Electrosurgical Excision Procedure of the 
Transformation Zone (LEEP), Large Loop Excision of the Transformation Zone (LLETZ) and 
occasionally hysterectomy. LLETZ produces the least morbidity and the most adequate 
specimen for histological examination 47. More than 90 % of the women are cured after this 
procedure 48.  
 
The treatment of invasive carcinoma depends on the stage of the disease. For micro-invasive 
carcinoma (stage IA1) a cone biopsy may be considered as therapeutic procedure, 
whereas  hysterectomy is the recommended treatment for higher stages of disease. In some 
cases of stage IA2 and IB1 disease, when preservation of fertility is desired, a large cone 
biopsy or trachelectomie with dissection of the lymph-nodes may be applied. 
 
 
1.7 Population based screening programs 
 
1.7.1 Principles of screening 
 
A first definition of screening was formulated by the US Commission on Chronic Illness in 1957 
where screening was described as ‘the presumptive identification of unrecognized disease or 
defect by the application of tests, examinations or other procedures, which can be applied 
rapidly. Screening tests sort out apparently well persons who apparently have a disease from 
those who do not’ 83. Most recently the UK National Screening Committee (re)defined 
screening in the second NSC report (2000) as ‘a public health service in which members of a 
defined population, who do not necessarily perceive that they are at risk of, or are already 
affected by, a disease or its complications, are asked a question or offered a test to identify 
those individuals who are more likely to be helped than harmed by further tests or treatment 
to reduce the risk of disease or its complications’ 84.  
 
The benefits of screening within the scope of disease prevention were recognized first in the 
1940s, at the time when effective treatment for tuberculosis was introduced. The application 
of screening in secondary prevention of other diseases such as cancer emerged in the 
following years and led to the landmark publication of a World Health Organization 
Monograph of Wilson and Jungner in 1968 86. They prescribed a number of basic criteria to be 
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fulfilled before screening is introduced. These classic screening criteria are summarized in 
table 2. Cochrane and Holland 86 formulated some additional criteria concerning the test to 
be used within a screening setting. In order not to compromise the participation in the 
screening program, a screening test must be acceptable to the population screened, simple 
to perform and relatively cheap. Furthermore, it must be easy to interpret and have a good 
accuracy. Both the sensitivity of the test for finding a condition as well as the specificity for 
giving a negative result when the condition is absent should be as high as possible.  
 
 
 
 
 
1.7.2 Cervical cancer screening 
 
In general, the goal of cancer screening as a secondary prevention measure is to reduce the 
extent of treatment for and mortality of cancer 85. If cancer screening focuses on the 
detection of (premalignant) precursor lesions,  successful screening should be followed by a 
reduction in cancer incidence. When cancer screening is undertaken this should be 
performed only in an organized setting with quality assurance at all levels of the screening 
program, continuous monitoring of effects and knowledge of the benefits and disadvantages 
of the screening 85,88. Benefits of cancer screening will be achieved only when compliance is 
high. Opportunistic screening activities may not achieve the benefits but rather cause 
unnecessary negative side-effects and should therefore be avoided.  The effectiveness of 
Table 2: Classic screening criteria Wilson and Jungner 86 
 
1. Important health problem 
2. Accepted treatment for patients with disease leading to better prognosis 
3. Facilities for diagnosis and treatment available 
4. Recognizable latent or early symptomatic stage 
5. Suitable diagnostic test available 
6. Test is acceptable to population 
7. Natural history  of the condition, including development from latent to declared disease 
adequately understood 
8. Agreement  whom to treat 
9. Cost of case-finding in relation to total costs of medical care  
10. Case-finding is a continuous process 
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cancer screening depends on the sensitivity of the screening test, participation rate of the 
invited, frequency of screening, number of screening tests offered during a lifetime, 
compliance with follow-up and effectiveness of early treatment 88. Negative side-effects 
mostly relate to sensitivity and specificity issues of the test and on side-effects of early 
treatment. Low sensitivity will give rise to false reassurance for those with a false-negative test 
result. Low specificity on the other hand will give rise to high numbers of false-positives cases, 
resulting in overtreatment, unnecessary anxiety and costs. Unfortunately, screening tests, 
even with all the safeguards applied, never will be perfectly accurate and will always be 
prone to a certain level of human and technical error. Even with the most extensive quality 
assurance mechanisms applied, errors will still occur. Accordingly, as also acknowledged in 
the NSC – Second Report 2000 84, screening can harm as well as help.  
 
Although the effectiveness of cervical cancer screening with cytology has never been 
proven by randomized controlled trials, it is generally accepted that it has reduced the 
incidence and mortality from cervical carcinoma in developed countries where cervical 
cancer screening programs have been implemented. Reductions of cervical cancer deaths 
of more than 70 % have been reported. Despite this success of the Pap test in decreasing the 
rate of cervical carcinoma in these countries, the public expectation of 100 % effectiveness 
has never been achieved in any screened population. Despite the introduction of various 
policies and new technologies to reduce the number of cervical cancer deaths even more, 
programs in western-Europe seem to have reached an irreducible minimum of cervical 
carcinomas. This is mainly caused by failures within the cervical screening programs. These 
include the failure of women to participate in screening at the recommended frequency or 
to participate at all, failures in smear taking, smear handling, screening and/or interpretation 
of abnormal  cells, reporting failures, failures in follow-up compliance after cytological 
abnormalities and failures in treatment and follow-up after treatment 89. All these issues have 
a more or less negative impact on the program sensitivity and thus on the effectiveness of 
cervical cancer screening. Several studies have shown that participation in screening has 
been suboptimal in more than half of the cases of cervical carcinoma 90-94 and that more 
than 50% of the cervical carcinomas occur in the 5% - 15% of women who have never been 
screened. Thus, compliance is an essential factor to the success of the cervical screening 
program and increasing the  compliance is the best and most simple way of improving the 
effectiveness of cervical screening. Organized screening programs are considered to reach 
higher coverage rates as compared to opportunistic screening and are therefore more 
effective. As mentioned above, other reasons for failure of screening are inadequate 
sampling and/or erroneous smear interpretation. Though there have been increasingly 
adverse press reports focusing on these issues, these errors represent only 12 % - 23 % of the 
failures and are less important than lack of compliance. Nevertheless, it is clear that the 
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sensitivity of the Pap test is limited. This limited sensitivity is ascribed to either smear taking 
(sampling errors) or smear reading or laboratory errors (screening or interpretation error). 
Approximately two-third of the false negative results are due to inadequate sampling, 
whereas one-third is caused by screening or interpretation errors 93,94.  Even though the 
estimated sensitivity of the Pap-test is only very moderate and ranges from 30 % to 87 % 96, it is 
essential to appreciate that through the repetitive nature of the screening even a 
moderately sensitive test, such as the Pap test, can be able to reduce the incidence and 
mortality from cervical cancer to a low residual level 61,97. Despite the limited role of sampling 
and screening errors in program failures, increasing attention is given towards new 
technologies, potentially reducing false-negative results in women who are screened. 
 
While there is ample evidence supporting the advantages of cervical cancer screening, 
there are also negative consequences and potential harms of screening large numbers of 
healthy women in order to prevent significant disease in only a few. Firstly, the 
gynaecological examination and smear taking is experienced as uncomfortable by many 
women. Secondly, there is the psychological impact of a positive screening result. 
Approximately 5 % of all smears made in a cervical screening program are considered 
abnormal or need to be repeated for other reasons. However, in a considerable number of 
cases this concerns equivocal or low-grade abnormalities with very high regression rates, 
which often would have been left undetected without screening. Besides that, in many other 
cases it concerns real false-positive results. The psychological impact of a positive test, even 
when the result is only slightly abnormal, is considerable. It results in anxiety and fear among 
women which should not be underestimated. For many, the concept of ‘pre-cancerous’ 
lesion is equivalent with a real risk of having cancer which in its turn is associated with death. 
A majority of women referred for colposcopy after a positive screening result described 
feeling ‘worried or alarmed’ or even ‘shocked, stunned and devastated’ 98. False-positive 
screening results lead to unnecessary interventions, with both human as well as financial 
costs. Overtreatment of false-positive cases and regressive premalignant lesions are 
considered major adverse effects of cervical cancer screening. Various complications after 
treatment have been reported. This included bleeding, infection, pain, cervical stenosis and 
cervical incompetence. Cervical incompetence has been associated with pre-term delivery 
99. The problem of false-positive results are  related to the specificity of the screening test. In 
screening situations where the prevalence of disease is low, a small decrease in specificity will 
have dramatic consequences both on financial and human costs. Finally, in contrast to the 
impact of false-positive screening results there is the misunderstanding that a negative test 
implies no risk, rather than a low risk for cervical cancer giving in its turn, rise to false 
reassurance and possibly underestimation and -investigation of alarming clinical symptoms. 
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A prerequisite for an effective and efficiently working cervical screening program is that 
optimal performing screening tests are used but also that optimal follow-up protocols are 
defined and monitored.  
 
 
1.7.3 Organization of cervical cancer screening  
 
Cervical cancer screening programs can be either opportunistic or organized. In 
opportunistic screening programs there is no central data collection and participation 
depends on self-motivation. Screening intervals are accordingly variable. Screening 
programs in the USA, France, Germany and the Southern European countries are more or less 
opportunistic. Components of an effectively and well-organized screening program are the 
central coordination and data collection, a defined target population and defined 
screening interval. Women receive a personal invitation to participate and are re-invited in 
case of non-attendance (call/recall system) 95. Furthermore clear and preferably nationally 
defined and monitored procedures for follow-up, after an evidence-based policy for follow-
up has been established, are essential. Evaluation, audit and quality control and assurance 
addressing every stage of the screening process should be an integral part of organized high-
quality screening program 85,100. Organized screening also implies ‘scientific analysis of 
outcome of the screening and quick reporting of these results to the population and screen 
providers’ 101. Organized cervical screening has been implemented among others in the UK, 
British Columbia, Canada, the Nordic countries and in the Netherlands 95. The screening 
strategies vary across the different countries in terms of screening interval and the age-range 
of women which are invited. It is generally recognized that coverage – i.e., the participation 
rate of the invited population – is essential to the success of cervical screening. Coverage is 
generally higher in well-organized screening programs 85,95. Moreover, adequate follow-up is 
an important feature of an efficient cervical screening program which is obviously better 
ensured in well-organized settings through fail-safe methods. Besides that, guidelines for 
quality assurance are applied more easily in an organized setting.  
 
In the Netherlands, a pilot project for cervical screening started in the region of Utrecht in the 
early 70s of the last century. This pilot for systematic cervical screening was extended to 3 
other regions (Utrecht, Nijmegen and Rotterdam) in 1976. Women aged 35 to 54 were invited 
centrally every 3 years. Based on the experiences in the pilot project, a nation-wide 
organized screening program was implemented in 1989. However, in the first half of the 90s it 
was recognized that the participation rate was very low (40 %-50 %). Also the follow-up 
compliance was unsatisfactory and follow-up policy varied due to a lack of clear-cut, 
nationally defined guidelines. As the existing program was considered ineffective, it was 
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reorganized in 1996. Changes focused on organization and the target population was 
extended to women aged 30 to 60 years with a 5-years screening interval. Criteria for minor 
cytologic abnormalities were also revised as well as repeat and referral policies. This resulted 
in a national guideline on cervical screening 102.  
 
The development of new techniques within the field of cervical cancer screening, such as 
liquid-based cytology and automated screening at the beginning of this century , led to the 
question whether these techniques would be applicable within cervical screening and have 
potential in improving the Netherlands cervical screening program. Therefore a systematic, 
evidence-based review on these emerging techniques was performed and published in 2002 
under the aegis of the ‘Kwaliteitsinstituut voor de Gezondheidszorg CBO’ and initiated by the 
Netherlands Pathology Society (NVVP) 103. One of the conclusions of the advisory committee 
was that before the introduction of a liquid-based method (ThinPrep®) in the organized 
Dutch cervical cancer screening program ‘further evaluation of the costs and benefits of the 
ThinPrep method should be undertaken to decide definitively whether to implement this 
method in the Netherlands population screening program’ 104. 
 
1.7.4 Quality assurance of screening 
 
Good quality assurance is an important component of a high-quality screening program, 
concerning all stages of organized screening from invitation, compliance, cell collection, 
handling and staining of the cell sample, microscopic evaluation, and reporting up to follow-
up management. A high-quality screening program is an effective and efficient working 
system with best possible patient care which depends on the quality of the chain of the 
whole process of consecutive activities in cervical screening 105. When focusing on the 
performance of the cytological screening test and evaluation of follow-up management and 
follow-up guidelines, a high-quality program aims at a balance between a minimum number 
of false negative and positive test results on the one hand and at a balance between 
unnecessary and inadequate follow-up of suspicious cases on the other hand, considering 
economic resources as well. The main challenge is to achieve a maximal reduction in the 
incidence and mortality of cervical cancer at the cost of a minimal number of women being 
exposed to the potentially negative side effects of screening 106. A paramount component of 
quality assurance of cervical cancer screening is monitoring and evaluation of existing 
guidelines. This implies also scientific analysis of the outcome of the screening and evaluation 
of new cancer screening tests with randomized trials before implementation in routine 
healthcare 101. In the Netherlands, along with the reorganization of the cervical screening 
program in 1996, guidelines on cervical screening and quality assurance were introduced by 
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the Dutch Society of Pathology. These guidelines have been in place for several years now 
and need to be evaluated on their effectiveness. 
 
 
 
1.8 Outline of the thesis 
 
The aim of this thesis is to evaluate existing guidelines for follow-up management on the one 
hand and the accuracy of a new screening test, liquid-based cytology with the ThinPrep 
system (Hologic Corporation, Marlborough, MA) on the other hand, with the objective to 
define recommendations for improvement of the quality of cervical screening within the 
frame of the Netherlands cervical screening program.  
 
The thesis addresses the following  research questions: 
1. Is the early guideline on the management of a negative Pap test without 
endocervical cells effective? 
2. Is the reporting guideline for normal endometrial cells in asymptomatic 
postmenopausal women optimal? 
3. How does the management guideline for repeated borderline abnormalities in the 
Dutch cervical screening program perform with respect to referral compliance and 
outcome? 
4. How does liquid-based ThinPrep cytology perform as compared with conventional 
cytology in terms of cytological detection rates and what is the relative accuracy of 
this screening test in the Netherlands? 
 
Chapter 2 deals with the question whether the early guideline on the management of a 
negative Pap test without endocervical cells (ECC-) has been effective. This guideline 
prescribed an early repeat of the Pap test after 6 months in case of a negative ECC- results. 
However, controversy exists about the clinical relevance of negative ECC- smears. In chapter 
2 cross-sectional results were combined with short-term follow-up of negative ECC- smears to 
estimate the true prevalence of squamous lesions in women with ECC- smears and compare 
this with the true prevalence of squamous lesions in ECC+ smears. In Chapter 3 the existing 
reporting guideline for normal endometrial cells in postmenopausal women without clinical 
complaints is evaluated. The clinical relevance of these cells in smears of these women has 
been subject of debate for years and this finding may lead to a diagnostic dilemma. First, the 
prevalence rate of endometrial (pre)-malignancies in asymptomatic postmenopausal 
women with normal endometrial cells in their smear is examined and next this prevalence 
rate is compared with a control group existing of asymptomatic postmenopausal women 
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without normal endometrial cells in their smears. Chapter 4 deals with the compliance with 
the guideline for referral and outcome after repeated borderline, or equivocal test  results. 
These borderline results are diagnosed frequently, but generally have only limited predictive 
value for high-grade lesions. Since this results in high economic costs and patient anxiety and 
possibly overtreatment, it is important to define the optimal management procedure. In the 
Netherlands a conservative follow-up management had been introduced in 1996 with repeat 
cytology at 6 and 18 months and referral for colposcopy in case of persistent borderline 
abnormalities. Compliance and outcome of this management procedure is studied in this 
chapter. Recent years new technology has impacted increasingly on cervical cancer 
screening. This was reflected in the CBO-guideline from 2002 where liquid-based cytology, 
HPV screening and automated screening had been evaluated with systematic, evidence-
based review. Based on this CBO-guideline, a randomized controlled trial (Nethcon-trial) was 
set up to compare the diagnostic accuracy, adequacy and cost-effectiveness of the liquid-
based ThinPrep cytology technique. In chapter 5 and chapter 6 the results from this trial are 
described and discussed. Finally, in chapter 7 the results of the various chapters are 
integrated in the moving field of cervical cancer screening and discussed in general. 
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Abstract 
 
Purpose of this study was to determine the prevalence rate ratio of squamous lesions in 
women with a recent smears without (ECC-) versus women having a smear with endocervical 
component (ECC+) and to estimate the true prevalence of these lesions in women with ECC- 
smears by addition of short-term follow-up results of negative ECC- smears. Results of initial 
smears in a 3 years period, as well as follow-up results of negative ECC- smears in the same 
period were retrieved. Women were categorized into two groups: having ECC- and ECC+ 
smears. The data were analysed for three outcome parameters, ASCUS or higher (ASCUS+), 
LSIL or higher (LSIL+) and HSIL or higher (HSIL+). Squamous abnormalities occurred far less 
frequent in women with initially ECC- than with ECC+ smears. Prevalence rate ratio  (PRR) was 
0.27 for ASCUS+, 0.39 for LSIL+ and 0.36 for HSIL+. Addition of follow-up results of negative 
ECC- smears, as a correction for false-negative ECC- smears, results in PRR’s which are still 
significantly lower than 1, and most marked in sub-set HSIL+ (PRR=0.60). We conclude that the 
true prevalence of squamous lesions in women with a recent ECC- smears is significantly 
lower as compared to ECC+ smears.  These findings lent support to the decision to abolish the 
repeat of ECC- smears in the Dutch population screening programme. 
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Introduction 
 
In 1996 the Dutch Population Screening Program has been reorganized. Changes focused on 
reduction of opportunistic screening, redefinition of ASCUS and AGUS and changes in the 
organization of the screening program. The age-range was changed from 35-55 to 30-60 
years, the screening interval was increased from 3 to 5 years, criteria for referral of the patient 
to the gynecologist or repeating of the smear were revised and the repeat advice for 
negative ECC- smears (adequate but limited by absence of endocervical component in the 
absence of abnormal cellular changes) was set at 6 months1 . After a second negative ECC- 
smear the patient is referred to the 5 years scheme of the screening program. Recently in the 
U.S.A. the Bethesda 2001 workshop advised to classify an ECC- smear as satisfactory for 
evaluation. An early repeat is not advised in the Bethesda system in the U.S.A., where women 
are already advised to have a smear taken each year. In the Netherlands screening 
program, the Bethesda recommendations for the management of ECC- smears have been 
discussed and the Dutch early repeat advice for ECC- smears has been under 
reconsideration. 
 
Generally a smear is thought to be most sensitive to detect abnormalities if the transformation 
zone (TZ) is fully sampled. The presence of endocervical cells is considered as a good marker 
for TZ-sampling. Also endocervical mucus and squamous metaplastic cells are described as 
TZ-markers 2-9. In the literature there has been disagreement about the clinical relevance of 
negative ECC- smears. Results of most cross-sectional studies 2,3,8,10,11 suggest that negative 
ECC- smears are representing high percentages of false-negative (FN) smears due to 
sampling error. This is reflected in a significant lower prevalence of squamous abnormalities in 
ECC- smears as compared to ECC+ smears.  
 
Retrospective studies show high proportions of negative ECC- smears preceding diagnosis 
CIN 3 and invasive carcinoma 12,-14. A recent meta-analysis 15 concluded that squamous 
abnormalities are more likely to be found in ECC+ smears as compared to ECC- smears. 
Longitudinal studies, on the other hand, show no differences in detection-rate of squamous 
abnormalities after follow-up of ECC- and ECC+ smears 5,7,16,17. These findings would not be 
expected if the group of ECC- smears  consists of high numbers of false negative smears. It 
has been suggested that the reason for this discrepancy might be a lower prevalence of 
squamous abnormalities in women with ECC- smears 3,16,17. The management of early repeat 
testing of negative ECC- smears in The Netherlands for the last 5 years can provide useful 
information for exploration of the true prevalence of squamous cervical lesions in ECC- 
smears. Therefore we performed a cross-sectional study design and added the results of short 
term follow-up of negative ECC- smears to the cross-sectional outcomes in order to correct 
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for false-negative ECC- smears. Because taking biopsies from the TZ, as the best golden 
standard, is obviously not feasible, we used cytologic follow-up results. 
The first aim of this study was to determine the prevalence rate ratio (PRR) of squamous 
lesions in women with an initial ECC- smear versus ECC+ smear.  
 
The second aim of the present study was to get a more accurate estimate of the true 
prevalence of cervical squamous lesions in women with ECC- smears as compared to ECC+ 
smears by correcting the PRR for false-negative results. We calculated the total number of 
abnormalities in women with ECC- smears by adding the abnormalities, found during short-
term follow-up of ECC- smears to the number of abnormalities found in initial ECC- smears. 
 
 
Study Population 
  
Results of initial smears of 180,264 women, diagnosed in 3 regional pathology laboratories in 
East-Netherlands in a 3 year period (1997-1999), as well as the follow-up results of 15,021 of 
15,796 negative ECC- smears in the same period were retrieved from the National Pathology 
Database (PALGA). Patients are identified by PALGA based on the first 4 characters of the 
name and date of birth. This results in a considerable number of administrative fusions. 
Therefore follow-up data were corrected for administrative fusions using additional personal 
data such as initial of the first name and place of birth. In some cases residence was used 
also. Using this methodology, cytologic diagnosis of the next following smear was determined. 
In case the next following examination was histology, this diagnosis was used as follow-up 
result. Smears showing epithelial atrophy were excluded from evaluation because of the 
known difficulties in recognizing endocervical and squamous metaplastic cells if combined 
with atrophic squamous cells 18. Inadequate smears were also excluded. Smears of remaining 
167,604 women were analyzed with respect to reported squamous abnormalities in two 
groups:  
 
1. ECC-: squamous cells present, endocervical and squamous metaplastic cells absent  
2. ECC+: endocervical cells and / or squamous metaplastic cells are present with 
sufficient number of squamous cells.  
 
Data were analyzed for three outcome parameters, ASCUS+ (ASCUS, LSIL, HSIL and cancer), 
LSIL+  (LSIL, HSIL and cancer) and HSIL+ (HSIL and cancer). These cut-off points were 
considered relevant because of the clinical management of these lesions. The maximum 
term for follow-up of negative ECC- smears was set at 24 months. 
 
Prevalence of squamous abnormalities 45 
 
Method 
 
We compared the prevalence of ASCUS+, LSIL+ and HSIL+ in the two  groups: women with 
smears with (ECC+) and without (ECC-) endocervical cells and determined the prevalence 
rate ratio (PRR = prevalence in ECC- / prevalence in ECC+) with 95% CI. Since we used a 
short follow-up period with a maximum of 24 months, we assumed that the abnormalities 
found after repeating negative ECC- smears were already present at the time of diagnosis of 
the negative ECC- smear and did not represent incidence disease. The number of 
abnormalities found in the repeat smears were added to the number of abnormalities initially 
found in ECC-. In this way we corrected for false negative ECC- smears. However, not all 
women with negative ECC- smear were repeated within 24 months. If we assume that the 
group of women who had a repeat smear and women without a repeat smear are 
comparable and thus the prevalence of squamous abnormalities is equally distributed 
among these two groups, we can calculate the expected total number of abnormalities in 
the ECC- group. The calculated total number of  abnormalities in ECC- smears is found using 
the equation:   
A1 + A2 + (%NRep / %Rep ) * A2 
where A1 is the number of abnormalities found in the initial ECC- smear, A2 is the number of 
abnormalities found after repeating negative ECC-, %Nrep is the percentage not-repeated 
smears and %Rep is the percentage repeated smears. This calculated number abnormalities 
in ECC- results in an adjusted prevalence in which false-negative results of ECC- smears are 
taken into account. Adjusted prevalence rate ratios in ECC- versus ECC+ smears were 
computed, including 95% CI, using SPSS software.  
 
 
Results 
 
Proportions of squamous abnormalities found in women with ECC+ and ECC- smears as well 
as PRR’s are shown in table 1 for the three outcome parameters: ASCUS+, LSIL+ and HSIL+. The 
overall number of ECC- smears in the studied period was 15985 (9.5 %). Squamous 
abnormalities are seen far less frequent in women with an initial ECC- smear (approximately 
one third) than in women with ECC+ smear. Prevalence rate ratios are significantly lower than 
1 for all three outcome parameters. The found prevalence might be an underestimation of 
the true prevalence of squamous abnormalities in women with an ECC- smear, since false-
negatives could be present in this group. In The Netherlands since 1996 all negative ECC- 
smears had a repeat advice of 6 months. Therefore short-term follow-up data for negative 
ECC- smears were available and correction for false-negative ECC- smears could be 
performed. Additional squamous abnormalities,  
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found after repeating negative ECC- smears, were added to the number of abnormalities 
found initially in ECC-, thus giving better insight in the true prevalence of abnormalities in 
women with ECC- smears. The number of squamous abnormalities, found after repeating 
negative ECC- smears is given in table 2. These squamous abnormalities were found in 
women who have had a repeat smear within a period of 24 months. The abnormality rate in 
repeat smears was independent of the time-interval between the initially negative ECC- 
smear and the repeat smear.  
 
 
No significant difference in abnormality rate was found in women with a repeat smear within 
8 months and those having a repeat smear between 8 and 24 months. Squamous 
abnormalities can also be expected to be found in the group of women who did not have a 
repeat smear within this period. The overall percentage of repeated negative ECC- smears 
was 58.2 % (table 2), with oldest (50-59 and over 60 years) women having less frequently a 
repeat smear within 24 months. Based on groups characteristics, we assumed that women 
who had a repeat smear and women without a repeat smear after an initially negative ECC- 
 
Table 1:  Number, prevalence and prevalence rate ratio (95 % CI) for ASCUS+, LSIL+ and HSIL+ in initial 
ECC- smears versus ECC+ smears, subdivide in age categories 
 
  ASCUS+ LSIL+ HSIL+  
  No * Yes * No * Yes * No * Yes * Total 
All 
ages 
ECC- 15,769 (98.6) 216 (1.4) 15,892 (99.42) 93 (0.58) 15,937 (99.7) 48 (0.30) 15,985 
ECC+ 144,025 (95.0) 7,594 (5.0) 149,331 (95.5) 2,288 (1.5) 150,344 (99.16) 1,275 (0.84) 151,619 
PRR 0.27 (0.24 - 0.31) 0.39 (0.31 - 0.47) 0.36 (0.27 - 0.48)  
30-60  
  
ECC- 13,221 (98.8) 164 (1.2) 13,320 (99.51) 65 (0.49) 13,357 (99.79) 28 (0.21) 13,385 
ECC+ 122,312 (95.0) 6,465 (5.0) 126,964 (98.6) 1,813 (1.4) 127,765 (99.21) 1,012 (0.79) 128,777 
PRR 0.24 (0.21- 0.28) 0.35 (0.27 - 0.44) 0.27 (0.18 - 0.39)  
<30 ECC- 1,659 (98.0) 33 (2.0) 1,675 (99.0) 17 (1.0) 1,682 (99.41) 10 (0.59) 1,692 
ECC+ 15,955 (94.6) 911 (5.4) 16,442 (97.5) 424 (2.5) 16,636 (98.6) 230 (1.4) 16,866 
PRR* 0.36 (0.26 - 0.51) 0.40 (0.25 – 0.65) 0.43 (0.23 – 0.82)  
30-39 ECC- 4,073 (98.6) 59 (1.4) 4,103 (99.3) 29 (0.70) 4,117 (99.64) 15 (0.36) 4,132 
ECC+ 42,741 (94.7) 2,395 (5.3) 44,118 (97.7) 1,018 (2.3) 44,496 (98.6) 640 (1.4) 45,136 
PRR 0.27 ( 0.21 – 0.35) 0.31 (0.22 – 0.45) 0.26 (0.15 – 0.43)  
40-49 ECC- 5,946 (98.9) 67 (1.1) 5,987 (99.57) 26 (0.43) 6,002 (99.82) 11 (0.18) 6,013 
ECC+ 54,458 (95.2) 2,744 (4.8) 56,591 (98.9) 611 (1.1) 56,895 (99.46) 307 (0.54) 57,202 
PRR 0.23 (0.18 – 0.30) 0.41 (0.27 – 0.60) 0.34 (0.19 – 0.62)  
50-59 ECC- 3,202 (98.8) 38 (1.2) 3,230 (99.69) 10 (0.31) 3,238 (99.94) 2 (0.06) 3,240 
ECC+ 25,133 (95.0) 1,326 (5.0) 26,255 (99.3) 184 (0.70) 26,374 (99.75) 65 (0.25) 26,439 
PRR 0.23 (0.17 – 0.32) 0.44 (0.24 – 0.84) 0.25 (0.06 – 1.03)  
60 ECC- 889 (97.9) 19 (2.1) 897 (98.8) 11 (1.2) 898 (98.9) 10 (1.1) 908 
ECC+ 5,758 (96.4) 218 (3.6) 5,925 (99.15) 51 (0.85) 5,943 (99.45) 33 (0.55) 5,976 
PRR 0.57 (0.36 – 0.91) 1.42 (0.74 – 2.71) 2.0 (0.99 – 4.0)  
* number (percentage) 
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smear are comparable (mean age 42 years with and 43.4 years without repeat smear).  
Therefore we concluded that extrapolation of the follow-up results of negative ECC- to 
 
 
women without a repeat smear was justified. We made an estimate of the true prevalence of 
abnormalities in ECC- smears by using the above-mentioned calculation method. The 
adjusted prevalences and prevalence rate ratio’s, including 95% CI for ASCUS+, LSIL+ and 
HSIL+ are shown in table 3. Adjusted prevalence of ASCUS+, LSIL+ and HSIL+ in women with 
ECC- smears was lower in comparison to women with ECC+ smears. Differences were most 
marked for the group of HSIL+. All PRR’s were significantly lower than 1. PRR’s for ASCUS+, LSIL+ 
and HSIL+ in ECC- were 0.72, 0.78 and 0.60 respectively. As age could act as a possible 
confounder, we stratified results on age. Age-category 30-60 years was analysed separately 
because this age-range is the target population of the screening program in The Netherlands 
as in many other countries. Table 1 shows statistically significantly lower percentages of 
squamous abnormalities in ECC- smears in all age-categories with exception of women over 
60 years of age.  Highest  percentages of abnormalities were found in the youngest age-
groups. This is especially true for categories LSIL+ and HSIL+ for both ECC+ as ECC- smears. 
Noteworthy is the high frequency of abnormalities in ECC- smears of women over 60 years, 
especially LSIL+ and HSIL+. In this group of women, 7 out of 10 cases (70 %) HSIL+ in the ECC-
group were squamous cell carcinomas in contrast with the ECC+ smears, where HSIL+ 
consisted in 13 out of the 33 cases (39 %) of squamous cell carcinomas. 
 
 
Table 2: Number of abnormalities, additionally found after repeating initially negative ECC smears, 
subdivided in age categories and by repeat interval 
 
Repeat smear after ECC- 
within 24 months* 
ASCUS+ LSIL+ HSIL+ 
No Yes No Yes No Yes 
All ages          9179 (58.2 %) 8,968 211 9,124 55 9,160 19 
30-60              7884 (59.6 %) 7700 184 7843 41 7868 16 
<30                   977 (58.9 %) 956 21 964 13 975 2 
30-39              2510 (61.6 %) 2457 53 2491 19 2501 9 
40-49              3801 (63.9 %) 3708 93 3786 15 3795 6 
50-59              1573 (49.1 %) 1535 38 1566 7 1572 1 
60                    318 (35.8 %) 312 6 317 1 317 1 
< 8 months      5186  5073 113 (2,18 %) 5160 26 (0,50 %) 5173 13 (0,25 %) 
8–24 months   3993  3895 98 (2,45 %) 3964 29 (0,73 %) 3987 6 (0,15 %) 
* number and percentage of initial negative ECC- smears 
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 The adjusted prevalence of ASCUS+, LSIL+ and HSIL+ in ECC- smears was lower compared to 
ECC+ smears for all age-categories, again with exception  of women over 60 years and also 
in case of LSIL+ in women 50-59 (table 3). The adjusted PRR for diagnosis ASCUS+, LSIL+ or 
HSIL+ in ECC- was significantly smaller than 1 for the target population of the Dutch screening 
program (30-60), PRR= 0.70, 0.71 and 0.52 respectively. All age-strata, with exception of 60 
years and older, showed lower estimates of the adjusted prevalence of abnormalities in ECC- 
as compared to ECC+ smears. However the number of cases in some of the age-strata were 
too small to show significant differences.  
 
Table 3:  Adjusted prevalence and prevalence rate ratio  (PRR) for ASCUS+, LSIL+ and HSIL+ in ECC- 
versus ECC+ smears, subdivided in age categories 
 
  % ASCUS+ % LSIL+ % HSIL+ 
All 
Ages 
ECC- 3.6 1.2 0.51 
ECC+ 5.0 1.5 0.84 
PRR* 0.72 (0.67 – 0.79) 0.78 (0.67 -0.90) 0.60 (0.48 – 0.75) 
30-60 
ECC- 3.5 1.0 0.41 
ECC+ 5.0 1.4 0.79 
PRR* 0.70 (0.64 – 0.77) 0.71 (0.60 – 0.85) 0.52 (0.40 – 0.69) 
<30 
ECC- 4.0 2.3 0.77 
ECC+ 5.4 2.5 1.4 
PRR* 0.76 (0.59 – 0.96) 0.92 (0.66 - 1.27) 0.56 (0.32 – 0.98) 
30-39 
ECC- 3.5 1.5 0.73 
ECC+ 5.3 2.3 1.4 
PRR* 0.66 (0.56 – 0.78) 0.64 (0.50 – 0.83) 0.51 (0.36 – 0.74) 
40-49 
ECC- 3.5 0.81 0.33 
ECC+ 4.8 1.1 0.54 
PRR* 0.74 (0.64 – 0.84) 0.76 (0.57 – 1.02) 0.62 (0.40 – 0.97) 
50-59 
ECC- 3.5 0.74 0.12 
ECC+ 5.0 0.70 0.25 
PRR* 0.71 (0.59 – 0.85) 1.06 (0.70 – 1.63) 0.50 (0.18 – 1.38) 
60 
ECC- 4.0 1.5 1.4 
ECC+ 3.6 0.85 0.55 
PRR* 1.09 (0.77 – 1.54) 1.81 (1.00 – 3.25) 2.59 (1.37- 4.91) 
* PRR= prevalence rate ratio (95% CI) 
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Table 4:  Adjusted prevalence and prevalence rate ratio (PRR) for ASCUS+, LSIL+ and HSIL+ in ECC- 
versus ECC+ smears, considering recurrent ECC- as not repeated. 
 
  % ASCUS+ % LSIL+ % HSIL+ 
All 
Ages 
ECC- 4.4 1.3 0.58 
ECC+ 5.0 1.5 0.84 
PRR* 0.88 (0.82-0.95) 0.88 (0.76-1.01) 0.68 (0.55-0.85) 
30-60 
ECC- 4.3 1.2 0.48 
ECC+ 5.0 1.4 0.79 
PRR* 0.87 (0.80-0.94) 0.84 (0.71-0.99) 0.61 (0.47-0.78) 
<30 
ECC- 4.7 2.7 0.83 
ECC+ 5.4 2.5 1.4 
PRR* 0.88 (0.70-1.09) 1.08 (0.80-1.46) 0.61 (0.36-1.04) 
30-39 
ECC- 4.2 1.7 0.82 
ECC+ 5.3 2.3 1.4 
PRR* 0.78 (0.67-0.91) 0.74 (0.58-0.94) 0.58 (0.41-0.82) 
40-49 
ECC- 4.5 1.0 0.40 
ECC+ 4.8 1.1 0.54 
PRR* 0.93 (0.83-1.05) 0.92 (0.70-1.20) 0.74 (0.49-1.13) 
50-59 
ECC- 4.5 0.93 0.15 
ECC+ 5.0 0.70 0.25 
PRR* 0.91 (0.77-1.07) 1.33 (0.91-1.95) 0.63 (0.25-1.56) 
60 
ECC- 4.8 1.7 1.5 
ECC+ 3.6 0.85 0.55 
PRR* 1.33 (0.97-1.82) 1.94 (1.09-3.43) 2.79 (1.50-5.20) 
* PRR= prevalence rate ratio (95% CI) 
 
 
Discussion 
 
The prevalence of squamous abnormalities found in  women with ECC+ smears amounts 
approximately three times the prevalence of these lesions in ECC- smears. This is in 
concordance with other published results. Bos et al. 3 reported a proportion of abnormalities 
in ECC+ smears amounting twice that of ECC- smears. Vooys et al.  8 found three times more 
HSIL+ in ECC+ smears as compared to ECC-. Martin-Hirsch et al. 12 reported a two- to three-
fold detection rate in ECC+ smears in contrast with ECC- smears. These results might be the 
effect of a reduced sensivity of ECC- smears in detecting squamous abnormalities, as 
suggested in most references. However a truly lower prevalence of these lesions in women 
with ECC- can also explain the difference. Therefore we calculated an estimate of the 
prevalence of ASCUS+, LSIL+ and HSIL+ in women with ECC- smears after correction for false-
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negative ECC- smears (adjusted prevalence). Results show that the adjusted prevalence of 
HSIL+ is significantly lower in women with ECC- as compared to ECC+ smears for age-
categories all ages and 30-60 years, being the population screening program age range 
[PRR= 0.60 (0.48-0.75) and PRR= 0.52 (0.40-0.69) respectively]. Addition of less severe 
abnormalities (ASCUS+ and LSIL+) to the analysis resulted in less lower adjusted PRR’s. There 
was one age-category showing opposite results. Women over 60 years showed more 
abnormalities having an ECC- smear, with the strongest effect seen in HSIL+. For this group of 
women a PRR= 2.59 (1.37-4.91) for detection of HSIL+ in ECC- was found. Closer examination 
of the category HSIL+ in ECC- in these older women showed that most of the lesions (seven of 
10) were diagnosed as squamous cell carcinoma. It is likely that taking a smear from a 
carcinoma results in a smear without endocervical cells since the transformation zone is 
replaced by tumor. A reason might also be less accurate reporting of endocervical cells in 
these cases. All other age-categories showed lower adjusted prevalence’s of squamous 
abnormalities in ECC- as compared to ECC+ smears. However the number of cases in some 
age-strata were too small to show significant differences.  
 
The calculation method used in this study to determine the prevalence of abnormalities in 
ECC- smears can result in too low an estimate of the number of abnormalities in ECC- smears, 
since the repeat-smear after a negative ECC- can be a recurrent negative ECC- smear. One 
might state that a ECC- smear is inadequate for detection of cervical lesions and therefore 
women with recurrent negative ECC- smears at follow-up should be excluded from the group 
of women with follow-up after an initial ECC- smear. On the other hand, it is important to 
remember that ECC- smears are capable in detecting at least some squamous lesions, as 
shown in table 1. Exclusion of women with recurrent negative ECC- smears from the group 
with follow-up results will then again provide a too high estimate of the true prevalence of 
cervical abnormalities. In this respect we calculated also the adjusted prevalence in ECC- 
with exclusion of women having recurrent ECC- repeat-smears. An overview of thus 
calculated adjusted prevalence’s in ECC- is given in table 4. Though probably too high, the 
adjusted prevalence rate ratio’s for all ages and 30-60 are still significantly lower than one for 
ASCUS+, LSIL+ (30-60 years). For the most risk full category HSIL+ the prevalence rate ratios 
amounts PRR=0.68 (0.55-0.85) and PRR=0.61 (0.47-0.78) for all ages and 30-60 years 
respectively. We conclude that, after correction for false-negative ECC- smears, the true 
prevalence of cervical abnormalities in women with an ECC- smear is significantly lower as 
compared to women with an ECC+ smear and thus this group represents a low-risk subset.  
 
This applies especially for severe lesions (HSIL+). The lower prevalence of abnormalities in 
women with ECC- smears as found in this study, suggests that women in the ECC- sub-
category are less susceptible to external stimuli such as HPV infections. This might be caused 
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by  a TZ, located higher in the endocervical canal or a TZ, which is transformed in a less 
sensitive epithelium through the squamous metaplastic pathway. 
 
The results presented in this study support the management of ECC- smears as proposed by 
the Bethesda 2001 System. In case of limited resources there can be little justification for 
advising women at low risk to have a repeat smear. Resources can be better aimed at high 
risk categories.  As a consequence early repeat testing of ECC- smears has recently been 
halted in the Dutch sceening program. Because of the anatomy of the TZ it is however of 
importance to continue to register the presence or absence of endocervical and squamous 
metaplastic cells for monitoring the quality of the performance of the smear-taker. 
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Abstract 
 
The objective of this study was to determine whether postmenopausal asymptomatic women 
with normal endometrial cells in their smear are at higher risk for endometrial pathology 
compared with women without these cells.  
Histological follow-up outcome and otherwise cytological follow-up of 29,144 asymptomatic, 
postmenopausal women was determined. Presence of normal endometrial cells, age, use of 
hormones and reported elevated maturation index were assessed. Impact of each variable 
on outcome as well as the combined effect was evaluated.  
Prevalence rate of (pre)malignant uterine disease was significantly higher when normal 
endometrial cells were found in the cervical smear (6.5%) as compared to smears without 
these cells (0.2%), resulting in a relative risk of 40.2 (95% CI 9.4 – 172.2). Neither age nor 
hormone use nor elevated maturation index showed significant impact the outcome.  
Asymptomatic postmenopausal women with normal endometrial cells in their smear are at 
significant higher risk for (pre)cancerous endometrial lesion than women without these cells. 
These cases should be reported to the physician with an explicit comment that normal 
endometrial cells in a smear of a postmenopausal woman is an abnormal finding, possibly 
associated with significant endometrial pathology. It raises the question whether further 
gynecological examination would be more appropriate.  
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Introduction 
 
In the Netherlands, endometrial adenocarcinoma is the most common malignancy of the 
female genital tract and the fourth most common cancer in females. With an incidence of 19 
cases per 100,000 this disease accounts for 1400 new cases and 400 deaths each year. The 
incidence of endometrial carcinoma rises with increasing age. Therefore, most endometrial 
carcinomas are found in postmenopausal women. 1 Besides age, unopposed estrogenic 
stimulation due to obesity or exogenous hormone use and diabetes are associated with 
endometrial carcinoma. Atypical endometrial hyperplasia is considered as a precursor lesion 
of endometrial carcinoma. 2 
 
Even though the cervical smear is a poor screening tool for detection of endometrial 
carcinoma because of its low sensitivity (25% - 55%) 3, a cervical smear may provide 
important diagnostic information when atypical endometrial cells are detected. It has been 
shown that the presence of atypical endometrial cells has a significant correlation with 
significant endometrial disease (20 % - 55 %) 3-5. However, the clinical significance of normal 
appearing endometrial cells in symptomatic as well as asymptomatic postmenopausal 
women has been subject of debate 6-8. It has been claimed that detection of normal 
appearing endometrial cells in cervical smears of symptomatic postmenopausal patients has 
little, if any impact on subsequent patient management 6,8. Finding these cells in smears of 
asymptomatic postmenopausal women, however, may lead to a diagnostic dilemma. 
Though the majority of patients with endometrial carcinoma or its precursor lesions are 
symptomatic at an early stage of the disease and present with abnormal uterine bleeding, 
asymptomatic patients with atypical hyperplasia or endometrial carcinoma have also been 
reported in frequencies varying from 2 % to 25 % 3,6,7,9-11.  
 
The Bethesda 2001 System 17 recommends the reporting of normal appearing endometrial 
cells in all women from the age of 40 onward, with an optional educational comment that 
endometrial cells after menopause may be associated with benign endometrial changes, 
hormonal alterations and, less commonly, endometrial abnormalities. In these cases, clinical 
correlation is recommended.  
 
In the Netherlands the guideline on cervical screening, as it is currently used, advocates the 
reporting of normal endometrial cells. In postmenopausal women a recommendation to the 
smear taker is added: in the presence of clinical symptoms that are associated with 
endometrial pathology, further gynecological investigation is advised. This was underscored 
by an additional alerting PAP classification PAP 3a (equivocal cytological findings or mild to 
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moderate abnormalities are found). However, recently this has been adjusted to PAP 1 (no 
abnormalies found).  
 
This study focuses on the diagnostic dilemma arising when normal endometrial cells are found 
in cervical smears of asymptomatic postmenopausal women (EM+). The first aim was to 
examine the prevalence rate of endometrial (pre)malignancy in these women. 
 
In most other studies, the prevalence rate of (pre)malignancy in the study population is 
provided but the findings are not related to a control group, that is to say postmenopausal 
women without endometrial cells in their smear (EM-). Therefore, the second aim of this study 
was to compare the prevalence rate of (pre)malignancy in asymptomatic postmenopausal 
women with normal endometrial cells in their smear (EM+) with the prevalence rate in women 
without these cells (EM-) in terms of prevalence rate ratio (PRR: prevalence rate in EM+ / 
prevalence rate in EM-). This reflects the relative risk (RR) for the presence of a (pre)malignant 
endometrial lesion when normal endometrial cells are found in the smear of an 
asymptomatic, postmenopausal woman.  
 
Interacting variables such as increasing age, use of exogenous hormones (hormone 
replacement therapy (HRT)) and elevated maturation index (MI) of squamous cells in the 
smear have been described earlier 3,10-14. Therefore, we examined the individual impact of 
these variables on the outcome as well as their combined effect on the PRR.   
 
 
Materials and Methods 
 
The results of 29,798 smears of women, participating in the Dutch cervical screening program 
and who were indicated as postmenopausal on their cytology requisition form (last 
menstruation more than one year ago) were retrieved from the files of the National 
Pathology Database (Pathologisch Anatomisch Landelijk Geautomatiseerd Archief: PALGA). 
All these smears were taken from the cervix and were considered as the initial smear.  
 
All women in the Netherlands are invited to participate in the screening program every 5 
year, starting on their 30th till they reach the age of 60. In case in the intervening 5-years 
period gynecological complaints arise, the woman is examined outside the screening 
program as a symptomatic patient. In this study screenees were, by definition, considered 
asymptomatic unless gynecological complaints or abnormal uterine bleeding were reported 
by the smear taker. On the requisition form this item is explicitly inquired. The Cervex-Brush® is 
the standard sampling device, used in the screening program. All cervical smears were 
 
Normal endometrial cells in smears of asymptomatic postmenopausal women 59 
 
diagnosed in one of the three regional pathology laboratories in East-Netherlands in a 6-year 
period (1997-2002). The retrieved results included case history with cytological as well as 
histological follow-up. The cytological records of the initiating smear were investigated for 
reported normal appearing endometrial cells in the diagnosis and classified EM+ when these 
cells were indicated and EM- when not indicated. Cytologically detected abnormal 
endometrial cells in the initial smear as well as concurrently recorded gynecological 
complaints or abnormal uterine bleeding was assessed. In 641 cases, gynecologic complaints 
or abnormal uterine bleeding was indicated on the requisition form. These cases were 
considered symptomatic and therefore excluded. Thirteen cases with abnormal endometrial 
cells were excluded also. The remaining 29,144 cases were eligible for the study.  
 
Follow-up was categorized in 4 groups: 1. no follow-up results present, 2. only negative follow-
up smears (smears without endometrial cells) present, 3. histological follow-up, obtained 
within 18 months after the initial smear, showing normal or benign endometrial pathology 
(endometrial polyps, leiomyomata, simple or complex hyperplasia without atypia) and 4. 
histological follow-up, obtained within 18 months, showing (pre)cancerous endometrial 
lesions (atypical endometrial hyperplasia and endometrial adenocarcinoma or sarcoma). In 
cases with both histology as well as follow-up smears, only histology was counted. Histology 
was evaluated for a follow-up period of eighteen months in order to maintain a clear 
correlation between the initial smear and the consecutive histology. 
 
Women with inconclusive or inadequate endometrial samples were evaluated by means of 
the results of their follow-up smears. Cases with normal histology or benign pathology as well 
as the cases with only negative follow-up smears were classified as outcome category A 
(outcome: normal/benign). Cases with histologically diagnosed endometrial (pre)malignancy 
were classified as outcome category B (outcome: (pre)malignant). Women without any kind 
of follow-up were excluded from analysis.  
 
From the reports of the initial smears, use of exogeneous hormones (hormone replacement 
therapy (HRT)), diagnosed elevated maturation index of the squamous cells and the age at 
the time of initial smear taking was assessed. Further on, age was categorized in younger 
than 55 years and 55 years and older. Elevated maturation index of the squamous cells was 
dichotomous (high maturation index reported (HM+) / not reported (HM-)). Use of 
exogeneous hormones (HRT) was categoric (HRT-, HRT+ and HRT unknown). 
 
Univariate analysis was first performed for calculation of prevalence rate of (pre)malignancy 
in EM+ and EM- as well as the prevalence rate ratio (PRR) and 95% confidence interval.  
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To stage the impact of age, HRT and HM on endometrial outcome, univariate analysis was 
performed for each of them. For assesment of combined impact of the variables, logistic 
regression analysis was applied. All statistical analyses were performed using SPSS software. 
 
 
Results 
 
During the 6-year study period, diagnoses of initial smears of 29,144 asymptomatic, 
postmenopausal women were evaluated for reported normal endometrial cells. Depending 
on the presence of histological or cytological follow-up, cases were categorized in four 
follow-up categories as shown in table 1.  
 
 
Table 1:  Follow-up and outcome categories of 29,144 asymptomatic, postmenopausal women 
 
Outcome 
category - 
Normal/Benign 
(A) 
(Pre) malignant 
(B) Total 
Follow-up categories no follow-up* 
negative follow-up 
smears* 
normal/benign 
histology* 
(pre) malignant 
histology*  
Asymptomatic / EM+ 25 (44.6) 23 (41.1) 6 (10.7) 2 (3.6) 56 (100.0) 
Asymptomatic /  EM- 21,613 (74.3) 7,282 (25.0) 181 (0.6) 12 (0.04) 29,088 (100.0) 
All asymptomatic 
cases 21,638 (74.2) 7,305 (25.1) 187 (0.6) 14 (0.05) 29,144 (100.0) 
* number (percentage) 
 
Two hundred one women (0.6 %) had histological sampling. A quarter (25.1 %) had at least 
one negative follow-up smear with a mean of 2.3 years between the initial smear and last 
negative smear, during which obviously no serious gynecological complaints developed, 
which provoked histological evaluation. Three out of four women (74.3 %) did not have any 
kind of follow-up. This is not surprising since the screening interval in the Netherlands is 5 years 
while the total follow-up period examined, was 3.2 years on average (range 0.7 – 6.7 years). 
Moreover, for a considerable part of the women the initial smear was the last smear taken 
within the cervical screening program since they had reached the age of 60 years. 
 
Fifty-six women had normal endometrial cells reported in their initial smear. In these cases 
follow-up was performed more often. Eight of these women (14.3 %) were evaluated with 
histology, 23 women (41.1 %) had routine follow-up smears while 25 women (44.6 %) had no 
follow-up results in their case history.  
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Normal endometrial cells were detected in only 0.2 % (56 out of 29,144) of the initial smears 
and was therefore a rather uncommon finding. 
 
In our study population, we were able to identify 14 cases with (pre)malignancy, diagnosed 
histologically within 18 months after the initial smear. At the time of the smear taking these 
women were reported to be asymptomatic. Detailed information on the outcome of the 
histological follow-up of both EM+ as well as EM- is provided in table 2. Two cases of 
(pre)malignancy were found in EM+. Both cases were endometrial adenocarcinomas. EM- 
showed 12 cases of endometrial (pre)malignancies: 8 adenocarcinomas, 3 atypical complex 
hyperplasias and 1 atypical simple hyperplasia. 
 
 
Table 2:  Histological follow-up results of 201 cases of asymptomatic, postmenopausal women 
 
Histologic diagnosis 
EM+ 
n (%) 
EM- 
n (%) Total 
Normal histology 6 (75.0) 100 (51.8) 106 (52.7) 
Endometrial polyps 0 (0.0) 54 (28.0) 54 (26.9) 
Simple hyperplasia without 
atypia 0 (0.0) 25(13.0) 25 (12.4) 
Complex hyperplasia 
without atypia 0 (0.0) 2 (1.0) 2 (1.0) 
Simple hyperplasia with 
atypia 0 (0.0) 1 (0.5) 1 (0.5) 
Atypical complex 
hyperplasia 0 (0.0) 3 (1.6) 3 (1.5) 
Endometrial 
adenocarcinoma 2 (25.0) 8 (4.1) 10 (5.0) 
Total 8 (100.0) 193 (100.0) 201 (100.0) 
 
The prevalence rates for uterine (pre)malignancy in EM+ and EM- as well as the prevalence 
rate ratio (PRR) for EM+ versus EM- are shown in table 3. The prevalence rate of 
(pre)malignancy in EM+ was 6.5 %. In contrast, the prevalence of (pre)malignancy in EM- was 
0.2 % resulting in a RR (or PRR) for EM+ versus EM- of 40.2 (95% CI = 9.4 – 172.2).  
 
To determine which other factors have impact on the outcome (pre)malignancy, univariate 
analysis was performed first (table 3). Variables included EM+ or EM-, age < 55 or ≥ 55 years, 
HRT and diagnosed elevated maturation index (MI). The only relevant variable was found to 
be the finding of normal endometrial cells in the initial smear (p<0.001). Age ≥ 55 years was 
nearly significant (p=0.07). HRT and maturation index were not significant in the univariate 
analysis, although we faced sparse data. 
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Table 3: Univariate analysis of prevalence rates of (pre)malignancy in EM+ and EM- in smears of 7,506 
women with cytologic or histologic follow-up 
 
 Cytologic and histologic follow-up 
 Outcome A 
Normal/Benign* 
Outcome B 
(pre)malignant* 
total 
EM+ 29 (93.5) 2 (6.5) 31 (100.0) 
EM- 7,463 (99.8) 12 (0.2) 7,475(100.0) 
Prevalence rate ratio  40.2 (9.4 – 172.2) #  
P value  < 0.001  
Age < 55 years 3,393 (99.9) 3 (0.1) 3,396 (100.0) 
Age ≥ 55 years 4,099 (99.7) 11 (0.3) 4,110 (100.0) 
P value  0.07  
HRT- 6,140 (99.9) 9 (0.1) 6,149 (100.0) 
HRT+  635 (99.7) 2 (0.3) 637 (100.0) 
HRT unknown 717 (99.6) 3 (0.4) 720 (100.0) 
P value  0.21  
Maturation index:  HM- 7,231 (99.8) 14 (0.2) 7,245 (100.0) 
HM+ 261 (100.0) 0 (0.0) 261 (100.0) 
P value  0.48  
* number (percentage) 
# PRR (95% CI) 
   
 
 
Finally a multivariate forward stepwise logistic regression analysis was performed to 
investigate combined impact of the other variables. Presence of normal endometrial cells 
appeared to be the sole prognostic parameter predictive of endometrial (pre)malignancy. 
 
 
Discussion 
 
Although the cervical smear is not the first test of choice for the detection of endometrial 
abnormalities, cytologically detected endometrial cells may provide useful information. This is 
especially true for abnormal endometrial cells. The significance of normal appearing 
endometrial cells in smears of postmenopausal women is still debated. Some studies found a 
clear association between the presence of normal epithelial endometrial cells in smears of 
both symptomatic and asymptomatic postmenopausal women and uterine (pre)malignancy 
3,5,7,10,11,13,15. Other studies however, failed to demonstrate this association or found that the 
presence of these cells had no consequences with regard to patient management since 
most of these patients presented with clinical symptoms 4,6,8. However, asymptomatic cases 
of endometrial carcinoma or hyperplasia have been reported previously 9,10,13,15. In our study 
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population of asymptomatic, postmenopausal women, we identified 14 cases of uterine 
(pre)malignancy within 18 months after the initial smear, underscoring that not all patients 
with uterine cancer or a precursor lesion are necessarily symptomatic in an early stage of the 
disease. 
 
We chose to include cases with negative follow-up smears (smears without normal or 
abnormal endometrial cells) in outcome category A (normal / benign), together with normal 
or benign histology. This is in contrast with many other studies, where only histological follow-
up is considered conclusive. The rationale for this is that we think that women, who had been 
evaluated with follow-up smears were monitored medically and did not develop alarming 
clinical symptoms in that specific period that would have provoked invasive endometrial 
sampling. Therefore we think it is valid to assume that these cases have a normal clinical 
outcome. A second reason is the possibility of introducing a selection bias when using 
histological follow-up results only, as stated by Chang et al. 16 and Mount et al. 12. Cases that 
were found to be at higher risk during follow-up are evaluated by endometrial sampling. In 
contrast, cases that are less likely to have endometrial disease during follow-up are excluded 
from analysis, resulting in a biased outcome. Though we tried to minimize selection bias, we 
cannot exclude this completely, since EM+ was examined more extensively with follow-up as 
compared to EM-. 
 
The finding of normal endometrial cells in our postmenopausal asymptomatic study 
population is a rather uncommon finding. We only found 56 cases EM+ in a population of 
29,144 women (0.2 %). This is in line with other studies, where normal endometrial cells were 
found in low proportions also (Sarode et al.14: 0.24 %, Cherkis et al.7: 0.23 %, Mount et al.12: 1.1 
%). The higher proportion EM+ smears in the study of Mount et al. was probably related to a 
high frequency of women who took HRT. 
 
In this study, (pre)malignant uterine disease was found in 6.5 % of the women who were 
diagnosed with normal endometrial cells in their smear (EM+). In order to facilitate 
comparison of the results of the present study with the outcomes of other studies, a review of 
proportions of (pre)malignancies found in other studies is provided in table 4. In the studies 
shown, the reported endometrial (pre)malignant disease in asymptomatic postmenopausal 
women with EM+ smears ranges 0.0 % - 5.4 %. The prevalence rate of (pre)malignant 
endometrial disease found in our study population corresponds fairly well with the results of 
some earlier studies, with exception of the studies performed by Gomez-Fernandez et al6 and 
Ashfaq et al 8. Both were unable to demonstrate any cases of (pre)malignancy in 
asymptomatic women with EM+ smears. The authors concluded that reporting of normal 
endometrial cells had no clinical relevance and could in fact account for a diagnostic 
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dilemma. This conclusion cannot be supported by the outcome of the present study where 
6.5 % of asymptomatic postmenopausal women with normal endometrial cells in their smears 
were diagnosed with endometrial adenocarcinoma within 18 months.  
 
 
Table 4:  Results of other studies correlating normal endometrial cells (EM+) in smears of 
postmenopausal, asymptomatic women with endometrial pathology 
 
 Follow-up 
clinical, cytological or histological evaluation  
Reference (pre)malignancy 
n (%) 
Total 
n 
Chang et al., 2001 16 2 (1.0) 217 
Ashfaq et al., 2001 8 0 (0.0) 24 
Gomez-Fernandez et al., 1999 6 0 (0.0) 24 
Siebers (present study) 2 (6.5) 31 
 Follow-up 
endometrial histology 
Reference (pre)malignancy 
n (%) 
Total 
n 
Montz, 2001 13  5 (5.4) 93 
Kerpsack et al., 1998 9 1 (3.6) 28 
Ng et al.,1974 15 6 (4.3) 140 
 
As it stands, the prevalence rate of (pre)malignant disease in EM+ is not particularly 
informative. To put the significance of normal endometrial cells in smears of postmenopausal, 
asymptomatic women into perspective, the prevalence rate in EM+ should be related to 
prevalence rate in EM-, resulting in PRR or RR  of EM+ for finding severe endometrial 
pathology. To our knowledge, the only other study using EM- as control group is the study 
described by Chang et al. 16. In this study, we also provide the RR of EM+ for (pre)malignant 
outcome. The RR is the risk of (pre)malignant uterine disease in the presence of normal 
endometrial cells in the cervical smear (EM+) compared with those without these cells. As 
shown in table 3 the RR was found to be 40.2 (95% CI 9.3 – 172.2). Chang et al. 16 found a 
relative risk of 5.36 (95% CI 1.3 – 22.1). However, their study population comprised not only 
asymptomatic women, but also symptomatic women and moreover their study population 
had another age distribution as 40 % of their cases was 60 years and older.  
 
Univariate analysis shows that neither HRT, nor cytologically diagnosed elevated maturation 
index had a significant impact on the detection of uterine (pre)malignancy. Age showed a 
borderline significance. This is surprising since age is known to be an important risk factor for 
severe endometrial pathology. Our study population, however, comprises a relative young 
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population, due to the nature of the selected cases. All women were screenees participating 
in the Dutch screening program. These women had their last invitation when they reached 
the age of 60 years. The effect of age might be more strongly marked when evaluating 
women of 60 years and older. However, we could not reliably define an asymptomatic study 
population older than 60 years.  
 
We found that the finding of normal endometrial cells in smears of asymptomatic, 
postmenopausal screenees results in a high relative risk (40.2) for the detection of atypical 
hyperplasia or endometrial carcinoma. Focusing on only endometrial adenocarcinoma as 
primary outcome the relative risk was found to be even higher. There is a 60 times greater 
probability of detecting endometrial carcinoma for EM+ than for EM- (95% CI 13.3 – 273). This 
is the result of the fact that both cases of (pre)malignancy in EM+ were endometrial 
carcinomas whereas only 8 out of the 14 cases of (pre)malignancies found in EM- were 
diagnosed as adenocarcinoma. The risk for detection of any kind of endometrial abnormality 
whatsoever (endometrial polyps, leiomyomata, hyperplasia with or without atypia or 
endometrial malignancy) was in our study population 5.2 higher (95% CI 1.3 – 20.1) for EM+ 
than for EM-.  
 
In the guidelines of the Dutch Screening program, the finding of normal endometrial cells in 
smears of postmenopausal women does not prompt the physician to further evaluation. 
Nevertheless, a specific comment is given, recommending further gynecologic investigation 
when a patient has or develops complaints that are suspicious for endometrial pathology, 
such as abnormal bleeding. The results of this study however show that 6.5 % of asymptomatic 
postmenopausal women with EM+ are diagnosed within 18 months as having endometrial 
(pre)malignancy and that the risk for detection of such lesions is up to 40 higher for EM + as 
compared to EM-. This underscores the importance of reporting the presence of normal 
endometrial cells in cervical smears of asymptomatic women in their postmenopause. 
Moreover, the question may arise whether direct examination of these women by a 
gynecologist would be preferable. This study shows that the prevalence of normal appearing 
endometrial cells in an asymptomatic, postmenopausal screening population is very low and 
therefore the number of women, referred for further evaluation would be limited. In addition, 
the results also indicate that the relative risk for endometrial (pre)malignancy is significant. 
Unfortunately, the relative small number of events may limit the validity of the results of the 
present study. However, it is our opinion that the results confirm the importance of making a 
clear statement to the physician that the finding of normal endometrial cells in a smear of a 
postmenopausal woman, even when she is asymptomatic, is an abnormal finding that may 
be associated with significant endometrial pathology. A definite conclusion whether it would 
be appropriate to refer these asymptomatic postmenopausal women for gynecological 
 
66 Chapter 3 
 
evaluation based on the finding of normally appearing endometrial cells would have to be 
determined by a more extensive study.  
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Abstract 
 
Borderline cytological abnormalities are diagnosed in high frequencies but have limited 
predictive value for high-grade cervical lesions, resulting in high costs, patient’s anxiety and 
over treatment. A conservative management strategy for the Dutch diagnostic equivalent of 
borderline nuclear changes (BNC) was introduced in The Netherlands in 1996, with repeat 
cytology at 6 and 18 months and referral for colposcopy if BNC is persistent. The objective 
was to analyse compliance with the current guidelines for referral, as well as the outcome 
after repeated BNC. Concurrently we investigated whether other variables are predictive for 
high-grade lesions.  
We retrieved 1,898 eligible cases of repeated BNC with 4 years follow-up from the national 
pathology database (PALGA) and performed a nationwide survey.  
The management strategy for women with repeated BNC in The Netherlands has been 
accepted and supported. Seventy-seven percent (77%) of the patients had visited a 
gynaecologist within one year and only 4.3% were lost to follow-up. We found that 25.2 % of 
the patients had a low-grade lesion or worse (CIN 1+)  and 10.2 % had a high-grade lesion or 
worse (CIN 2+), among which were four malignancies. The only variable associated with CIN 
or worse was age. Women under 40 years were found to be at higher risk. This finding may be 
used for prioritizing women for colposcopy on basis of their age. More stringent use of the 
diagnosis of BNC, higher thresholds for colposcopically directed biopsy and introduction of 
HPV triage, combined with more specific new techniques or combination of techniques such 
as molecular markers for P16, MIB-1 and L1 may reduce the unnecessary high referral rate 
and over treatment of healthy women. 
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Introduction 
 
Cytological screening of the uterine cervix aims at the detection and treatment of 
premalignant and early invasive lesions in order to reduce mortality from cervical cancer. The 
quality of a screening program depends among others on an acceptable ratio between 
positive and negative – or unintended – effects. A well-known negative effect is over 
treatment caused by false positive test results. 
 
Equivocal cytological abnormalities such as borderline nuclear changes (BNC) from the UK 1  
and atypical squamous cells of undetermined significance (ASC-US) and atypical glandular 
cells (AGC) from Bethesda 20012 account for considerable proportions of false positive results 
2-13. While being least predictive for high-grade lesions, these equivocal abnormalities are 
usually found in high proportions 3,4,6,7. ASC-US is defined as “cytologic changes that are 
suggestive of a squamous intraepithelial lesion, but lack criteria for a definitive interpretation” 
2 where as BNC is used in cases where “the pathologist has genuine doubt as to whether or 
not the cells are dyskaryotic” 1.  
 
Strategies for management of equivocal abnormalities vary from country to country, but are 
all aiming at the reduction of the number of patients receiving unnecessary treatment. 
Immediate colposcopy, with or without resection, conservative management with 
cytological follow-up and HPV triage are the most applied strategies 3,10,13-16. 
 
The Dutch equivalent of BNC and ASC-US / AGC is PAP 2, an additional class provided in the 
Dutch CISOE-A classification system 17 and used within the national screening program. 
Historically the proportion of PAP 2 exceeded 10 %, since inflammatory cellular changes were 
also included in this category 18,19. These women were seen every 12 months for a repeat 
smear until a negative smear was obtained, or until they were referred to a gynaecologist 
when the abnormality progressed to a high-grade lesion. The result was that the Dutch 
cervical screening program was considered highly inefficient and cost ineffective by the 
Dutch Health Care authorities. As a consequence, the screening program was reorganized in 
1996. A major change concerned the redefinition of equivocal cytological abnormalities 
(PAP 2) with more precise criteria 1,20, corresponding with Bethesda’s ASCUS and the British 
BNC. The main goal was to decrease the proportion PAP 2 and concurrently increase the 
positive predictive value of this cytological diagnosis 18. At the same time the management 
of these abnormalities was changed. For triage of these women, a conservative 
management with repeat cytological testing was chosen: women with an initial BNC test 
result are advised to have a repeat test after 6 and 18 months, taken by the general 
practitioner (GP) (figure 1). When this repeat test shows persisting or progressing abnormality, 
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the patient will be referred to a gynaecologist for colposcopic evaluation. When colposcopy 
is abnormal, a directed biopsy is performed and when colposcopy proves normal the patient 
is referred back to the GP. 
 
At the time of introduction of the new management guidelines, Dutch gynaecologists feared 
overloading of their colposcopy clinics with women with persistent equivocal abnormal 
cytology, not harbouring any significant cervical lesions. General practitioners (GPs) were also 
sceptical about the benefit of referring women with repeated BNC results for colposcopy and 
some were even reluctant to do so. This major change in the cervical screening program has 
now been implemented for several years but until now the compliance with the current 
guidelines for referral and the outcome after repeated BNC have not been evaluated 18, 
whilst good follow-up compliance is one of the critical elements for adequate performance 
of cervical screening 21,22. 
 
First repeat smear after 6 months
Initial BNC
Normal LSIL or morePersisting BNC
Second repeat smear 
after 12 months
Referral to gynaecologist for 
colposcopic directed biopsy 
and / or treatment
BNC or moreNormal
Return to screening program
GP’s
Figure 1: Management of borderline nuclear changes (BNC) in the Netherlands
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We undertook this study to  
1. determine the compliance of GPs to refer women with repeated BNC results for 
colposcopy  
2. evaluate the significance of repeated BNC by determining the detection rate of CIN 1 
or worse (CIN 1+: CIN 1, CIN 2, CIN 3 and carcinoma) and CIN 2 or worse (CIN 2+: CIN 2, 
CIN 3 and carcinoma)  
3. concurrently investigate the value of other predictors for CIN 1+ or CIN 2+ in patients 
with repeated BNC Pap tests including age 8,11,23,24, cytological type of borderline 
abnormality 4,25-28, concurrent infection or inflammation (among which HPV-associated 
cellular changes) 27,29,30, reported clinical symptoms and prior smear history of the 
patient 28. 
 
Study Population 
 
The patient population was retrieved from the national pathology database (PALGA), a 
nationwide network for registry of histology and cytopathology in The Netherlands. Since 1990 
every pathology department in The Netherlands supplies this database with all their cytology 
and histology results. Women advised to visit a gynaecologist, based on a repeated 
cytological diagnosis PAP 2 (BNC) in 2000 (n=2,885) were selected from PALGA. This included 
case history with an average of 4 years of follow-up results (range 3.75 years – 4.75 years). 
Women who had the cytological diagnosis CIN 1 or worse in the previous 5 years and who 
were not evaluated histologically, and thus not treated for the lesion, were excluded. Cases 
with persistent borderline test results that had been taken by a gynaecologist were excluded 
also. This was done because we were interested in incident cases with persistent BNC that 
had been obtained by a GP, in order to also assess the GP referral compliance in The 
Netherlands. This resulted in 1,898 cases eligible for analysis.  
 
Methods 
 
For evaluation of the adherence to the current guidelines for referral, the cases were 
categorized, based on histological or cytological follow-up results: 
 
1. adequately referred patients: patients who were examined by a gynaecologist in the 
first year, following the second BNC result by means of histological sampling or 
cervical smear taking; 
2. referral unknown: neither histology nor cytology that had been taken by a 
gynaecologist within the first follow-up year was found; 
3. no follow-up: patients without any follow-up results in the 4 years period. 
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Follow-up histology of the uterine cervix was used for assessment of the outcome after 
repeated BNC. However, when no histology was obtained, the result of the last follow-up 
cytology was used as the outcome. Patients with more than one histology result had their 
outcome based on the most severe (highest grade) histological diagnosis. Cases with 
histologically proven CIN 1 or worse and CIN 2 or worse as well as cases without histology but 
with a final cytological diagnosis consistent with CIN 1 or worse or CIN 2 or worse were 
classified CIN 1+ and CIN 2+ respectively.  
 
Finally, for identification of other variables impacting on the outcome, the following 
parameters were assessed and classified: age (in decades) at the time of the second BNC 
result, type of atypical cells (atypical squamous cells, atypical metaplastic cells or atypical 
glandular cells), concurrent inflammatory disease or infection, diagnosed in the second BNC 
smear (bacterial, viral (HPV associated changes), other micro-organisms (monilia or 
trichomonas), non-specific inflammation), clinical symptoms as these had been reported by 
the GP as well as the number of smears taken prior to the second BNC test result (1, 2-5 or >5). 
These parameters were used for univariate and logistic regression analysis with SPSS in order to 
identify relevant and independent risk factors.  
 
 
Results 
 
The study population comprised 1,898 women who had their smears taken by a general 
practitioner and who were advised to visit a gynaecologist based on repeated BNC test 
results. Characteristics of the study population are displayed in table 1. Mean age was 44.1 
+/- 9.1 years, with median age of 45 years at the time of the second BNC diagnosis. In 68.4 % 
of the cases the second BNC diagnosis was based on the finding of atypical squamous cells. 
In 27.7 % this was based on atypical metaplastic cells. Only 3.9 % had repeated atypical 
glandular cells (AGC). Concurrent specific infection (HPV, bacterial or other infection (monilia 
or trichomonas)) was found in 19.2 % (364 out of 1,898) of the patients, among which 183 
cases with cellular changes suggestive for HPV-infection (9.6 %). However, in most samples 
(54.6 %) no signs of inflammation or infection were found. Clinical complaints had been 
reported in 13.0 % of the cases at the time that the second BNC smear was taken. The mean 
number of cytological examinations, taken prior to the second BNC smear, was 5.8. Most 
women had 2-5 previously performed Pap tests in their history.   
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Table 1: Descriptive statistics of the 1,898 cases in the study population at time of the second BNC 
smear 
 
2nd BNC Years (sd) % (n) 
Age    
Median 45.0   
Mean (sd) 44.1 (9.1)   
10-19  0.2 (4) 
20-29  3.7 (71) 
30-39  24.5 (465) 
40-49  40.9 (776) 
50-59  25.3 (481) 
60-69  5.0 (95) 
70-79  0.3 (6) 
Cytological type of diagnosed atypical cells   
Atypical squamous cells   68.4 (1,299) 
Atypical metaplastic cells  27.7 (525) 
Atypical glandular cells  3.9 (74) 
Inflammatory disease     
Signs of HPV-infection  9.6 (183) 
Bacterial infection  6.9 (131) 
Other infections  2.6 (50) 
Non-specific inflammation  26.2 (497) 
No inflammation or infection  54.6 (1,037) 
Clinical symptoms    
Reported  13.0 (247) 
Not reported  87.0 (1,651) 
Number of preceding smears    
Median 5.0   
Mean (sd) 5.8 (4.5)   
< 2  10.7 (203) 
2-5  49.0 (930) 
> 5   40.3 (765) 
  
 
As shown in table 2 one thousand four hundred and seventy four (1,474) women visited a 
gynaecologist within a year, resulting in an adequate referral rate of 77.7 % (1,474 out of 1,898 
women). Follow-up of 343 patients showed neither histology nor cytology had been taken by 
a gynaecologist within the first year. It is unknown whether these patients had been visiting a 
gynaecologist in the first year and had colposcopy without sample taking or whether they 
were followed by their GP (referral unknown). Only a minority of 81 patients (4.3 %) were lost 
to follow-up. 
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Thus 1,817 cases with either histological or cytological follow-up were eligible for analysis of 
outcome. The outcome after 4 years of follow-up is shown in table 2. Outcome was based on 
histology in 1,151 cases (63.3 %). In the remaining 666 cases (36.7 %) the outcome was based 
on cytology. Outcome CIN 1+ and CIN 2+ comprised almost exclusively of histologically 
confirmed lesions (98.7 % and 98.4 % respectively). Only 6 cases of CIN 1 or worse – among 
which 3 cases of CIN 2 or worse – were diagnosed by cytology without histological 
confirmation. 
 
Overall, CIN 1+ was detected in 25.2 % of the cases (457 out of 1,817).  CIN 2+ was found in 
10.2 % (186 out of 1,817) of the cases. Notably, among these cases were 4 women (0.2 %) 
with carcinoma (one invasive squamous cell carcinoma, two micro invasive squamous cell 
carcinomas and one endocervical adenocarcinoma).  
 
In total 1,151 women underwent histological sampling under colposcopic guidance, of which 
61 % (700) showed histologically no signs of an intraepithelial lesion. These cases represent 
false positives, which had received unnecessary histological sampling. 
 
For identification of other risk factors for outcome CIN 1+ or CIN 2+ after repeated BNC, a 
univariate analysis was performed. The results are shown in table 3. Variables that impacted 
both outcome CIN 1+ as well as CIN 2+ were: age (p < 0.001), the number of Pap tests in the 
prior history (p < 0.001) and concurrently diagnosed infections or inflammatory disease (p = 
0.001 and p = 0.005 for CIN 1+  and CIN 2+ respectively). Cellular changes suggestive for HPV 
infection were associated with outcome CIN 1+ and to a lesser extend with CIN 2+. Type of 
atypical cells was not predictive for CIN 1+ (p = 0.09) or CIN 2+ (p = 0.84). The same was true 
for clinical symptoms as reported by the general practitioner (CIN 1+ p = 0.14; CIN 2+ p = 
0.35). 
 
Logistic regression analysis with age, cytological cell type, concurrently detected infection or 
inflammatory disease, clinical symptoms and number of Pap tests in the medical history as 
independent variables, indicated that the number of smears in the history as well as 
concurrent inflammation or infection were strongly age-related and became insignificant 
when controlled for age. Therefore, age was shown to be the sole relevant variable related 
to outcome CIN 1+ as well as CIN 2+. Younger patients under 40 years of age, were shown to 
be at higher risk of harbouring a clinical relevant cervical lesion. 
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Discussion 
 
The optimal management of BNC is the subject of ongoing discussion. Basically there are two 
conflicting conditions that should be met: on the one hand there is the need to identify as 
much as possible CIN, on the other hand there is the urge to minimize the number of 
unnecessarily treated false positive cases. Various strategies for triaging BNC have been 
proposed. In The Netherlands a conservative management strategy has been chosen in 1996 
with repeat cytological testing after 6 months and 18 months and persistent BNC referred for 
colposcopy. A critical element in this management strategy is an appropriate and high 
follow-up compliance 21,22. The current study aimed at assessing follow-up compliance and 
outcome after repeated BNC results in The Netherlands.  
 
The data, used in the study were retrieved from the national pathology database, which 
contains pathology results from all 70 laboratories for pathology in The Netherlands, thus 
representing the nationwide practice. We showed that in The Netherlands the follow-up 
compliance was very high: only 4.3 percent of the patients with persistent BNC were lost to 
 
Table 3:  Univariate analysis of other risk factors impacting outcome of 1,817 cases 
 
 CIN 1+ CIN 2+ 
 no 
% (n) 
yes 
% (n) 
p-value no 
% (n) 
yes 
% (n) 
p- 
value 
Age category           
10-19 50.0 (2) 50.0 (2)  75.0 (3) 25.0 (1)  
20-29 47.8 (32) 52.2 (35)  76.1 (51) 23.9 (16)  
30-39 61.5 (273) 38.5 (171)  80.9 (359) 19.1 (85)  
40-49 77.9 (580) 22.1 (165) < 0.001 91.7 (683) 8.3 (62) < 0.001 
50-59 85.3 (394) 14.7 (68)  96.3 (445) 3.7 (17)  
60-69 82.2 (74) 17.8 (16)  94.4 (85) 5.6 (5)  
70-79 100.0 (5) 0.0 (0)  100.0 (5) 0.0 (0)  
Cytological cell type           
Atyp. squamous 
cells 
73.4 (912) 26.6 (331)  89.6 (1114) 10.4 (129)  
Atyp. metaplastic 
cells 
77.6 (389) 22.4 (112) 0.09 89.8 (450) 10.2 (51) 0.84 
Atyp.l cylindrical 
cells 
80.8 (59) 19.2 (14)  91.8 (67) 8.2 (6)  
Inflammatory 
disease 
          
HPV 63.5 (106) 36.5 (61)  83.2 (139) 16.8 (28)  
Bacterial 72.7 (88) 27.3 (33)  86.8 (105) 13.2 (16)  
Other 71.4 (35) 28.6 (14) 0.001 81.6 (40) 18.4 (9) 0.005 
Non-specific 79.9 (385) 20.1 (97)  91.3 (440) 8.7 (42)  
None 74.7 (746) 25.3 (252)  90.9 (907) 9.1 (91)  
Clinical symptoms           
No 75.4 (1194) 24.6 (389)  90.0 (1425) 10.0 (158)  
Yes 70.9 (166) 29.1 (68) 0.14 88.0 (206) 12.0 (28) 0.35 
Nr of preceding 
smears 
          
1 62.1 (113) 37.9 (69)  80.8 (147) 19.2 (34)  
2-5 74.1 (655) 25.9 (229) < 0.001 89.9 (795) 10.1 (89) < 0.001 
> 5 78.8 (592) 21.2 (159)  91.7 (689) 8.3 (62)  
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follow-up during a 4-year period. The majority of the patients had no delay in diagnosis (77.7 
%) and visited a gynaecologist within the first follow-up year. This might be an 
underestimation, since referral for colposcopy does not necessarily yield a cytological or 
histological result. A patient may have been referred back to the GP without sample taking in 
case of normal colposcopy, as illustrated in figure 1. The referral compliance rate of at least 
77.7 % as found in the present study is in contrast with the findings of Bos et al.18. Their results 
indicated that less than 50 percent of the women with repeated BNC were referred for 
colposcopy. Their study, however, assessed the referral compliance in 1996, the year in which 
the new management guidelines had been implemented. It is likely that GP’s at that time still 
had to be convinced of the usefulness of referring women for colposcopy after repeated 
BNC. The results of the present study indicate that the current management protocol has 
been accepted to a large extent by GPs. Not only acceptance by GPs, but clear guidelines 
on the management of cervical abnormalities as set on a national level, as well as the use of 
follow-up guidance systems might have influenced the referral compliance positively. The 
effectiveness of the management protocol for BNC, as used in The Netherlands depends to a 
large extend on a high follow-up and referral compliance. The results show that this condition 
has been met.  
 
The diagnostic borderline categories (BNC as well as ASC-US) is not easy to interpret as it may 
reflect a heterogeneous population of abnormalities with a mixture of differently behaving 
biological processes 22. For example, atypia secondary to stimuli other than HPV infection, 
mimicking a cervical lesion and cell populations showing abnormalities that have been 
caused by transient HPV infections may be diagnosed as BNC and account for false positive 
results during follow-up. On the other hand, BNC may also represent sub-optimally sampled 
cervical lesions that may progress or regress, all resulting in different outcomes depending on 
the time of follow-up. Comparison with results of other studies is therefore hampered, also 
because different classification systems are in use. Besides differences in diagnostic 
accuracy, frequency of cytologically detected minimal abnormalities as well as variations in 
prevalence of underlying CIN in study populations and different lengths of follow-up make 
comparison and interpretation difficult.  
 
The results of the present study show that 25.2 % of the cases with repeated BNC results had 
concomitant CIN 1+ or developed this during the 4-year follow-up period. In 10.2 % of the 
cases high-grade lesions (CIN 2+) were found. Among these lesions there were four cases of 
cervical carcinoma (0.2 %). The detection rate of CIN 1+ or CIN 2+ after repeated BNC results 
is provided in only a limited number of other studies, mainly concerning BNC from the UK. 
These studies reported detection rates of CIN 1+ ranging from 34 % up to 80 %. CIN 2+  was 
reported in rates varying from 14.9 % to 35 % 4,5,10,11,27. Another study from The Netherlands 16 
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found an equal proportion of CIN 2+ after two consecutive BNC results (10.0 %) as in the 
present study.  
 
Most other studies provide information on CIN or worse after a single or initial BNC smear. In 
these studies CIN 1+ was found in 10 % - 46 % and CIN 2+ in 1.7 % - 14 % 7,8,9,12,13,20,23,24,26,29,30. 
One study, focusing on atypical squamous metaplastic cells 25 even found  CIN 1+ in 62 % 
and CIN 2+ in 44 %. Carcinoma following a borderline result was reported in only a limited 
number of studies and in low frequencies, ranging from 0.1 % up to 3.8 % 9,12,20,27,29,31.  
 
The detection rate of CIN 1+ as found in the present study is lower as compared to other 
studies that evaluated detection rates after repeated BNC results. Indeed, the detection 
rates we found are more in line with the results from studies that explored outcome after an 
initial BNC result. This was an unexpected finding since we investigated the outcome of a sub-
selection of women with persistent BNC, who are thought to be at increased risk for 
underlying CIN. Despite the clear and more precise criteria for BNC as these had been set on 
a national level within the reorganized national screening program, the diagnostic accuracy 
of BNC in The Netherlands is apparently lower than in other countries, resulting in a relatively 
low predictive value for CIN or worse. Continuing education and monitoring of the predictive 
value of BNC is an important tool to improve the accuracy of this category. As has been 
stated above, diagnostic imperfection is not the sole cause for low accuracy of BNC. 
Prevalence of CIN in the study population, regression and progression of lesions, length of 
follow-up and stringency with which BNC is applied in daily practice, all play a role. In order 
to minimize the influence of variables such as regression rates and length of follow-up, it is 
more appropriate to look at CIN 2+ as outcome, since the regression rate of minimal 
abnormalities and CIN 1 is thought to be very high (47 % - 68 %) 7. However, in The 
Netherlands the detection rate of CIN 2+ after repeated BNC is also relatively low as 
compared to other studies. The question is whether the practice of referring patients with 
repeated BNC is inefficient in The Netherlands. Although more stringent use of BNC could 
improve the predictive value, it is important to keep in mind that, despite the fact that 
detection of a high-grade lesion in only 10 percent of the patients with repeated BNC is not 
very high and thus reflects a relatively low individual risk, the diagnostic category BNC 
accounts for a considerable number of high-grade lesions due to the high frequency of this 
cytological diagnosis. Kinney et al. 32 showed that 39% of the biopsy-confirmed high-grade 
disease was detected in follow-up to ASC-US. Besides the considerable number of cases with 
CIN 2 and CIN 3, we also identified four cases with cervical carcinoma, stressing the 
importance of close follow-up of this diagnostic category. 
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However, the relatively low predictive value of repeated BNC for CIN or carcinoma has a 
major disadvantage. Many women without any cervical lesions are referred for colposcopy, 
leading to considerable anxiety in women and unnecessary costs for society. Beside this, a 
large proportion of these women underwent invasive procedures like histological biopsy and 
LEEP/LLETZ. In our study 1,151 out of 1,817 women with follow-up (63 %) had histological 
sampling of which 700 (61 %) had no abnormality detected. This tremendous over treatment 
is clearly due to the low specificity of colposcopy, since histological samples are taken under 
colposcopic guidance. Using higher thresholds for colposcopy along with continuing 
education may decrease this over treatment of otherwise healthy women. 
 
In the current study, CIN 1+ and CIN 2+ on follow-up of BNC was age dependent and we 
were not able to identify other independent predictors for CIN 1+ or CIN 2+. Cellular changes 
suggestive for HPV infection and other infections of the uterine cervix, as well as the number 
of Pap smears in the medical history were shown to be age related. It is well known that 
prevalence of HPV is higher in young, sexually active women. We found that women under 
40 years are at significantly higher risk for CIN 1+ or CIN 2+ after the diagnosis BNC as 
compared to older women. Age has shown to have prognostic value in other studies also 
3,8,10,11,22,23,24,30,31. Peri- and postmenopausal alterations such as changing hormonal levels may 
result in equivocal atrophic changes in older women and lead to overcalling of otherwise 
normal cellular changes. Selection on age, especially of women older than 40 years of age, 
might prove to be useful in defining a subcategory of patients who are at low risk for CIN 2+ 
and can remain under careful cytological surveillance. 
 
In contrast to other studies, which have reported atypical squamous metaplastic cells and 
atypical glandular cell as high-risk subcategories 3,4,25-28, we found no significant differences in 
outcome between atypical squamous cells, atypical metaplastic cells or atypical glandular 
cells in our study population. Sub typing of the PAP 2 category seems to provide no additional 
value in The Netherlands diagnostic practice.  
 
As the predictive value of BNC is low, it might be useful to triage these women before referral 
for colposcopy with HPV detection 14. HPV triage is undergoing evaluation in The Netherlands 
and may prove to be a cost-effective improvement with substantially lower burden for 
women, as measured by the number of referrals for colposcopy 33-35. However, specificity of 
HPV testing has proven to be low 36,37. Research of other, new techniques or markers for high-
grade disease such as p16INK4A, MIB-1 or HPV L1 capsid protein may also help to improve 
specificity.   
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In conclusion we state that the management protocol for referring women with repeated 
BNC in The Netherlands has been accepted and supported. The observed over treatment of 
healthy women must be reduced. This may be realized by prioritizing women for colposcopy 
on the basis of their age, but also by a more stringent use of BNC by the pathologist, use of 
higher thresholds for colposcopically directed biopsy by the gynaecologist and the 
introduction of HPV triage, possibly in combination with other molecular biomarkers such as 
p16INK4A, MIB-1 or HPV L1 capsid protein. Ongoing research for the value of these techniques is 
needed. 
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Abstract 
 
OBJECTIVE To compare test positivity rates of liquid-based and conventional cytology. 
METHODS This study was a cluster randomized controlled trial with family practice as the unit 
of randomization, performed within the Dutch national cervical screening program. Women 
aged 30–60 yrs (n=89,784) recruited from 246 family practices were included. One-hundred 
twenty-two practices (49,222 individuals) were randomly assigned to the experimental arm 
and 124 practices (40,562 participants) to the conventional arm. Inclusion was performed in a 
3-year period between April 2003 and July 2006. Cytological test positivity rates of liquid-
based compared with conventional cytology was compared in terms of crude and adjusted 
odds ratios, applying a per-protocol analysis. 
RESULTS Crude ratios of the odds of test positivity rates of liquid-based compared with 
conventional cytology for atypical squamous cells of undetermined significance or more 
severe, low-grade squamous intraepithelial lesion or more severe, and high-grade squamous 
intraepithelial lesion or more severe were 0.95 (95% confidence interval [CI] 0.82-1.10), 1.00 
(95 % CI 0.83-1.20), and 0.97 (95% CI 0.77-1.22), respectively. Liquid-based cytology resulted in 
fewer  unsatisfactory tests (odds ratio 0.30, 95% CI 0.23-0.38). The results did not change when 
the odds ratios were adjusted for age, study site, study period and urbanization level. Of 128 
women screened with liquid-based cytology one unsatisfactory preparation is avoided. 
CONCLUSIONS This study found no statistically significant difference in cytological test 
positivity rates between liquid-based and conventional cytology. However, liquid-based 
cytology resulted in significantly fewer unsatisfactory tests. 
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Introduction 
 
Although successful in reducing the incidence of and mortality from cervical carcinoma, the 
diagnostic accuracy of screening with conventional Pap tests is hampered by the 
occurrence of both false-negative and false-positive results. Besides sampling issues during 
test taking, erroneous results are in a great part due to problems with sample preparation and 
cytologic interpretation. Liquid-based cytology has been developed to address these issues1-
3. 
 
Numerous studies have been done comparing the performance of liquid-based cytology 
with conventional cervical cytology; however these studies resulted in substantial controversy 
about whether liquid-based cytology performs better than conventional cytology. Although 
most studies reported an increased detection of squamous intraepithelial lesions (SIL) and 
decreased inadequacy rates, several systematic reviews yielded contradictory results 
depending on the choice of the outcome measure and selection criteria for inclusion of 
individual studies 4-11. 
 
We initiated a large-scale population-based cluster randomized controlled trial (RCT), 
including almost 90,000 cases. The objective was to prospectively test the cytologic test 
positivity rates of atypical squamous cells of undetermined significance or more severe 
(ASCUS+), low-grade squamous intraepithelial lesions or more severe (LSIL+) and high-grade 
squamous intraepithelial lesions or more severe (HSIL+) of the ThinPrep system (using the 
ThinPrep 3000 Processor, Cytyc Corporation, Boxborough, MA) in comparison with 
conventional cervical cytology. For practical reasons, we used family practices as unit of 
randomization in the cluster design. This report presents the baseline outcomes in terms of 
odds ratio (OR) for the cytological test positivity rates of ASCUS+, LSIL+ and HSIL+, taking 
cluster design into account and applying a per-protocol analysis. 
 
 
Materials and methods 
 
The randomized controlled trial was performed within the framework of the national cervical 
screening program in two regions in the Netherlands, in collaboration with local 
gynecologists, pathologists, and family physicians. The screening program invites women 
aged 30-60 years every five years to have a Pap test done by a family physician. Two clinical 
laboratory sites (PAMM Laboratories, Eindhoven and Radboud University Nijmegen Medical 
Centre, Nijmegen) participated in the trial. All family practices feeding the study sites were 
eligible for random assignment to the experimental arm (preparation of the test using the 
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liquid-based system) or control arm (preparation of the test using conventional cervical test 
preparation). Women who were visiting their family practice for participation in the national 
cervical screening program were all included in the study and received a conventional Pap 
test or a liquid-based sample according to the random allocation of their respective family 
practice. Ethical approval for this study was obtained by the Dutch Ministry of Health, Welfare 
and Sport.  
 
The sample size for this study was calculated based on the baseline assumption of 0.6% of 
HSIL+ in the participants and liquid based cytology detection of  a 33% increase in cervical 
intraepithelial neoplasia 2 at α = 5% and β = 20%. With these parameters, we initially 
computed the sample size of 28,269 by ignoring the clustering of women within practices. To 
account for the clustering effect, we assumed from the previous routine data from the two 
sites, an intraclass correlation coefficient of 0.05 with average cluster size of 250 and standard 
deviation of 200. This led us to the coefficient of variation of 0.8 and a design effect of 1.59  12. 
By multiplying the design effect by sample size without clustering effect, we obtained a 
sample size of 44,947 women to be screened in each arm. 
 
The inclusion of 89,960 women screened started in April 2003 and was completed in July 2006. 
One hundred seventy-six participants were excluded from analysis because their GP was not 
randomly assigned. Identification data, clinical data, and the screening results of the 
remaining 89,784 participants were stored in the local pathology databases.  
 
Allocation was based on clusters rather than on individuals, with family practice as the unit of 
randomization. This was done to prevent contamination by patient preference (selection 
bias) and for other practical reasons. All practices connected to the two study sites were 
ranked by postal code, and subsequently, the codes 0 (conventional) or 1 (liquid-based) 
were allocated using a binomial random number generator 13. The family practices in the 
catchment areas of the two study sites were stratified by level of urbanization (high 
urbanization meaning an urban area with more than 100,000 inhabitants) by sorting on postal 
code. They were assigned to one of the study arms by assigning them at random to 
conventional or liquid-based screening by the study database manager. All practices 
participated in the randomization procedure and agreed with the outcome of randomization 
after being informed by mail. Family practices allocated to the experimental arm were 
provided with material for test taking with the liquid-based system. Practices allocated to the 
control arm were provided with the conventional test-taking material. Adherence to the 
assignment was checked periodically during the study. 
For obvious reasons blinding for the method could not be realized for sample taking and test 
reading. 
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Family physicians or their assistant took the cervical samples. At the start of the trial, all family 
practices were informed about the study and consented to participation. Next, the practices 
that converted to liquid-based cytology received additional training, either by a regional 
course or by in-practice training by the manufacturer.  
 
All cervical samples were obtained using the Rovers Cervex-Brush (Rovers Medical Devices 
BV, Oss, the Netherlands). Conventional tests were prepared in the usual way, whereas liquid-
based cytology users were instructed to rinse their cell samples in PreservCyt (Cytyc 
Corporation) transport medium according to the manufacturer’s instructions by rotating the 
brush in the solution 10 times while pushing against the PreservCyt vial wall 1. At the 
laboratory, liquid-based samples were prepared using the ThinPrep 3000 Processor. 
 
At the start of the trial, one of the participating laboratories had experience with screening 
liquid-based slides for 1 year; the other laboratory did not have previous experience with 
liquid-based cytology. Before implementation of the liquid-based method in the laboratories, 
cytotechnologists and cytopathologists attended a 3-day training course, provided by the 
manufacturer. The course finished with a test, which was mandatory before starting to screen 
liquid-based cytology slides. During the learning stage a minimum of 200 liquid-based slides, 
taken from the routine workload, were screened within a multiple screening protocol by two 
cytotechnologists until cytologic consensus was reached. After these 200 liquid-based slides, 
cytotechnologists had a final test, and when they passed they were allowed to screen liquid-
based cytology independently. Technical operators received instruction for operating and 
maintenance of the ThinPrep 3000 Processor from Cytyc Corporation. 
  
Both liquid-based and conventional slides were randomly examined by the trained 
cytotechnology staff and routinely reported using the Dutch CISOE-A classification, which 
can be translated to the Bethesda 1991 subcategories (ASCUS/AGUS, LSIL and HSIL) 14,15. 
Abnormal slides with diagnosis HSIL+ were reviewed by a senior cytotechnologist and a 
trained pathologist as were slides with diagnosis ASCUS/AGUS/LSIL combined with advice for 
referral to a gynecologist. Cases of ASCUS/AGUS/LSIL with repeat advice followed a multiple 
screening protocol, with review by a senior cytotechnologist.  
Cytological diagnoses were categorized in four diagnostic categories:  
1. normal (including benign cellular change) 
2. ASCUS/AGUS 
3. 3. LSIL (low-grade intraepithelial squamous lesions with addition of low-grade 
glandular lesions) 
4. 4. HSIL/carcinoma (high-grade intraepithelial squamous lesions or squamous cell 
carcinoma with addition of adenocarcinoma in situ and cervical adenocarcinoma)). 
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All participants from the randomized practices were included in an intention-to-treat analysis. 
Only those participants who had the proper test (ie, the study arm their family practice had 
been assigned to by randomization) were included in the per-protocol analysis. Proportions 
were compared by using Χ2 tests whereas continuous variables were compared by Student t-
test. The test positivity rates of the experimental (liquid-based cytology) arm relative to the 
control arm were assessed for the cytologic outcome of ASCUS, LSIL, ASCUS+ (ASCUS, LSIL, 
HSIL and carcinoma), LSIL+ (LSIL, HSIL and carcinoma) and HSIL+ (HSIL and carcinoma) taking 
intracluster coefficients into account for assessment of the confidence intervals. Additionally, 
unsatisfactory rates were analyzed. 
 
Crude and adjusted (controlling for age, urbanization level, study period [defined as first and 
second half of the study, using the median preparation date as separator] and clinical 
laboratory site) odds ratios (ORs) for cytological outcomes were computed using univariable 
and multivariable logistic regression analysis, also taking the cluster design into account. The 
number needed to screen was computed as the reciprocal of the risk difference (1/(rate liquid-
based – rateconventional). Analyses were performed with SPSS 14.0.2 (SPSS Inc., Chicago, IL) and 
Stata 9.2 (StataCorp LP, College Station, TX) software. 
 
 
Results 
 
As shown in Figure 1 and Table 1 there were 89,784 participants, recruited from 246 practices 
included in the intention-to-treat analysis and 85,076 participants from 246 practices in per-
protocol analysis. The number of practices was evenly distributed over the two study arms 
(122 in the experimental arm and 124 in the control arm). Nevertheless, the overall distribution 
of individuals between the two study arms was unbalanced, with more samples examined in 
the experimental (liquid-based cytology) arm (n=49,222) than in the control arm (n=40,562). 
This was mainly caused by an uneven distribution of liquid-based and conventional slides at 
site 1 (PAMM laboratory) (57.7% liquid-based compared with 42.3% conventional), due to 
allocation, by chance, of six large (n>1,000) practices to liquid-based compared with only 
one to the control arm. The largest clinical laboratory (site 1) examined almost twice the 
number of slides (57,045) as compared with site 2 (32,739). In site 1, proportion of liquid-based 
cytology preparation was similar in high-urbanization areas as compared with low-
urbanization areas (site 1: 57.9% liquid-based in high-urbanization compared with 57.5% in 
low-urbanization area; P=0.37). In site 2, more liquid-based preparations were processed from  
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Table 1: Population characteristics (Intention-to-treat analysis) 
 
 Urbanization Liquid-based  
n (%) 
Conventional 
n (%) 
P difference Total 
Study site 
Site 1 (PAMM) 
 
High 
 
12,206 (57.9) 
 
8,877 (42.1) 
 
.37* 
 
 Low 20,682 (57.5) 15,280 (42.5)   
Subtotal site 1  32,888 (57.7) 24,157 (42.3)  57,045 
      
Site 2 (RUN-MC) High 5,036 (52.3) 4,602 (47.7) < .001*  
 Low 11,298 (48.9) 11,803 (51.1)   
Subtotal site 2  16,334 (49.9) 16,405 (50.1)  32,739 
Age      
 Less than 30  325 (56.9) 246 (43.1)   
30-34  10,364 (55.7) 8,233 (44.3)   
35-39  7,233 (56.0) 5,673 (44.0)   
40-44  8,959 (55.5) 7,181 (44.5)   
45-49  5,935 (54.7) 4,910 (45.3) < .001*  
50-54  6,183 (53.2) 5,450 (46.8)   
55-59  8,698 (53.4) 7,602 (46.6)   
More than 59  1,525 (54.6) 1,267 (45.4)   
      
Less than 45  26,881 (55.8) 21,333 (44.2)   
45 or more  22,341 (53.7) 19,229 (46.3) < .001*  
      
Mean (y)  43.8 y (±9.2) 44.1 y (±9.2) < .001†  
25th percentile  35 35   
50th percentile  44 44   
75th percentile  50 50   
      
Number of cases in intention-to-treat analysis 49,222 (54.8) 40,562 (45.2)  89,784 
Number of cases in per-protocol analysis 46,066 (54.1) 39,010 (45,9)  85,076 
      
Practice characteristics      
      
No of practices  122 124  246 
 
Age‡ (y) 
  
43.9 
(39.8 to 47.8) 
 
44,2 y 
(38.9 to 50.3) 
 
.099† 
 
  
High 
 
48 (55.2) 
 
39 (44.8) 
 
.195* 
 
 Low 74 (46.5) 85 (53.5)   
*Chi-square test; †Student t-test; ‡ means are averages over practices; range in practices 
 
 
practices in high-urbanization areas (52.3% liquid-based in high-urbanization areas and 48.9% 
in low-urbanization areas, P<.001). Women aged younger than 45 years were relatively more 
often examined with the experimental method ( 55.8% liquid-based cytology) as compared 
to women aged 45 years or older (53.7% liquid-based cytology). 
  
The crude ORs, taking the cluster effect into account, for the various cytologic diagnostic 
categories are shown in Table 2. Only women with a satisfactory index test were included for 
calculation of proportions of test positivity. The ratios of the odds for test positivity of liquid-
based compared with conventional cytology were never significantly different from unity. In 
contrast the crude OR of the unsatisfactory rate was 0.30 (95% CI 0.23-0.38), indicating that in 
the experimental arm, significantly fewer tests were classified as unsatisfactory as compared 
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with the control arm. We also performed an intention-to-treat analysis on the dataset but this 
did not change the results. 
 
As shown in the flow diagram (Fig. 1) test positivity rates of the various cytologic categories 
varied significantly with the study site (p<.001) as well as with level of urbanization (p<.001). 
Test positivity rates were higher for all three cytologic cutoffs in study site 2. The same was 
seen for high-urbanisation level, both in study site 1 as well as study site 2. The odds ratios for 
cytologic abnormalities never differed significantly from unity. These findings did not vary 
significantly by laboratory, urbanization or study period (data not shown). 
 
To adjust for potentially confounding variables (age, site, urbanization level, and experience 
with liquid-based cytology) we used logistic regression. Table 3 provides the crude ORs as well 
as adjusted ORs (adjusted for differences in age, study site, study period and urbanisation 
level). Again, none of the diagnostic categories showed a significant difference between the 
two study arms. The unsatisfactory rate in the liquid-based cytology arm, however, remained 
significantly lower as compared with the unsatisfactory rate in the control arm (OR 0.29, 95% 
confidence interval [CI] 0.23-0.38)). The number needed to screen to observe an additional 
cervical abnormality was not statistically significantly different from zero. Per 128 women 
screened with liquid-based cytology, one unsatisfactory preparation is avoided (number 
needed to screen -128, 95% CI -111 to -151). 
Table 2: Per-Protocol analysis:  Crude rates of cytological test positivity and unsatisfactory samples of 
liquid-based compared with conventional method by category of cytological abnormality and 
unsatisfactory tests and Odds Ratios of liquid-based compared with conventional cytology, taking 
the cluster design into account 
Cytological category Liquid-based Conventional OR (95% CI) 
 n % n %  
ASCUS/AGUS 769 1.67 700 1.81 0.92 (0.77 - 1.10) 
LSIL 191 0.42 154 0.40 1.04 (0.82 - 1.33) 
ASCUS+ 1,243 2.71 1,099 2.85 0.95 (0.82 - 1.10) 
LSIL+ 474 1.03 399 1.03 1.00 (0.83 - 1.20) 
HSIL+ 283 0.62 245 0.64 0.97 (0.77 - 1.22) 
Subtotal 45,913  38,576   
Unsatisfactory 153 0.33 434 1.11 0.30 (0.23 - 0.38) 
Total 46,066  39,010   
 
OR, odds ratio; CI, confidence interval; ASCUS, atypical squamous cells and atypical glandular cells of 
undetermined significance; LSIL= low-grade squamous epithelial lesion; HSIL= high-grade squamous epithelial 
lesion; ASCUS+= ASCUS/AGUS or more severe; LSIL+= LSIL or more severe; HSIL+= HSIL or more severe 
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Table 3: Per-protocol analysis: Crude odd ratios and adjusted odd ratios for observing cytological 
abnormalities (defined at three cytological cutoffs) or unsatisfactory tests in liquid based compared 
with conventional cytology, taking the intracluster coefficient into account 
Cytologic detection Crude OR Adjusted OR* 
 (95% CI) (95% CI)  
ASCUS+ 0.95 (0.82 to 1.10) 0.97 (0.88 to 1.07) 
LSIL+ 1.00 (0.83 to 1.20) 0.98 (0.84 to 1.15) 
HSIL+ 0.97 (0.77 to 1.22) 0.96 (0.79 to 1.18) 
   
Unsatisfactory 0.30 (0.23 to 0.38) 0.29† (0.22 to 0.37) 
OR, odds ratio; CI, confidence interval;  
*adjusted for age, study site, urbanization level and study period 
† Statistically significant 
 
Discussion 
 
In this large-scale population–based, cluster randomized controlled trial including almost 
90,000 cases, we found no difference in performance between the liquid-based method 
(experimental arm) and conventional cytology (control arm) in terms of cytological test 
positivity rates for the various cutoff points. The cluster randomization of practices resulted in 
unequal numbers of subjects in the two arms. The overrepresentation of number of cases in 
the experimental arm in clinical laboratory site 1 was caused by some large centers of family 
practices that had been assigned to the experimental arm. These centers were operating in 
a high-urbanization area that resulted in an overrepresentation of liquid-based tests in this 
stratum. Potential confounding, due to unequal distribution of factors and the clustering, was 
controlled for by logistic regression with and without correction for design effect.  
 
Neither the crude nor the adjusted ORs were found to differ significantly from unity in the per-
protocol analysis, suggesting that the test positivity rates of liquid-based  cytology are similar 
to conventional cytology. On the other hand, we found a strong reduction in unsatisfactory 
rates in the experimental liquid-based arm as compared to conventional cytology (OR 0.29, 
95% confidence interval 0.23 to 0.38). Applying an intention-to-treat analysis on the data set 
did not change results, indicating that the per-protocol analysis did not alter the outcome. 
 
There were striking differences in test positivity rates between the two participating clinical 
laboratory sites as well as between women living in low- and high-urbanization areas. The 
difference in test positivity rates between the study sites may reflect differences in cytological 
interpretation of the laboratory, but may also be the result of differences in the prevalence of 
cervical abnormalities. The relation we found between urbanization level and the prevalence 
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of abnormalities of the squamous and glandular epithelium corroborates the results obtained 
by other investigators16: the higher the urbanization level the higher the prevalence of 
cervical epithelial lesions. To evaluate a potential learning effect for liquid-based cytology, 
we analyzed the results from the first half of the trial as well as the second half, but we did not 
find a significant effect on the ORs.  
 
Most previously performed studies used a split sample design. Although looking perfectly 
controlled, this study design has raised concerns with respect to a possible disadvantage for 
liquid-based cytology when the collected cellular material is split, with a conventional test 
made first, and the residual material immersed in the fixative solution5. Studies using a two-
cohort design (in which conventional tests and liquid-based samples are taken from women 
belonging to separate but similar populations) frequently found higher test positivity rates for 
liquid-based cytology17-23. In contrast, we found no difference in test positivity rates between 
liquid-based and conventional tests, irrespective of the diagnostic cutoff value. Whereas we 
used a randomized study design, the other studies compared cytological detection rates 
with historical cohorts. Most of these studies reported a substantial and statistically significant 
increase in cytologically detected abnormalities for liquid-based cytology, with the most 
impressive increase found in screening centers with low rates of abnormalities20,24. The present 
study was also performed in a low-risk screening population, but we did not find higher 
detection rates with liquid-based cytology. The higher detection rates reported with the 
liquid-based technique in other studies may be caused by the introduction of the liquid-
based technique, creating a higher awareness and enthusiasm for the new technique 
(intention bias). Also improved quality control, coinciding with the introduction of the new 
technique, may have resulted in an increased detection of cytological abnormalities8. Finally, 
when using historical data as a control group, differences in the study populations may have 
biased the results. On the other hand, it may also be the case that the quality of 
conventional screening in the Netherlands is so high that introduction of the new technique 
has little additional value.  
  
Only two other randomized controlled trials have been published25,26. The study from 
Obwegeser25 was unpowered (n=1,999) and found no difference in test positivity rates 
between liquid-based and conventional cytology. Ronco et al26 found a significantly higher 
test positivity rate for liquid-based cytology as compared with conventional cytology (relative 
frequency 1.57, 95% CI 1.13 - 2.18). However, this higher test positivity rate in liquid-based 
cytology was at the expense of a reduced positive predictive value.  
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Several other studies found higher rates of LSIL and lower rates of ASCUS/AGUS11,16-18,20. This 
observation was not found in the present study since both ASCUS and LSIL detection rates did 
not differ significantly between the liquid-based and conventional study arm. 
 
We did find significantly lower unsatisfactory rates when using liquid-based cytology as 
preparation technique, which will be advantageous in settings with high proportions of 
unsatisfactory tests. However, in the Netherlands the unsatisfactory rate for conventional tests 
is already very low, which reduces the added value of liquid-based cytology in terms of 
absolute reduction of the number of unsatisfactory tests. Use of the liquid-based method 
results in this study in a reduction of unsatisfactory tests of 8 per 1,000 tests.  
 
A clear additional benefit of the liquid-based method is the availability of residual material for 
human papillomavirus reflex testing in case of ASC-US or LSIL3,27. However, presently, negative 
triage of ASC-US and LSIL in the Netherlands is not allowed on program tests but only for the 
follow-up tests of borderline and low-grade program tests. 
 
The present study does not yet allow the conclusion that the diagnostic accuracy of liquid-
based and conventional cytology is equal with respect to histologically defined outcomes. It 
may be theoretically possible that liquid-based cytology would be more sensitive for cervical 
intraepithelial neoplasia and that the conventional Pap test is less specific or vice versa. 
Therefore, for definite conclusions, comparison with a blindly verified reference standard is 
needed to assess the relative sensitivity and positive predictive value for histologically 
confirmed cervical intraepithelial neoplasia and cancer. These results will be available after 
completion of the follow-up period and be the subject of a future report.  
 
Our conclusions are that both methods perform equally well in terms of test positivity rates 
within the setting of the Dutch cervical screening program. The liquid-based method does 
result in fewer unsatisfactory tests, but in the framework of the Netherlands cervical screening 
program, this adds little extra because unsatisfactory rates for conventional screening are 
already very low. However, the liquid-based technique does offer other additional 
advantages such as availability of material for reflex human papillomavirus testing and other 
molecular tests. 
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Abstract 
 
CONTEXT Liquid-based cytology (LBC) has been developed as an alternative for 
conventional cervical cytology. Despite numerous studies and systematic reviews controversy 
remains about the diagnostic accuracy of LBC. 
OBJECTIVE To assess the performance of LBC compared with conventional cytology in terms 
of detection of histological confirmed cervical intraepithelial neoplasia (CIN). 
DESIGN AND SETTING Cluster randomized controlled trial with family practice (FP) as unit of 
randomization, performed within the Dutch cervical screening program between April 2004 
and July 2006, with 18 months of follow-up per patient and ending in January 2008. 
PARTICIPANTS Screenees, aged 30-60 years (n=89,784), recruited from 246 FPs and 
randomized to LBC (122 practices, 49,222 individuals) or conventional cytology (124 
practices, 40,562 individuals). 
INTERVENTION Screening using LBC or conventional PAP test. Review of all follow-up of 
screen-positive women blinded to the type of cytology and the initial result.  
MAIN OUTCOME MEASURES Intention-to-treat and per-protocol analysis of the detection rates 
(DR) of, and positive predictive values (PPV) for histological verified CIN in both cytology 
systems. Outcomes are presented as crude and adjusted rate ratios (adjustment for age, 
urbanization, study site and period). 
RESULTS The adjusted DR ratios for CIN grade 1 or more severe (CIN1+) was 1.01 (95% CI 0.85 – 
1.19), for CIN2+ 1.00 (0.84 – 1.20), for CIN3+ 1.05 (0.86 – 1.29) and for carcinoma 1.69 (0.96 – 
2.99). The adjusted PPV ratios, considered at several cytological cutoffs and for various 
outcomes of CIN never differed significantly from unity.  
CONCLUSION This study indicates that LBC does not perform better than conventional PAP 
test in terms of relative sensitivity and PPV for detection of cervical cancer precursors.  
Performance of liquid-based compared with conventional cytology 105 
 
Introduction 
 
The conventional PAP test (CP) is considered suboptimal due to false-negative and false-
positive test results. This is caused by poor quality of sampling and preparation, (obscuration 
by blood or inflammation, bad cell fixation and inhomogeneous distribution of cells) as well as 
errors in detection- and interpretation. Liquid-based cytology (LBC) was developed as an 
alternative for the CP. With LBC, the cervical cells are collected with a traditional sampling 
device and rinsed into a vial with preservation solution rather than being smeared on a slide1-
3. Because only a representative portion of the sample is used in LBC, the residual material in 
the vial may be used for ancillary testing such as reflex HPV testing and other molecular tests3.  
 
The accuracy of LBC has been compared with conventional cytology in numerous studies, 
however with disparate results. Recent systematic reviews concluded that there is still 
insufficient evidence that LBC is superior or inferior in the detection of high-grade lesions, due 
to the lack of well designed comparative studies4-7.  
 
The objective of this prospective trial was to compare the screening performance of LBC and 
CP in terms of test positivity rates, histological detection rates and positive predictive values. 
The evaluated LCB method was the ThinPrep® system (Hologic Corporation, Marlborough, 
MA). The cytological results of the trial, in terms of differences in test positivity and specimen 
adequacy, were recently published8. The present report focuses on the histological detection 
rates and positive predictive values. 
 
 
Methods 
 
Study Design and Study Population 
 
Participants in this randomized controlled trial were women aged 30 to 60 years, participating 
in the Dutch cervical screening program. Women are invited for a Pap test every 5 years. The 
sample is taken by the family physician. The NETHCON trial was performed by two clinical 
laboratories (PAMM Laboratories, Eindhoven (study site 1) and Radboud University Nijmegen 
Medical Centre, Nijmegen (study site 2)) in collaboration with local gynecologists, 
pathologists and family physicians. Ethical approval was obtained by The Dutch Ministry of 
Health, Welfare and Sport. Informed refusal was offered with an information folder. 
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FPs, feeding the clinical study sites, were randomly assigned to the experimental arm (LBC 
(ThinPrep® Pap test)) or the control arm (CP). All screened women from the randomized FPs 
were included in the study.  
 
Screen positive women were followed prospectively for 18 months after the initial screening 
test. When available, histologic follow-up was used as a reference standard. Abnormal cases, 
in particular women with minor abnormalities, without histologic follow-up were followed with 
follow-up smears. The main outcomes were the ratios of the detection rates of histologically 
confirmed CIN or cervical carcinoma in LBC versus CP. The absolute test sensitivity cannot be 
assessed in a RCT, unless the reference standard is applied to all screened subjects. However, 
the ratio of the detection rates (DR) equals relative sensitivity.  As the prevalence of disease is 
equal in both arms due to randomization, the ratios of the PPVs reflect differences in 
specificity. Thus, a second outcome were the ratios of PPVs of cytologically or histologically 
confirmed outcome of CIN1/LSIL or more severe (CIN1+/LSIL+) or CIN2+/HSIL+, where verified 
cytology outcomes are added to those with histological outcomes.  
 
The calculation of the sample size was documented previously8 and was based on 0.6% 
detection of CIN2+ using CP and an expected 33% increase using LBC with α = 5% and β = 
20%, an intraclass correlation coefficient of 0.05, an average cluster size of 250 and a 
standard deviation of 200. This resulted in a coefficient of variation of 0.8 and design effect of 
1.59 9. By multiplication of the design effect by sample size without cluster effect, a sample 
size of 44,947 women in each arm was obtained. 
 
Recruitment started in April 2003 and was completed in July 2006 after enrollment of 89,960 
women. 176 Cases were excluded from analysis because the FP had not been randomized. 
Local pathology databases were used for data storage. Initial cytological cytology results 
were linked with the cytologic and histologic follow-up outcome assessed within an 18-month 
period. Follow-up data were retrieved from the local and national pathology databases, 
which contain the results of all histology and cytology specimen examined in The 
Netherlands10. 
 
Cluster randomization 
 
A cluster randomization was chosen for practical reasons and to prevent contamination by 
preference of patient or physician (selection bias). The FPs connected to the two study sites 
served as the units of randomization. Stratification by urbanization level (areas with low and 
high level defined as containing less or more than 100,000 inhabitants) was done by ranking 
according to postal code. Subsequently, the FPs were allocated to CP or LBC using a 
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binomial random number generator11.  All practices were included in the randomization 
procedure and informed by mail on the results of the randomization. They all agreed with the 
outcome. Adherence of the FPs to their assignment was checked periodically. 
 
Blinding 
 
The gynecologists, pathologists, cytotechnologists and other study personnel who were 
involved in the follow-up and review of histology and cytology were blinded for the cytology 
system used for cytological screening to prevent selective assessment bias. 
 
Test taking 
 
All FPs were informed about the study before the start of the trial and consented with 
participation. Practices who were assigned to the LBC arm received written instructions about 
sample collection with LBC and an additional training, either by a regional course or by in-
home instruction by the manufacturer. Sample taking was done by the family physician or by 
their assistant.  
 
The Rovers® Cervex-Brush® (Rovers Medical Devices B.V., Oss, The Netherlands) was used for 
sample taking in both study arms. The conventional Pap tests were prepared in the traditional 
way by spreading the sampled cells quickly onto a glass slide and performing cell fixation 
within a few seconds. LBC samples were prepared according to the manufacturer’s 
instruction by transferring the sampled cells from the Cervex-Brush into PreservCyt® transport 
solution by firmly rotating and pushing the brush against the vial wall 10 times. LBC samples 
were processed at the laboratory with the ThinPrep® 3000 Processor1,12. 
 
Cytology 
 
The introduction phase for LBC started with a 3-day training course for cytotechnologists and 
pathologists which was provided by the manufacturer and was finished with a test. During the 
learning stage, a minimum of 200 LBC slides were taken from the routine workload and 
screened. All slides were rescreened by another cytotechnologist. Primary screening of LBC 
was not allowed before the learning stage was successfully finished with a final test. A training 
course for the technical operators of the ThinPrep 3000 was also provided by Hologic 
Corporation. One study site had already screened LBC slides for one year before the start of 
the study. The other study site had no prior experience with screening LBC. Smears were 
screened and classified by cytotechnologists according to the CISOE-A classification system. 
This Dutch classification system can be easily translated into the Bethesda 1991 subcategories 
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ASCUS/AGUS, LSIL and HSIL12,13. Borderline and low-grade abnormalities were reviewed by a 
supervising cytotechnologist and high-grade abnormalities were reviewed by both a 
supervising cytotechnologist and cytopathologist. Cytological test results were categorized 
as: 
1. Within Normal Limits 
2. ASCUS/AGUS (atypical squamous or glandular cells of undetermined significance)  
3. LSIL (low-grade intraepithelial squamous lesions or low-grade glandular lesions) 
4. HSIL (high-grade intraepithelial squamous lesions, squamous cell carcinoma, 
adenocarcinoma in situ (AIS) or cervical adenocarcinoma) 
 
Referral, follow-up and outcome 
 
Screen positive cases had follow-up tests in accordance with the guidelines of the Dutch 
Society of Pathologists (NVVP)12 and the Dutch Society of Obstetrics and Gynecology 
(NVOG). Follow-up tests included cytological testing, colposcopy or histology. The follow-up 
protocol as practiced in the Netherlands is shown in figure 3. Women with equivocal or low-
grade cytological abnormalities (ASCUS/AGUS or LSIL) on the initial test were offered repeat 
cytology. When both the first test (at 6 months) and the second test (at 18 months) are 
normal, the patient was referred back to the screening program. When the initial abnormality 
is found to persist or progress in the first or second repeat test, the patient is advised to visit a 
gynecologist for colposcopy. Histology is taken from colposcopically abnormal areas. High-
grade cytological abnormalities (HSIL or more) on initial or repeat test are immediately 
referred to a gynecologist for colposcopy and further histological evaluation.  
FPs received a reminder when follow-up tests are not performed within a previously defined 
time-frame, according to routine national procedures.  
Assessment of the primary final outcome was based on blinded review of all histological 
follow-up. The secondary final outcome was also based on reviewed histological follow-up, 
but in cases where there was no histological follow-up, this outcome was based on blinded 
review of follow-up cytology.   
 
Review of the reference standard (histology or cytology) 
 
Cervical histology was blindly reviewed in all test positive cases where histology was 
performed within the time frame of 18 months. The most severe diagnosis was registered 
when more histological specimen were available in the follow-up period. When no histology 
was available within 18 months, the most severe cytology was reviewed and used for 
assessment of the secondary outcome. Review of histology was done by a panel of four 
experienced pathologists who were blinded for the cytological system, the original  
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OUTCOME
return to screening-
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ASCUS/AGUS/ LSIL
HSIL+
REPEAT SMEAR 1
(6 months)
Normal
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REPEAT SMEAR 2 
(18 months)
COLPOSCOPY / 
HISTOLOGY
Normal
Abnormal
OUTCOME
INITIAL SMEAR  .
Fig. 3. Referral and follow-up protocol in accordance with the guidelines of the Dutch Society of Pathologists
(NVVP) and the Dutch Society of Obstetrics and Gynecology (NVOG)
 
cytological  and histological findings and all follow-up data. Review of cytology was done by 
experienced cytotechnologists, using the same protocol. Discrepancy or concordance 
between the original diagnosis and review diagnosis was assessed using four classes:  
1. WNL (Within Normal Limits) 
2. ATYPIA/CIN1 (atypia or CIN1 and their glandular equivalents for histology and 
ASCUS/AGUS/LSIL for cytology) 
3. CIN2/CIN3 (CIN2 or CIN3 and their glandular equivalents for histology and HSIL/AIS for 
cytology) 
4. Malignant (comprising squamous- and endocervical adenocarcinoma). 
 
In case of different outcomes within the same class, the reviewed histological diagnosis was 
used as outcome. In case the review diagnosis fell in another class compared to the original 
diagnosis, a second experienced pathologist (or cytotechnologist in case of cytology) did a 
blinded review. When this second review diagnosis fell in the same class as the original or first 
review diagnosis, this second review diagnosis was used as outcome. However, if the second 
review did not concur with the two previous assessments, the case was discussed using a 
double headed microscope by the two reviewers and a consensus diagnosis was reached. 
This consensus diagnosis was used as the final outcome. The final outcome was categorized 
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as CIN1+/LSIL+ (CIN1, CIN2, CIN3, carcinoma or the cytological equivalents) or CIN2+/HSIL+ 
(CIN2, CIN3, carcinoma or the cytological equivalents). 
 
Statistical analysis 
 
Only participants from randomized practices were included in the intention-to-treat analysis. 
The per-protocol analysis included only participants who received the test determined by 
randomization.  Χ2-tests were used for comparison of proportions. Crude rate ratios were 
computed as ratios of the DRs or PPVs. Odds ratios for finding a verified outcome in LBC 
versus CP, adjusted for confounding factors were computed by logistic regression. The 
following confounding factors were included in multivariate analyses: age, urbanization level, 
study site and period. Period was defined as first and second half of the study, using the 
median preparation date as separator. Odds ratios were converted into rate ratios using 
established methods14-16. 
The ratios of the DR of verified cervical abnormalities in the LBC relative to the CP arm was 
assessed for the primary histological outcome of CIN1+, CIN2+, CIN3+ and carcinoma. The 
cluster design was taken into account for calculation of 95% confidence intervals. Statistical 
testing was two-sided and significance was defined at p<0.05. Binomial exact 95% 
confidence intervals (CI) were computed around proportions. Analyses were performed with 
Stata 10.0 (StataCorp LP, College Station, TX) software. 
 
Results 
 
A total of 89,960 women, recruited from 327 FPs were enrolled in the trial. The flow of 
participants through the trial is shown in figure 1. FPs that were not connected to one of the 
study sites but nevertheless requested cytological assessment on an occasional base had not 
been randomized and were excluded from analysis (176 cases from 81 practices),  leaving 
89,784 participants from 246 FPs for evaluation (49,222 individuals from 122 practices with LBC;  
40,562 individuals from 124 practices with CP). In the intention-to-treat analysis, another 625 
inadequate smears were excluded. This left 89,197 individuals for evaluation (49,038 
individuals in LBC arm; 40,121 individuals in CP arm). Moreover, in the per-protocol analysis 
4,670 participants who received another test than the one to which their FP was assigned 
(contaminants) were excluded resulting in 84,489 participants from 246 practices (45,913 with 
LBC and 38,576 with CP). Cases that had been lost to follow-up were withdrawn from both 
analyses. 
 
Despite a balanced distribution of FPs over the study arms (122 in the LBC arm and 124 in the 
conventional arm), differences were found in the number of participants over the two study 
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arms (table 1). By chance, 6 large practices (with 1000 women or more) belonging to study 
site 1 (Eindhoven) and operating in urban areas were allocated to the LBC arm whereas only 
one was allocated to the CP arm. Study site 1 is a high-volume laboratory and evaluated 
considerably more slides compared to study site 2. LBC was performed more often in high- 
than low-urbanization areas (56.1% LBC in high- versus 54.2% LBC in low-urbanization areas). A 
higher proportion of younger participants was examined with LBC as compared with older 
participants.  The differences were statistically significant (p<0.001). 
 
In the intention-to-treat analysis (table 2) 2,474 women with cytological abnormalities were 
identified (1.321 in LBC, 1.153 in CP arm). The follow-up results of women with abnormal 
cytology are given in the flowchart in figure 2. Most cases (56.4%) were followed cytologically 
(LBC 55.7%, CP 57.2%). Histology was performed in 36.3% of the cases (LBC 36.3% and CP 
36.3%). Six cases had only colposcopy during follow-up and 171 cases (6.9%) were lost to 
follow-up (LBC 7.3% and CP 6.4%). None of the differences in follow-up procedures between 
LBC and CP were statistically significant. Outcome verification of cytological borderline and 
low-grade abnormalities was mainly based on revised cytological follow-up (71.3%) whereas 
high-grade cytological lesions were generally verified with histology (91.2%). Only 3.8% of the   
Screening pop. Study site 1
Women: n=57,175
Practices: n=204
Screening pop. Study site 2
Women: n=32,785
Practices: n=123
Cluster randomisation
Intention-to-treat analysis
LBC
Women: n=32,762
Practices: n=75
Intention-to-treat analysis
Conventional 
Women: n=23,857
Practices: n=78
Intention-to-treat analysis
LBC
Women: n=16,276
Practices: n=47
Intention-to-treat analysis
Conventional
Women: n=16,264
Practices: n=46
Total screening population
Women: n=89,960
Practices: n=327
Cluster randomisation
Contaminants excluded
Women: n= 2,490
Nonrandomised practices excluded
Women n= 130
Practices: n= 51
Nonrandomised practices excluded
Women n= 46
Practices: n= 30
Contaminants excluded
Women: n= 885
Contaminants excluded
Women: n= 635
Contaminants excluded
Women: n= 660
Screening pop. Study site 1
Women: n=57,045
Practices: n=153
Screening pop. Study site2
Women: n=32,739
Practices: n=93
Per Protocol Analysis
LBC
Women: n=30,272
Practices: n=75
Per Protocol Analysis
Conventional 
Women: n=22,972
Practices: n=78
Per Protocol Analysis
LBC
Women: n=15,641
Practices: n=47
Per Protocol Analysis
Conventional
Women: n=15,604
Practices: n=46
Inadequate cytology 
excluded
Women: n= 126
Inadequate cytology 
excluded
Women: n= 300
Inadequate cytology 
excluded
Women: n= 58
Inadequate cytology 
excluded
Women: n= 141
LBC
Women: n=32,888
Practices: n=75
Conventional 
Women: n=24,157
Practices: n=78
LBC
Women: n=16,334
Practices: n=47
Conventional
Women: n=16,405
Practices: n=46
Fig. 1 Participants flow of enrollment and allocation in the trial including verified histological follow-up results 
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Table 1: Population characteristics 
Variable   LBC 
n (%) 
CP 
n (%) 
p-value 
difference 
Total 
 
Study site  
  
Site 1 (Eindhoven) 
 
32,888 (57.6) 
 
24,157 (42.4) 
 
< 0.001* 
 
57,045 
  Site 2 (Nijmegen) 16,334 (49.9) 16,405 (50.1)  32,739 
       
Urbanization  High 17,242 (56.1) 13,479 (43.9) < 0.001* 30,721 
  Low 31,980 (54.2) 27,083 (45.9)  59,063 
       
Age  <30 y 325 (56.9) 246 (43.1)  571 
  30-34 y 10,364 (55.7) 8,233 (44.3)  18,597 
  35-39 y 7,233 (56.0) 5,673 (44.0)  12,906 
  40-44 y 8,959 (55.5) 7,181 (44.5)  16,140 
  45-49 y 5,935 (54.7) 4,910 (45.3) < 0.001* 10,845 
  50-54 y 6,183 (53.1) 5,450 (46.9)  11,633 
  55-59 y 8,698 (53.4) 7,602 (46.6)  16,300 
  >59 y 1,525 (54.6) 1,267 (45.4)  2,792 
       
Study period  Period 1 24,250 (54.1) 20,563 (45.9)  44,813 
  Period 2 24,972 (55.5) 19,999 (44.5)  44,971 
       
Number of cases in intention-to-treat analysis 49,222 (54.8) 40,562 (45.2)  89,784 
Number of cases in per-protocol analysis 46,066 (54.1) 39,010 (45,9)  85,076 
Cluster characteristics       
No of practices   122 124  246 
 
Urbanization 
  
High 
 
48 (55.2) 
 
39 (44.8) 
 
0.195* 
 
87 
  Low 74 (46.5) 85 (53.5)  159 
 
*Chi-square test 
 
Table 2: Intention-to-treat analysis: Follow-up and verification of test-positive cases 
 LBC CP  Total 
  
n 
% of test 
positives 
 
n 
% of test  
positives 
p-value 
difference 
 
ASCUS/AGUS and LSIL       
Cytology 725 71.1 642 71.4  71.3 
Colposcopy 4 0.4 2 0.2  0.3 
Histology 203 19.9 188 20.9 0.343 20.4 
Cases with follow-up 932 91.5 832 92.5  92.0 
 
Lost to follow-up 
 
83 
 
8.1 
 
67 
 
7.5 
 
 
 
7.8 
missing 4 0.4 0 0.0  0.2 
Subtotal 1,019 100.0 899 100.0 1,918 100.0 
 
 
HSIL+ 
 
 
     
Cytology 11 3.6 17 6.7  5.0 
Colposcopy 0 0.0 0 0.0  0.0 
Histology 277 91.7 230 90.6 0.145 91.2 
Cases with follow-up 288 95.4 247 97.2  96.2 
 
Lost to follow-up 
 
14 
 
4.6 
 
7 
 
2.8 
  
3.8 
Subtotal 302 100.0 254 100.0 556 100.0 
 
 
Overall 
      
Cytology 736 55.7 659 57.2  56.4 
Colposcopy 4 0.3 2 0.2  0.2 
Histology 480 36.3 418 36.3 0.297 36.3 
Cases with follow-up 1,220 92.4 1,079 93.6  92.9 
 
Lost to follow-up 
 
97 
 
7.3 
 
74 
 
6.4 
 
 
 
6.9 
missing 4 0.3 0 0.0  0.2 
Total 1,321 100,0 1,153 100,0 2,474 100,0 
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initial HSIL+ lesions were lost to follow-up as compared to 7.8% of borderline and low-grade 
cytology. All follow-up histology and cytology was reviewed and the result of the review was 
used as study outcome. Cases that were lost to follow-up were excluded from analysis.  
 
Table 3  presents the intention-to-treat and per-protocol results of the detection rates (DRs) of 
histological verified CIN or carcinoma in LBC and CP, as well as the crude and adjusted DR 
ratios. Irrespective of the grade of the initial cytological abnormality that triggered further 
follow-up, DR ratios were close to one and none significantly differed from unity. 
 
Table 4 provides the correlation between the baseline cytological result  and the verified 
outcome (histology, colposcopy or cytology) for LBC and CP in the intention-to-treat analysis. 
With LBC, ASCUS/AGUS resulted in 2.7% (CI: 1.6% - 4.1%) in the detection of CIN3+/severe 
dysplasia or cancer, in 4.2% (CI: 2.8% - 5.9%) in detection of CIN2/moderate dysplasia, in 5.1% 
(CI: 3.6% - 6.9%) in CIN1/LSIL, and in 88.1 % (CI: 85.5% - 90.3%) in absence of CIN/SIL. For CP 
these figures were 3.5% (CI: 2.3% - 5.2%) for CIN3+/severe dysplasia or cancer, 2.6% (CI: 1.6% -
4.2%) for CIN2/moderate dysplasia, 6.5% (CI: 4.7% - 8.6%) for CIN1/LSIL and 87.4% (CI: 84.6% - 
89.8%) in absence of CIN/SIL. An LBC result of LSIL resulted in 18.7% (CI: 13.4% - 25.8%) in an 
outcome of CIN3+/severe dysplasia or cancer, 9.1% (CI: 5.4% - 14.2%) in CIN2/moderate  
Baseline cytology
LBC
n = 49,038
Conventional
n = 40,121
Lost to follow-up
missing
Follow-up available
Cytology outcome
NILM
ASCUS/AGUS
LSIL
HSIL+
Colposcopy outcome
No abnormality
Atypia
Low-grade
High-grade+
Histology outcome
No abnormality
Atypia
CIN1
CIN2
CIN3+/AIS
ASCUS/AGUS
n=820
LSIL
n=199
HSIL+
n=302
ASCUS/AGUS
N=741
LSIL
n=158
HSIL+
N=254
72 11 14 61 6 7
3 1 0 0 0 0
745 187 288 680 152 247
635 90 11 571 71 17
535
80
16
4
57
21
9
3
6
2
2
1
468
76
23
4
47
16
7
1
9
2
6
0
3
3
0
0
0
1
1
0
0
0
0
0
0
0
0
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
107
20
18
22
27
20
96
11
13
23
14
35
277
8
5
14
52
198
107
22
26
21
15
23
81
13
9
17
22
20
230
8
12
10
53
147
Fig. 2 Flowchart of the follow-up outcome of abnormal cytological test results (intention-to-treat)
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Table 3. Detection rates (DR) of verified histological confirmed CIN or cervical cancer in LBC and in 
CP  and the crude and adjusted DR ratios (DRLBC/DRCP) 
 Intention-to-treat analysis  
Verified histological 
outcome  
DR in LBC 
(N=48,941) 
DR in CP 
(N=40,047) 
Crude DR ratio Adjusted* DR ratio 
 N % n % (95% CI) (95% CI) 
CIN 1+ 405 0.83 (0.75-0.91) 328 0.82 (0.74-0.91) 1.01 (0.88 – 1.17) 1.01 (0.85 – 1.19) 
CIN 2+ 346 0.71 (0.63-0.78) 280 0.70 (0.62-0.78) 1.01 (0.86 – 1.18) 1.00 (0.84 – 1.20) 
CIN 3+ 253 0.52 (0.45-0.58) 190 0.47 (0.41-0.54) 1.09 (0.90 – 1.31) 1.05 (0.86 – 1.29) 
Carcinoma 30 0.06 (0.04-0.08) 14 0.03 (0.02-0.05) 1.75 (0.91 – 3.31) 1.69 (0.96 – 2.99) 
  Per-protocol analysis   
Verified Histology  DR in LBC 
(N=45,818) 
DR in CP 
(N=38,504) 
Crude DR ratio Adjusted DR ratio 
 n % n % (95% CI) (95% CI) 
CIN 1+ 382 0.83 (0.75-0.92) 312 0.81 (0.72-0.90) 1.03 (0.89 – 1.19) 1.02 (0.85 – 1.21) 
CIN 2+ 327 0.71 (0.64-0.80) 270 0.70 (0.62-0.79) 1.02 (0.87 – 1.20) 1.00 (0.83 – 1.20) 
CIN 3+ 235 0.51(0.45-0.58) 181 0.47 (0.40-0.54) 1.09 (0.90 – 1.33) 1.04 (0.85 – 1.28) 
Carcinoma 27 0.06 (0.04-0.09) 13 0.03 (0.02-0.06) 1.75 (0.90 – 3.38) 1.66 (0.90 – 3.03) 
 
CIN1+, cervical intraepithelial neoplasia grade 1 or more severe; CIN2+, cervical intraepithelial neoplasia grade 2 
or more severe; CIN3+, cervical intraepithelial neoplasia grade 3 or more severe; DR, detection rate; CI, 
confidence interval) 
*(adjusted for age, study site, urbanization level and study period and taking the cluster design into account) 
 
dysplasia, in 17.1% (CI: 12.0% - 23.3%) in CIN1/LSIL and in 55.1% (CI: 47.7% - 62.3%) no CIN or a 
verified outcome less than LSIL was found.  For CP these figures were 13.8% (CI: 8.8% - 20.0%), 
14.3% (CI: 9.3% - 21.1%), 15.8% (CI: 10.4% - 22.6%) and 55.9% (CI: 47.6% - 64.0%) respectively. 
HSIL+ in LBC resulted in 87.1% (CI: 83.3% - 91.0%) (n=251) in verified high-grade cervical lesions 
as compared to 81.0% (CI: 76.0% - 85.9%) (n=200) with CP. The PPVs of LBC and CP and their 
ratios for different levels of test positivity and outcome thresholds are presented in table 5 for 
both the ITT and PP approaches. The PPVs of LBC and CP were comparable since both the 
crude and adjusted positive predictive value ratios never differed significantly from unity, 
irrespective of the cytological or verified outcome cut-off value.  
 
 
Comment  
 
The performance of LBC and CP were prospectively compared in terms of detection rates of 
and positive predictive values for cervical cancer precursors. This was done in a large-scale, 
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(WNL, Within normal limits; ATYPIA/ASCUS, atypical epithelium or atypical squamous cells of undetermined 
significance; CIN1/LSIL, Cervical intraepithelial neoplasia grade1 or low-grade squamous epithelial lesion; 
CIN2/moderate dysplasia, Cervical intraepithelial neoplasia grade 2 or cytological moderate dysplasia; 
CIN3+/severe dysplasia+, Cervical intraepithelial neoplasia grade 3 or more severe or cytological severe dysplasia or 
more severe) 
# Chi2 test 
 
 
population-based, cluster randomized controlled trial including almost 90,000 participants. 
Strength of the present study is that it is to our knowledge the largest high quality study to 
date, performed in a population-based setting with blind verification of follow-up outcomes 
of all test positive cases contrasting with many previous studies which often suffer from 
methodological flaws [4,5].  Despite careful cluster randomization, the distribution of 
individuals over the two study arms was unbalanced. This was the result of allocation of a few 
large FP centers to the experimental arm. These centers were mainly serving densely 
populated areas. However, we controlled for possible confounding by applying multi-variate 
logistic regression with correction for cluster effects.  
 
As shown in a previous publication, no differences were found in the cytologic test positivity 
rates between LBC and CP [8]. Nevertheless, these cytologic findings contribute insufficient 
evidence to claim equal diagnostic accuracy. In both the intention-to-treat and per-protocol  
Table 4. Baseline cytology versus verified follow-up outcome (blindly verified histology, colposcopy or 
blindly reviewed final cytology). Absolute numbers and proportion of tests positives with verified 
outcome (=n/N, with 95 % confidence intervals). 
 
Intention-to-treat Verified follow-up outcome  
Baseline Cytology WNL/ATYPIA or 
ASCUS 
CIN1/LSIL CIN2/moderate 
dysplasia 
CIN3+/severe 
dysplasia+ 
P-
value
# 
 
ASCUS/ 
AGUS  
LBC (N=725) n=656  
88.1% (85.5-90.3) 
n=38  
5.1% (3.6-6.9) 
n=31 
4.2 % (2.8-5.9) 
n=20 
2.7 % (1.6-4.1) 
 
0.224 
CP  (N=680) n=594 
87.4% (84.6-89.8) 
n=44 
6.5% (4.7-8.6) 
n=18 
2.6 % (1.6-4.2) 
n=24 
3.5 % (2.3-5.2) 
 
LSIL LBC (N=187) n=103 
55.1% (47.7-62.3) 
n=32 
17.1% (12.0-23.3) 
n=17 
9.1% (5.4-14.2) 
n=35 
18.7% (13.4-25.8) 
 
0.330 
CP (N=152) n=85 
55.9% (47.6-64.0) 
n=24 
15.8 % (10.4-22.6) 
n=22 
14.3% (9.3-21.1) 
n=21 
13.8% (8.8-20.0) 
 
HSIL+ LBC (N=288) n=21 
7.3% (4.6-10.9) 
n=16 
5.6% (3.2-8.9) 
n=52 
18.1% (13.8-23.0) 
n=199 
69.1% (63.4-74.4) 
 
0.084 
CP (N=247) n=31 
12.6% (8.7-17.3) 
n=16 
6.5% (3.7-10.3) 
n=53 
21.5% (16.5-27.1) 
n=147 
59.5% (53.1-65.7) 
 
Per-protocol   
 
ASCUS/ 
AGUS  
LBC (N=696) n=613  
88.1% (84.4-90.4) 
n=35  
5.0% (3.5-6.9) 
n=28 
4.0% (2.7-5.8) 
n=20 
2.9% (1.8-4.4) 
 
0.529 
CP  (N=640) n=563 
88.0% (82.2-90.4) 
n=38 
5.9% (4.2-8.1) 
n=18 
2.8% (1.7-4.4) 
n=21 
3.3% (2.0-5.0) 
 
LSIL LBC (N=179) n=98 
54.8% (47.2-62.2) 
n=31 
17.3% (12.1-23.7) 
n=16 
8.9% (5.2-14.1) 
n=34 
19.0% (13.5-23.5) 
 
0.416 
CP (N=149) n=85 
57.1% (48.7-65.1) 
n=23 
15.4% (10.0-22.3) 
n=21 
14.1% (8.9-20.7) 
n=20 
13.4% (8.4-20.0) 
 
HSIL+ LBC (N=269) n=21 
7.8% (5.0-11.9) 
n=15 
5.6% (3.2-9.2) 
n=51 
19.0% (14.8-24.7) 
n=182 
67.7% (63.2-74.7) 
 
0.233 
CP (N=238) n=30 
12.6% (8.7-17.5) 
n=14 
5.9% (3.2-9.7) 
n=52 
21.9% (16.8-27.6) 
n=142 
59.7% (53.1-66.0) 
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Table 5. Positive predictive values (in italics, computed from the number of true positives=n over the 
number of verified test positives=N) at three cutoffs for verified follow-up outcome in LBC and CP, crude 
and adjusted* PPV ratios (PPVLBC / PPVCP) 
 
 
Intention-to-treat analysis 
 
 
LBC 
n 
PPV (95% CI) 
CP 
n  
PPV (95% CI) 
Crude PPV ratio  
(95% CI)  
Adjusted PPV ratio# 
(95% CI)  
Baseline cytology 
ASCUS+ 
 
N=1,220 
 
N=1,079 
  
CIN1+/LSIL+ n=440 
36.1% (33.4 – 38.8) 
n=369 
34.2% (31.4 – 37.0) 
 
1.05 (0.94 – 1.18) 
 
0.97 (0.81 – 1.18) 
CIN2+/HSIL+ n=354 
29.1% (26.5 – 31.6) 
n=285 
26.4% (23.8 – 29.0) 
 
1.10 (0.96 – 1.25) 
 
0.99 (0.80 – 1.22) 
Baseline cytology LSIL+  
N=475 
 
N=399 
  
CIN1+/LSIL+ n=351 
73.9% (69.9 – 77.9) 
n=283 
70.0% (66.5 – 75.4) 
 
1.04 (0.95 – 1.13) 
 
1.03 (0.74 – 1.42) 
CIN2+/HSIL+ n=303 
63.8% (59.5 – 68.1) 
n=243 
60.9% (56.1 – 65.7) 
 
1.05 (0.94 – 1.16) 
 
1.03 (0.66 – 1.78) 
Baseline cytology HSIL+  
N=288 
 
N=247 
  
CIN2+/HSIL+ n=251 
87,1% (83.3 – 91.0) 
n=200 
81.0% (76.0 – 85.9) 
 
1.08 (0.99 – 1.16) 
 
1.08 (0.67 – 1.75) 
 
Per-protocol analysis 
 
 
LBC 
n 
PPV (95% CI) 
CP 
n  
PPV (95% CI) 
Crude PPV ratio  
(95% CI)  
Adjusted PPV ratio# 
(95% CI)  
Baseline cytology 
ASCUS+ 
 
N=1,144 
 
N=1,027 
  
CIN1+/LSIL+ n=412 
36.0% (33.2-38.9) 
n=349 
34.0% (31.1-37.0) 
 
1.06 (0.94 – 1.19) 
 
0.99 (0.81 – 1.21) 
CIN2+/HSIL+ n=331 
28.9% (26.3-31.7) 
n=274 
26.7% (24.0-29.5) 
 
1.08 (0.94 – 1.24) 
 
0.99 (0.79 – 1.23) 
Baseline cytology LSIL+  
N=448 
 
N=387 
  
CIN1+/LSIL+ n=329 
73.4% (69.1-77.5) 
n=272 
70.3% (65.5-74.8) 
 
1.04 (0.96 – 1.14) 
 
1.06 (0.76 – 1.49) 
CIN2+/HSIL+ n=283 
63.2% (58.5-67.6) 
n=235 
60.7% (55.7-65.6) 
 
1.04 (0.93 – 1.16) 
 
1.04 (0.77 – 1.40) 
Baseline cytology HSIL+  
N=269 
 
N=238 
  
CIN2+/HSIL+ n=233 
86.6% (82.0-90.4) 
n=194 
81.5% (76.0-86.2) 
 
1.06 (0.98 – 1.15) 
 
1.09 (0.66 – 1.79) 
 
CIN1/LSIL or more severe; CIN2+/HSIL, CIN2/HSIL or more severe; ASCUS+, atypical squamous/glandular cells of 
undetermined significance or more severe; LSIL+,  low-grade squamous epithelial lesion or more severe; HSIL+, high-
grade squamous epithelial lesion or more severe; PPV, positive predictive value; CI, confidence interval) 
#adjusted for age, study site, urbanization level and study period, taking clustering into account 
 
 
analyses was demonstrated that LBC was not superior to CP regarding detection rates of 
histological confirmed outcomes. The same was found for the positive predictive values. 
Altogether, these findings provide strong evidence that the performance of LBC is not  
superior to that of CP when applied within a well-organized and quality-controlled cervical 
screening program. 
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These findings are partly in contrast with the results of other studies comparing performance 
of LBC and CP [17-39]. Most studies used a non-randomized study design and compared only 
cytological test positivity rates. Only a limited number focused on biopsy-confirmed cervical 
lesions or (blind) gold standard verification. 
 
The results of various systematic reviews varied depending on the quality criteria for inclusion 
of individual studies [4-7]. Our results are in line with those of a recently published meta-
analysis, including only clinical studies with complete gold standard verification or 
randomized screening trials with nearly complete verification of cytological abnormalities [5]. 
 
A randomized study design was applied in only three other studies [40-42]. One study was 
underpowered (n=1.999) but also found no difference in performance of LBC and CP [40]. 
Another, large-scale study (n=45.174) from Ronco et al. [41] found no statistically significant 
difference for detection of CIN2+ between LBC and CP but reported a reduced positive 
predictive value for LBC. This was, in contrast to the current trial, the result of an increased 
frequency of minor cytological abnormalities with LBC without an increase in high-grade CIN 
on histology. In accordance to the present study they reported a significant decrease in 
unsatisfactory rates too. Finally, in a smaller study (n=13.484) from Strander et al. [42] LBC 
detected significantly more high-grade lesions but this was at the expense of a 30% increase 
in abnormal cytology samples. 
 
In contrast, the present study found no difference in sensitivity in terms of histological 
detection rates of cervical lesions or in positive predictive value between LBC and CP, 
indicating that the accuracy of both methods is comparable [44]. This may be caused by 
high quality standards of conventional screening in the Netherlands. 
 
Because of randomization, it can plausibly be assumed that the prevalence of CIN was equal 
in both arms. Therefore, the lack of difference in DR and PPV in this RCT demonstrates that 
LBC is neither more sensitive nor more specific in detecting cervical cancer precursors than 
the conventional PAP smear. A reduced unsatisfactory rate was found when using LBC [8] 
even though the added value was limited since the unsatisfactory rates were already low. 
On the other hand, the cost of an individual LBC test is higher as compared to a CP test, but 
in unequivocal cases it has the possibility of concomitant testing on the residual material for 
the presence of hrHPV or other molecular cell cycle related biomarkers. 
 
In conclusion, LBC is neither more sensitive nor more specific in detecting cervical 
intraepithelial neoplasia or cancer. 
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General discussion 
 
The primary goal of cervical cancer screening is to decrease the incidence of cervical 
cancer by early detection of premalignant cervical lesions. In the Netherlands a reorganized 
cervical screening program has been active since 1996. The reorganization focused on 
organizational changes, changes in the screening interval and age-range as well as on the 
redefinition of follow-up policies. These were laid down in national guidelines. An important 
component of quality assurance of organized cervical screening is monitoring and 
evaluation of existing guidelines. In this thesis some of the national management and 
reporting guidelines as defined during the 1996 reorganization of the cervical screening 
program were evaluated. Furthermore, the performance of another preparation technique 
for cervical smears - liquid-based cytology (LBC) – for use within the cervical screening 
program was investigated. For this purpose we studied the accuracy and adequacy of the 
ThinPrep system, one of the liquid-based preparation techniques. 
 
In chapter 2 we investigated whether the first management guideline from 1996 with an 
advice to repeat a negative ECC- Pap test (missing endocervical component in the absence 
of cellular abnormalities (Pap1)) after 6 months has been effective. In Chapter 3 the reporting 
guideline for the presence of normal endometrial cells in asymptomatic postmenopausal 
women was evaluated. In chapter 4, the compliance and outcome after repeated 
borderline smears were studied and discussed. Lastly, in chapter 5 and 6 the cytological 
detection rates and relative accuracy of LBC as compared with conventional cytology were 
investigated. In this final chapter the main findings of the various studies will be discussed 
within the scope of the quickly changing field of cervical cancer screening. The next years, 
the current program will be prone to serious changes due to new developments, of which the 
most important are HPV testing, automated screening and HPV-vaccination which all will 
have their impact. The conclusions discussed here should therefore be considered in the 
context of these future developments. 
 
In general, in this thesis it was demonstrated that evaluation of the early guidelines was useful 
in proposing recommendations on measures for a more effective follow-up management in 
the cervical screening program. Furthermore, the study on the performance of LBC in the 
cervical screening program showed that the relative accuracy of the ThinPrep technique is 
equal to that of conventional cytology. However, this technique offers other advantages that 
could make implementation of LBC in the cervical screening program profitable. 
 
In chapter 2 the prevalence of squamous cervical lesions in women with a recent negative 
ECC- smear was compared with the prevalence of these lesions in women with a ECC+ 
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smear. In order to estimate the true prevalence, short-term follow-up results of negative ECC- 
smears were additionally used. This was possible because the first follow-up guideline from 
1996 advised women with a negative ECC- test result to have a follow-up smear made after 6 
months. In case the follow-up smear was a recurrent negative ECC- smear, the woman was 
referred back to the 5-years scheme of the screening program. The effectiveness of this 
follow-up protocol was tested because the clinical relevance of negative ECC- smears was 
disputed in literature. This was especially relevant because negative ECC- results are 
diagnosed rather frequently in the Netherlands (in about 10 percent of the cases) and thus 
results in a considerable burden for the screening population and laboratories on the one 
hand and on public resources on the other hand. The conclusion of this study was that the 
estimated true prevalence of cervical lesions in women with a recent negative ECC- smear is 
significantly lower as compared to women with a recent negative ECC+ Pap test and that 
there is no justification for these women at low risk to have a repeat smear. This conclusion 
was in concordance with the change in the management for negative ECC- smears as 
proposed by the Bethesda 2001 System in which a negative ECC- smear is considered 
satisfactory. Based on the new insights provided by this and another important evaluation 
study from the Netherlands 1 as well as other international studies 2,3, early repeat testing for 
ECC- smears in the Netherlands has been abolished in 2002. This guideline was slightly 
adjusted in 2007. When the uterine cervix has not been visualized during smear taking or was 
found to be abnormal, a negative ECC- is considered inadequate and diagnosed as Pap 0 
and repeated in short term (after 6 weeks). However, administrative failures in the reporting of 
the cervical status during smear taking in combination with a negative ECC- diagnosis, also 
leads to an inadequate test result (Pap 0). The impact of this policy-change should be 
monitored and evaluated closely as well as the outcome of inadequate test results that are 
based on the absence of transformation zone components combined with an abnormal or 
unseen / unreported cervical status. The increasing use of LBC may also have impact on the 
effectiveness of the adjusted guideline for ECC- smears, since some studies reported an 
increase in ECC- results after implementation of LBC. Most of these studies used a split-sample 
design in which a conventional smear is made first and the residual material is used for LBC 
subsequently 4-8 resulting in a possible disadvantage for LBC. In direct-to-vial studies this 
increase in ECC- was not seen 4,9. However, our study on the accuracy and adequacy of the 
ThinPrep technique (NETHCON trial) found an increase in ECC- results when using LBC (results 
not yet published). Careful monitoring and evaluation of the effectiveness of this issue is 
strongly recommended. 
 
The clinical relevance of normal endometrial cells in cervical smears of asymptomatic 
postmenopausal women – being equivalent with the older age-cohorts in the cervical 
screening program – is also disputed worldwide. Though a cervical smear is not a screening 
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tool for the detection of endometrial lesions, these lesions can be diagnosed occasionally 
through the finding of abnormal endometrial cells in the Pap test. This can be considered as 
an extra benefit of cervical cancer screening. The finding of normal endometrial cells in 
smears of women in their postmenopause however, especially when there are no clinical 
complaints such as abnormal bleeding, may lead to a diagnostic dilemma. In the 
Netherlands, reporting of normal endometrial cells is advocated. An additional remark for the 
clinician is given when normal endometrial cells are found in smears of postmenopausal 
women: ‘in the presence of clinical symptoms that are associated with endometrial 
pathology, further gynecological investigation is advised‘. In the 1996 guidelines this was 
underscored by the alerting Pap classification Pap3a. This policy was changed during 2004. 
Reporting of the alerting Pap3a classification was abandoned and replaced by a Pap1 
classification. Even though the additional remark was maintained, an important signal to the 
clinician has been lost with the abolishment of the alarming Pap class, because many 
clinicians only look at the Pap-class of the test result. The Bethesda 2001 System also 
advocates reporting of normal endometrial cells in women older than 40 years of age with an 
optional educational comment that ‘endometrial cells after menopause may be associated 
with benign endometrial changes, hormonal alterations, and, less commonly, endometrial 
abnormalities’. Clinical correlation is recommended. In chapter 3 it is shown that only very 
few asymptomatic postmenopausal women are diagnosed with normal appearing 
endometrial cells in their smear (0.2 %). In 6.5 % of these cases an endometrial (pre)-
malignancy was found. As compared with women with smears without endometrial cells the 
Relative Risk was 40 times higher. These results would justify a direct referral to a gynaecologist 
since the number of women concerned is only very limited while the relative risk is significant. 
However, the number of cases in the study is limited which could diminish the validity of the 
results. Therefore it is recommended to perform a more extensive study, using the worldwide 
unique PALGA database, to come to a more definite conclusion whether it would be 
appropriate to refer these cases for gynaecological evaluation directly. In the mean time it 
would make sense to reconsider the reporting of the Pap3a diagnosis for these cases in order 
to provide the clinician with an extra alert. In view of new developments in the field of 
cervical screening it would be a loss if the incidental detection of endometrial lesions would 
be complicated by the introduction of new technology such as LBC or automated screening. 
The impact of these new technologies with regard to this issue should be evaluated carefully. 
 
With the reorganization of the screening program in 1996, the cytological criteria for 
borderline abnormality were redefined. In the period before, the proportion of borderline 
cytology exceeded 10 % as inflammatory changes were classified Pap 2 as well. In 1996, the 
threshold for borderline abnormality was elevated in such way that inflammatory changes 
were classified as normal. As a result the frequency of borderline cytology decreased 
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sharply10. Along with the redefinition of the borderline abnormalities, the follow-up 
management was changed also. Where in former days women with borderline cytology 
were seen every 12 months until the abnormality progressed or normalized, women with an 
initial borderline abnormality have cytological triage after 6 months since 1996. Persistent 
borderline abnormalities are referred for colposcopy. In case the initial abnormality 
normalized after 6 months, a second repeat smear after the next 12 months is made. The 
expectation was that the cytological triage after 6 months would improve the predictive 
value and reduce unnecessary smear-taking and costs as compared to the old situation. On 
the other hand there was scepticism concerning the demand for colposcopy and 
effectiveness of this new follow-up guideline. The effectiveness depends on a high referral 
compliance and acceptable predictive value for significant cervical lesions. In chapter 4 we 
studied these items and found that the referral compliance was high, despite earlier 
scepticism. A minimum of 77.7 % of women with repeated borderline cytology was 
adequately referred for colposcopy, indicating that the management protocol had been 
accepted for the greater part by the general practitioners. The predictive value of repeated 
borderline cytology was found to be 25.2 % for CIN 1 or more severe and 10.2 % for CIN 2 or 
more. These figures are lower than generally found in studies performed outside the 
Netherlands and suggest that the accuracy of borderline cytology is lower as compared to 
other countries. Careful monitoring of the predictive value of borderline abnormalities and 
continuous education is of utmost importance for improving the predictive value without 
compromising the sensitivity of screening. In our study we found four cases of cervical 
carcinoma after repeated borderline cytology, emphasizing the significance of this 
cytological diagnosis. However, this was at the cost of a considerable level of over-
diagnostics and over-treatment, harming many healthy women and leading to unnecessary 
costs. This could be improved by prioritizing women for colposcopy based on their age, clear-
cut use of criteria for borderline cytology, higher thresholds for colposcopic directed biopsy, 
but most important, HPV triage eventually combined with other molecular testing. Recently 
negative HPV-triage has been implemented in the follow-up procedure for borderline and 
mildly dysplastic cytology. The follow-up smear after an initial borderline smear is allowed to 
be additionally HPV-triaged. LBC is especially attractive for this purpose, since next to 
cytological assessment the HPV test can be performed on the same cell sample. Women with 
HPV-negative smears and normalized cytology are referred back to the next round of the 
screening program. Women with HPV-negative smears and persistent borderline cytology are 
followed cytologically after 12 months instead of being referred to the gynaecologist. HPV-
triage on the initial borderline smear is not allowed. This together illustrates the quickly 
changing landscape in which cervical cancer screening in the Netherland is performed. The 
effectiveness of the implementation of HPV-triage has to be monitored and compared to the 
earlier guideline. Optimal registration of the results of HPV-triaging is a prerequisite in which 
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PALGA should play a vital role. Attention should also be focused on continuing research on 
the additional value of other molecular biomarkers for optimizing the specificity of HPV-triage. 
 
Liquid-based cytology, of which ThinPrep is one of the representatives, is widely practiced in 
the Netherlands. Nevertheless, use of LBC within the cervical screening program was not 
allowed until recently. The reason was the lack of sufficient evidence for the superiority of LBC 
as compared to conventional cytology. The conclusion of the evidence-based review ‘CBO 
guideline cervical cytology’ – on the applicability of automated screening, LBC and HPV-
detection in the cervical screening program – which has been published in 2002, was that 
‘further evaluation of the costs and benefits of the ThinPrep method should be undertaken to 
decide definitively whether to implement this method in the Netherlands population 
screening program’. Several publications indicated that the absence of high-quality studies 
hampered drawing definitive conclusions on the accuracy and adequacy of LBC 11-13. This 
was the motive to start a cluster randomized controlled trial in the Netherlands (Nethcon). This 
trial focuses on the accuracy, adequacy and cost-effectiveness of the ThinPrep technique in 
comparison to conventional cytology. In chapter 5 the cytological test positivity and 
inadequacy rates were studied. In chapter 6 the diagnostic accuracy of the ThinPrep 
method was investigated. The large-scale trial, that included almost 90,000 participants 
detected no difference in test positivity rates between LBC and conventional cytology. On 
the other hand a significant reduction in unsatisfactory rate for LBC was found. The results as 
such provided insufficient evidence to conclude that the accuracy of LBC and conventional 
cytology is equal. Correlation with a reference standard of the test positive cases is required. 
This was further studied in chapter 6. This was expressed in terms of ratios of verified 
histological detection rates and positive predictive values. No difference was found in 
histological detection rates nor in positive predictive values between the two study arms. 
Therefore, the diagnostic accuracy of ThinPrep as compared to conventional cytology is 
considered to be equal. As mentioned, LBC was found to result in reduced unsatisfactory 
rates. However, in the scope of the Dutch cervical screening program, this advantage of LBC 
is limited since the unsatisfactory rate of conventional cytology is already low. The main 
advantage of LBC in the setting of the Dutch cervical screening program is the availability of 
residual material for HPV testing and other molecular tests. This is of increasing concern since 
the role of HPV testing is expected to grow in the next years. LBC assists adjunctive testing 
and can achieve greater laboratory efficiency by increasing throughput as a result of a 
reduced screening time. HPV testing is presently implemented in the follow-up management 
of initially borderline and low-grade program smears as a negative triage tool. It is not unlikely 
that the results of presently running studies, which are focusing on combined HPV/cytology 
testing 14 and on reflex HPV triage of borderline and low-grade program smears will have 
consequences for the role of HPV-testing within the screening program in the near future. As 
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been mentioned before, other advantages of LBC comprise the reduced screening time and 
screening comfort for cytotechnologists and the positive experiences of general practitioners 
with LBC. Other new developments in cervical cancer screening profit from the increasing 
use of LBC too. LBC is especially suited for automated screening, a technique that will be 
used increasingly in the near future. A possible higher productivity and higher sensitivity for the 
detection of CIN by the combination of LBC and automated screening may prove to be 
favorable. However, future research should clarify whether implementation of this new 
technology combined with LBC in the screening program is accurate, adequate and cost-
effective. In summary, accuracy of LBC is equal as compared with conventional cytology 
and implementation of LBC in the cervical screening program should therefore be based on 
cost-technical and other qualitative considerations and viewed in the perspective of other 
new developments in cervical screening.   
 
Future perspective 
 
Cervical cancer screening is a secondary prevention measure that has proven to be 
capable in effectively reducing the incidence and mortality of cervical cancer. However, a 
further reduction is hindered by issues of adherence, failures in the screening program and a 
limited sensitivity of the screening test. As a matter of fact, the most effective and challenging 
way to minimize the number of cervical cancer cases through screening still seems to be the 
improvement of adherence and coverage15. Besides that, skilled quality management is 
considered more important by some authors than novel screening approaches, especially in 
developing countries 16. Nevertheless, new technology will unquestionably going to play a 
role in cervical cancer prevention in the near future.  
 
Since the recognition of persistent infection with hrHPV as the necessary cause of cervical 
cancer and its precursor lesions, a strategy of primary prevention through prophylactic HPV 
vaccination has become available. Two prophylactic vaccines have been developed. Firstly 
the bivalent Cervarix (GlaxoSmithKline Biologicals, Rixensart, Belgium) – protecting against 
infection from oncogenic HPV types 16 and 18 – and secondly the quadrivalent HPV vaccine 
Gardasil (Sanofi Pasteur MSD)), protecting against oncogenic HPV types 16 and 18 and low 
risk HPV types 6 and 11, which are associated with anogenital warts. HPV16 and 18 are 
considered to be responsible for approximately 70% of the cervical cancers. Thus a maximum 
reduction of 70% may be achieved. This can be accomplished only when vaccination 
coverage is high and women are vaccinated before their sexarche. The results of 
randomized, double-blind, placebo controlled phase III clinical trials show that the vaccines 
are highly immunogenic. The antibody titers persist for at least 7 years after vaccination. 
However, the long-term prophylaxis is not yet known. The necessity of booster  injections can 
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only be assessed during long-term follow-up. Clinical trials show that the efficacy for 
protection against persistent HPV16/18 infections in HPV16/18 negative women amounts 90% 
or more 17. Additionally, cross-protection against other hrHPV types, such as HPV31/45 has 
been reported. Protection against CIN was high but not 100%. However, it will take longer 
follow-up time before current clinical trials will be conclusive about efficacy of vaccination in 
reduction of cervical carcinoma. Possible threats for the effectiveness of vaccination is type 
replacement (replacement with other hrHPV types than the types that are targeted by the 
vaccine within the vaccinated population) and development of escape mutants (vaccine 
resistant mutant subtypes). Finally, long-term adverse effects are unknown and should be 
monitored carefully also. Despite these uncertainties The Dutch Health Council approved 
introduction of the HPV vaccine in the National Vaccination Program for 12-year old girls, 
starting in 2009 18. The preventive effect of HPV vaccination will not be seen within the next 10 
to 15 years and will not eliminate screening requirements. Moreover, screening will remain 
important to protect vaccinated women against non-HPV16/18 hrHPV induced cervical 
carcinomas. However, deteriorated compliance for cervical screening may become a threat 
as women may assume to be fully protected by HPV vaccination. Self-sampling followed by 
HPV-testing might be an attractive option to maintain acceptable participation rates. Primary 
prevention through HPV vaccination will have a significant impact on the rate and 
distribution of abnormal cytology and thus on the secondary prevention strategy. Guidelines 
for cervical screening will need revision in long term and the optimal screening policy within 
the context of effective HPV vaccination will have to be assessed. The challenge will be to 
achieve a cost-effective synergy between HPV vaccination and cervical cancer screening. 
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Cervical carcinoma is still one of the leading causes of death from cancer in women 
worldwide. In the Netherlands, the incidence and mortality from cervical carcinoma is 
among the lowest in Europe as a result of  cervical cancer screening with the so-called Pap 
test. Cervical cancer screening has been organized in a national program in the Netherlands 
since 1988. The program consists of various stages including invitation, smear-taking, cell 
processing and microscopic evaluation by the laboratory, reporting, follow-up management 
and possibly treatment. Screen-detected premalignant cervical lesions can be treated 
effectively, thus preventing the development of cervical cancer. Persistent infections with 
high-risk human papilloma virus (hrHPV) types are a necessary cause for development of 
(pre)-cancerous cervical lesions. HPV infection is very common with a life time risk of 80%. 
However, most infections are transient and cervical cancer is a rare consequence of a hrHPV 
infection.  
 
The goal of cancer screening is reduction of incidence and mortality of cancer. Cancer 
screening is most effectively performed within an organized setting with quality assurance at 
all levels and continuous monitoring of effects. However, a 100 % effectiveness has never 
been achieved in any screened population, despite the introduction of various policies and 
new technologies. Failures in any stage of the screening program results in a reduced 
effectiveness. This gives rise to several negative side-effects such as false reassurance in case 
of false-negative and to overtreatment, unnecessary anxiety and costs in case of false-
positive tests. Therefore optimally performing screening tests and best possible follow-up 
protocols must be used and monitored. Nationally defined guidelines help to achieve a 
maximal reduction in the incidence of cervical cancer at the cost of a minimal number of 
women exposed to the negative side-effects of screening. Monitoring and evaluation of 
these guidelines are an essential component of quality assurance of cervical screening. 
Implementation of new tests or procedures should be evidence-based and preferably 
evaluated with randomized trials. The aim of this thesis is to evaluate existing guidelines for 
follow-up management on the one hand and the accuracy of liquid-based cytology (LBC) 
with the ThinPrep system, a new cytological test for cervical screening on the other hand with 
the objective to define recommendations for improvement of the quality of the Dutch 
screening program. 
 
In chapter 2 the effectiveness of the first guideline on the management of a negative (Pap1) 
test without endocervical cells (ECC-) from 1996 has been evaluated. The clinical relevance 
of ECC- results have been questioned in literature. Since the first follow-up guidelines adviced 
woman with a negative ECC- smear to have a repeat smear after 6 months, we could 
estimate the true prevalence of cervical lesions in women without endocervical cells in their 
smears as compared to women with endocervical cells by adding the results of short-term 
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follow-up of negative ECC- smears to the cross-sectional prevalence. The results show that 
the estimated true prevalence of squamous lesions in women with recent ECC- smears is 
significantly lower as compared with women with ECC+ smears and that there is no 
justification for these women at low risk to have a repeat test after 6 months. In accordance 
to the Bethesda 2001 System and based on new insights, the early repeat testing for ECC- 
smears in the Netherlands has been abolished in 2002 and the guideline on the management 
of ECC- smears was adjusted slightly again in 2007. Careful monitoring and evaluation of the 
effectiveness of this guideline is strongly recommended.  
 
Chapter 3 describes a study on the reporting guideline for normal endometrial cells in 
asymptomatic postmenopausal women. The relevance is also disputed worldwide. The 
finding of normal endometrial cells in postmenopausal women without any clinical 
complaints may lead to a diagnostic dilemma. In the Netherlands an additional remark for 
the clinician is provided. The policy of an alerting Pap3a classification was changed during 
2004 when this was replaced by a Pap1 classification. This was the reason why we started a 
study to determine whether postmenopausal asymptomatic women with normal endometrial 
cells in their smear are at higher risk for significant endometrial pathology as compared with 
women without these cells in their smears. We found a 40.2 times significant higher relative risk 
and therefore these cases should be reported to the physician with an explicit comment that 
this is an abnormal finding,  possibly associated with significant endometrial pathology. 
However, the relative small number of cases may limit the validity of the results and it is 
recommended to perform a more extensive study to come to a more definite conclusion 
whether it is appropriate to refer these cases for gynaecological examination. In the mean 
time the reporting of these cases as Pap3a should be reconsidered.  
 
The management guideline for repeated borderline abnormalities with respect to referral 
compliance and outcome is investigated in chapter 4. With the reorganization of the cervical 
screening program in the Netherlands in 1996, cytological criteria for borderline abnormality 
(Pap2) were redefined as well as the follow-up management. A conservative management 
with cytological triage after 6 months was chosen. Women with persistent or progressing 
borderline lesions are referred to a gynaecologist for colposcopic evaluation. Compliance 
with the referral guidelines and the outcome after repeated borderline abnormalities had not 
been evaluated. In this study we found that the referral compliance was high (78 %). The 
predictive value of persistent borderline abnormality was found to be 25.2 % for CIN 1 lesions 
or more severe and 10.2 % for CIN 2 or more severe abnormality. This is lower than usually 
found in other studies performed outside the Netherlands suggesting that the cytological 
accuracy of borderline cytology in the Netherlands is moderate. Careful monitoring of the 
predictive value of borderline abnormalities and continuing education of cytotechnologists  
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is crucial for improving the predictive value without compromising the sensitivity of screening. 
We suggest prioritizing women for colposcopy based on age, but more important is a clear 
use of criteria for borderline cytology, higher thresholds for colposcopic directed biopsy and 
HPV triage perhaps combined with other molecular testing on remaining cell material. With 
respect to HPV testing, use of liquid-based cytology (LBC) is especially attractive. Residual 
LBC material can be used for additional testing such as HPV or molecular testing. Negative 
HPV-triage is implemented recently in the follow-up management of borderline abnormality 
and mild dysplasia in the Netherlands. Monitoring of the effectiveness of this HPV-triage, a 
good registration of the HPV test results should be given attention in the near future. The 
additional value of molecular biomarkers is subject of continuing research worldwide and 
therefore not yet implemented in the Dutch guidelines.  
 
In chapter 5 and chapter 6, the performance of LBC ThinPrep cytology as compared with 
conventional cytology as well as the relative accuracy of this screening test as applied within 
the Dutch screening program is evaluated. Until recently use of LBC within the screening 
program was not allowed because of insufficient evidence for the superiority of LBC 
compared with conventional cytology. The Nethcon cluster randomized controlled trial 
started in the Netherlands in 2003 with the objective to evaluate the accuracy, adequacy 
and cost-effectiveness of the ThinPrep technique in comparison to conventional cytology 
when applied in the Dutch cervical screening program. The trial included almost 90,000 
participants from 246 randomized family practices. In chapter 5 the cytologic test positivity 
rates of LBC was compared with conventional cytology in terms of crude and adjusted odds 
ratios in a per protocol analysis. Independent on the cytological cut-off for abnormality, no 
difference in cytological detection rates were found between LBC and conventional 
cytology. However, LBC did result in a statistically significant reduction of unsatisfactory 
smears. The actual relative accuracy of LBC can be assessed only after correlation of the 
test-positive cases with a reference standard. Generally, the reference standard for a 
cytological diagnosis is histology. Preferably this reference standard (histology) is blindly 
reviewed. This is studied in chapter 6. The diagnostic accuracy of LBC compared with 
conventional cytology is assessed and expressed in terms of ratios of verified histological 
detection rates and positive predictive values in a per-protocol analysis. The results show that 
there is no statistically significant difference in diagnostic accuracy between LBC and 
conventional cytology. Nevertheless, LBC has some important advantages: reduced 
unsatisfactory rates, availability of residual material for HPV testing and other molecular tests, 
reduced screening time and screening comfort for cytotechnologists and preference of the 
smear-takers for LBC. Besides that, LBC is especially suited for automated screening.  
 
Summary 139 
 
In the chapter 7, the results are discussed in general and placed in sight of emerging future 
developments within the Dutch cervical screening program. The recent availability of two 
prophylactic HPV vaccines will have a significant impact on future screening both worldwide 
as in the Netherland. Despite several limitations and uncertainties, HPV vaccination is 
promising in reducing the incidence of cervical cancer in future. Vaccination of 12 years old 
girls with the bivalent HPV vaccine (Cervarix) has started in the Netherlands in 2009. Even in 
vaccinated populations, screening still will have an important role, yet this will be in a revised 
design.  
 
In summary, this thesis has shown that the field of cervical screening is changing very rapidly. 
Good monitoring and evaluation of every change is important as well as evaluation of new 
technology before introduction in the national screening program. 
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Baarmoederhalskanker of cervixcarcinoom is wereldwijd nog steeds een van de belangrijkste 
oorzaken van sterfte aan kanker bij vrouwen. Nederland behoort bij de Europese landen 
waar de incidentie en sterfte aan baarmoederhalskanker het laagste is als gevolg van een 
screeningprogramma voor baarmoederhalskanker. Hierbij wordt gebruik gemaakt van de 
zogenaamde Paptest. Dit bevolkingsonderzoek (BVO) op baarmoederhalskanker wordt in 
Nederland sinds 1988 landelijk uitgevoerd en is nationaal georganiseerd. Het BVO is een 
ketenproces bestaande uit het uitnodigen van de vrouw, het maken van een uitstrijkje door 
de huisarts of de praktijkassistente, de beoordeling van het uitstrijkje door het laboratorium, 
rapportage van de uitslag via de huisarts aan de vrouw en eventueel vervolgonderzoek en 
soms behandeling door de gynaecoloog. Het doel van screening is het vroegtijdig opsporen 
van (pre)maligne afwijkingen van de cervix. Deze kunnen effectief behandeld worden 
waardoor de ontwikkeling van een cervixcarcinoom kan worden voorkomen. (Pre)maligne 
epitheliale afwijkingen van de cervix ontstaan als gevolg van een persisterende infectie met 
een hoogrisico humaan papilloma virus (hrHPV). Infectie met het HPV-virus komt erg vaak 
voor. Geschat wordt dat 80 % van de vrouwen ooit in haar leven besmet raakt met een HPV-
virus. De meeste HPV infecties zijn voorbijgaand, maar een enkele keer persisteert de infectie 
en dit kan uiteindelijk resulteren in de ontwikkeling van (pre)maligne afwijkingen van de 
cervix. Dit wordt echter beschouwd als een zeldzame complicatie van besmetting met een 
hrHPV.  
 
Het doel van screening op kanker is het reduceren van de incidentie en mortaliteit van deze 
ziekte. Deze is het meest effectief wanneer screening in een georganiseerde setting wordt 
uitgevoerd, met kwaliteitsbewaking op elk niveau van de keten en met continue monitoring 
van de effecten. Ondanks de toepassing van verschillende screening-strategieën en de 
introductie van nieuwe technologieën is het nog nooit gelukt om in een gescreende 
populatie 100 % effectiviteit te bereiken. Dit is het gevolg van fouten die kunnen plaatsvinden 
op elk niveau van het screeningprogramma. Dit resulteert in ongewenste negatieve 
bijeffecten, zoals een onterechte geruststelling bij een fout-negatieve en onnodige 
ongerustheid en overbehandeling in geval van een fout-positieve uitslag. Daarom is het van 
belang een zo betrouwbaar mogelijke screeningstest te gebruiken evenals de meest 
optimale follow-up protocollen. Nationale richtlijnen zijn essentieel in het vinden van een 
balans tussen maximale reductie van kanker ten koste van zo weinig mogelijk negatieve 
bijeffecten. Het monitoren en evalueren van deze richtlijnen zijn een essentieel onderdeel 
van de kwaliteitsbewaking van cervixscreening. Daarnaast moet de implementatie van 
nieuwe testen of procedures ‘evidence-based’ zijn en bij voorkeur onderzocht door middel 
van gerandomiseerde klinische trials. Het doelstelling van deze thesis is het evalueren van 
enkele van de bestaande follow-up richtlijnen en onderzoeken van de accuratesse van 
liquid-based cytology (LBC) ofwel dunnelaag cytologie met de ThinPrep methode. Dit moet 
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resulteren in aanbevelingen voor verdere verbetering van de kwaliteit van het Nederlandse 
bevolkingsonderzoek naar baarmoederhalskanker.  
 
In hoofdstuk 2 wordt de effectiviteit onderzocht van eerste richtlijn uit 1996 met betrekking tot 
de uitvoering van vervolgonderzoek na een negatieve (Pap1) uitstrijk waarin geen 
endocervicale cellen werden gevonden, een zogenaamde ECC- uitstrijk. De klinische 
relevantie van een ECC- uitslag zonder verdere afwijkingen is ondanks veel onderzoek nog 
steeds onduidelijk. De eerste richtlijn voor ECC- uitstrijken, met herhaling van het onderzoek 
na 6 maanden, biedt een goede mogelijkheid om de daadwerkelijke prevalentie van 
afwijkingen in vrouwen met een ECC- uitstrijk te schatten en te vergelijken met ECC+ 
uitstrijken. Dit is mogelijk door de resultaten van de korte termijn follow-up van ECC- uitstrijken 
toe te voegen aan de cross-sectionele prevalentie. De resultaten laten zien dat de 
geschatte prevalentie van plaveiselcellige afwijkingen bij vrouwen met een recente ECC- 
uitstrijk significant lager is in vergelijking met vrouwen met een recente ECC+ uitstrijk. Er 
bestaat derhalve geen goede rechtvaardiging om deze groep van laag-risico vrouwen een 
vervroegd herhalingsadvies te geven. Het vervroegde herhalingsadvies bij een ECC- uitstrijk is 
in 2002 afgeschaft maar in 2007 weer in geringe mate aangepast. Zorgvuldige monitoring en 
evaluatie van de effectiviteit van deze nieuwste richtlijn voor ECC- wordt aanbevolen. 
 
In hoofdstuk 3 worden de resultaten gepresenteerd van een studie over de richtlijn voor 
rapportage van normale endometriumcellen in uitstrijken van postmenopauzale vrouwen 
zonder klinische klachten. De relevantie van deze cellen is wereldwijd onderwerp van 
discussie. Deze cellen horen  normaal niet voor te komen in uitstrijken van postmenopauzale 
vrouwen maar aangezien zij niet afwijkend zijn kan dit leiden tot een diagnostisch dilemma. In 
Nederland is het beleid om in deze gevallen een opmerking aan de uitslag toe te voegen 
dat deze bevinding niet normaal is. Tot 2004 werd in deze gevallen een Pap3a gegeven, 
daarna werd dit vervangen door een Pap1. Deze aanpassing van de richtlijn was de reden 
voor het onderzoek naar de waarde van normale endometrium cellen bij postmenopauzale 
vrouwen zonder klinische klachten. Dit onderzoek liet zien dat vrouwen in de postmenopauze 
bij wie normale endometriumcellen in de uitstrijk werden gevonden een 40.2 keer hoger 
relatief risico hadden op de aanwezigheid van (pre)maligne endometrium laesies. De 
conclusie is dat deze bevinding aan de clinicus moet worden gerapporteerd met de 
toevoeging van een expliciete opmerking dat dit een abnormale bevindingen is welke 
mogelijk geassocieerd is met significante endometrium pathologie. Een beperking van deze 
studie is het relatief kleine aantal cases hetgeen de validiteit verminderd. Een direct 
verwijsadvies van deze patiënten wordt om deze reden op dit moment nog niet aanbevolen 
anders dan nadat deze bevindingen in een grotere studie worden bevestigd. In de tussentijd 
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is het verstandig de afschaffing van de Pap3a uitslag te heroverwegen, teneinde de clinicus 
extra te attenderen. 
 
De follow-up richtlijn met betrekking tot persisterende borderline afwijkingen (Pap2) wordt in 
hoofdstuk 4 onderzocht. Tijdens de reorganisatie van het bevolkingsonderzoek in 1996 werd in 
Nederland, tegelijk met de cytologische criteria voor een Pap2, het follow-up beleid 
geherdefinieerd. Er werd in Nederland gekozen voor een conservatief follow-up beleid met 
cytologische triage na 6 maanden. Wanneer de afwijking persisteert of progressief is, wordt 
de vrouw naar de gynaecoloog verwezen voor verder onderzoek (colposcopie). De naleving 
van dit verwijsbeleid noch de uitkomsten hiervan waren sinds de invoering onderzocht. Uit 
deze studie blijkt dat de naleving van het verwijsadvies met 78 % hoog is. De positief 
voorspellende waarde van een persisterende Pap2 uitslag was 25,2 % voor CIN 1 of ernstiger 
en 10,2 % voor CIN 2 of meer. Dit is lager dan over het algemeen bij andere buitenlandse 
studies wordt gevonden. Dit suggereert dat de accuratesse van een Pap2 diagnose in 
Nederland matig is. Om de voorspellende waarde van de Pap2 diagnose te verbeteren 
zonder de sensitiviteit van de screening aan te tasten is deelname aan 
nascholingsprogramma’s van cytologisch analisten van groot belang, evenals een 
nauwkeurige bewaking van de voorspellende waarde. Verder is priorering van vrouwen op 
basis van leeftijd een mogelijkheid. Echter, een meer stringent gebruik van de criteria voor 
Pap2, het gebruik van een hogere drempelwaarde voor colposcopisch geleide biopten door 
de gynaecoloog of toepassing van HPV triage, eventueel gecombineerd met moleculair 
onderzoek van het restmateriaal van de uitstrijk ligt meer voor de hand. Gebruik van 
dunnelaag cytologie heeft een groot voordeel boven de conventionele uitstrijk met 
betrekking tot de uitvoering van aanvullende testen zoals HPV- en moleculaire testen. Na het 
maken van een cytologisch preparaat kan het overgebleven materiaal voor aanvullende 
testen worden gebruikt. Negatieve triage met behulp van een HPV test is sinds kort in 
Nederland toegestaan in het follow-up traject van geringe afwijkingen. De effectiviteit van 
deze nieuwe triage methode moet goed gecontroleerd worden. Verder is een goede 
registratie van de resultaten van de uitslag van de HPV test van groot belang. Onderzoek 
naar de toegevoegde waarde van het gebruik van moleculaire biomarkers bij de triage van 
cytologisch geringe afwijkingen is momenteel wereldwijd nog onderwerp van studie en in 
Nederland daarom nog niet vastgelegd in de richtlijn.  
 
Hoofdstuk 5 en 6 handelen over de prestatie van LBC ThinPrep cytologie in vergelijking met 
conventionele cytologie. Tevens wordt de relatieve accuratesse van de ThinPrep methode 
onderzocht indien deze wordt toegepast binnen het Nederlandse bevolkingsonderzoek naar 
baarmoederhalskanker. Dit was tot voor kort niet toegestaan omdat er onvoldoende bewijs 
was voor de geclaimde superioriteit van LBC. Daarom werd in Nederland in 2003 de Nethcon 
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gerandomiseerde gecontroleerde trial gestart met als doel de accuratesse, geschiktheid en 
kosten-effectiviteit van de ThinPrep methode te vergelijken met conventionele cytologie. 
Voor de trial werden 90.000 deelneemsters geïncludeerd afkomstig uit 246 gerandomiseerde 
huisartspraktijken. In hoofdstuk 5 wordt de cytologische test positiviteit van ThinPrep door 
middel van een per protocol analyse vergeleken met conventionele cytologie, uitgedrukt in 
ruwe en gecorrigeerde odds ratio’s. Er wordt voor geen enkel cytologisch afkappunt verschil 
in cytologische test positiviteit gevonden tussen de twee technieken. De ThinPrep LBC 
techniek geeft wel significant minder uitstrijken van onvoldoende kwaliteit. De werkelijke 
relatieve accuratesse van LBC ten opzichte van conventionele cytologie kan alleen worden 
bepaald als de test-positieven worden vergeleken met een referentie standaard. Als 
referentie standaard voor cytologie wordt over het algemeen histologie gebruikt. Deze 
referentie standaard (histologie) is dan bij voorkeur blind gereviseerd. De relatieve 
accuratesse van LBC wordt onderzocht in hoofdstuk 6. Deze wordt uitgedrukt in ratio’s van 
de geverifieerde histologische detectie percentages en de positief voorspellende waarden 
in een per protocol analyse. De resultaten tonen aan dat er  geen statistisch significant 
verschil is in diagnostische accuratesse tussen ThinPrep en conventionele cytologie. 
Desalniettemin blijkt het gebruik van de ThinPrep methode diverse andere voordelen te 
hebben. Het percentage onvoldoende kwaliteiten is lager dan bij conventionele cytologie, 
er is rest materiaal beschikbaar voor de uitvoering van een (reflex) HPV test of andere 
moleculair biologische test, de tijd van screening is korter, het screenen van een dunnelaag 
preparaat is voor de cytologisch analist veel comfortabeler en het gebruik van LBC heeft de 
sterke voorkeur van de praktijkassistenten en de huisartsen. Daarnaast is dunnelaag cytologie 
bij uitstek geschikt voor computer ondersteund screenen.  
 
In hoofdstuk 7 worden de resultaten van de verschillende hoofdstukken in bredere zin 
bediscussieerd in het licht van toekomstige ontwikkelingen binnen het bevolkingonderzoek 
baarmoederhalskanker in Nederland. De recente beschikbaarheid van twee profylactische 
HPV vaccins zal wereldwijd en in Nederland een grote invloed hebben op de toekomstige 
screening naar baarmoederhalskanker. Ondanks verschillende beperkingen en allerhande 
onzekerheden is HPV vaccinatie veelbelovend met betrekking tot een verdere reductie van 
de indicentie van baarmoederhalskanker in de nabije toekomst. In het voorjaar van 2009 is in 
Nederland gestart met de vaccinatie van meisjes van 12 jaar met één van de beschikbare 
HPV vaccins welke is gericht tegen 2 hrHPV typen. Desalniettemin zal ook in een 
gevaccineerde populatie screening op baarmoederhalskanker nodig blijven, zij het in een 
aangepaste vorm.  
 
Samengevat laat deze thesis zien dat het gebied van cervix screening onderhevig is aan 
snelle veranderingen waarbij een goede monitoring en evaluatie van elke aanpassing van 
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groot belang is, evenals onderzoek naar nieuwe technieken, voordat deze worden 
geïntroduceerd in het landelijke screening programma. 
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opgezet! Ik heb de tijd onder jouw leiding als bijzonder motiverend ervaren waarvoor ik je 
altijd dankbaar zal zijn! Mijn co-promoter dr J Bulten, beste Hans, voor jou een bijzonder 
woord van dank! Jij hebt mij ondersteund bij de verschillende onderzoeken welke tot dit 
proefschrift hebben geleid en mij begeleid richting afronding van dit proefschrift. Dit alles op 
de voor jouw zo kenmerkende zeer nauwgezette, beschouwende en rustige manier. De vele 
en bijzondere hoogtepunten waarin jij als bijzonder kleurrijk persoon figureerde zal ik mij nog 
lang blijven herinneren: om je verhalen over ‘tante Grada en de caravan’ maar vooral ook 
om jou rol als reisleider tijdens onze talrijke congressen kan ik smakelijk blijven lachen. Tredend 
in de voetsporen van Paulus op de Areios Pagos in Athene, die van Marie-Antoinette op haar 
schavot aan het Place de la Concorde in Parijs en van Lord Byron, Goethe en Casanova op 
het terras van Caffè Florian op het San Marco plein in Venetië heb ik heel wat gezellige uren 
in jouw gezelschap doorgebracht. Het inspirerende bezoek aan het Museo Thyssen-
Bornemisza in Madrid bleek je zo te hebben uitgeput dat je in slaap viel op het terras tot je 
gewekt werd door luid applaus van een buslading uitbundige Madrilenen. In Rovaniemi, 
Finland liet je echter zien dat er in jou ook nog een primitieve natuurmens schuilt en dat het 
bakken van worsten op een openhoutvuur in het bos ook geen enkel probleem vormt voor 
een ‘heer van stand’. Kortom: dank voor je inspirerende begeleiding en al je gezelligheid en 
humor! Prof. dr LFAG Massuger, beste Leon, als promotor ben ik je dank verschuldigd voor je 
stimulerende en kritische betrokkenheid. Je was elk overleg vol nieuwe ideeën en inzichten. 
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Jouw betrokkenheid bij de vrouwen en patiënten om wie het hier allemaal draait treft me 
zeer. Prof. dr JHJM van Krieken, beste Han, hartelijk dank voor je begeleiding als mijn 
promotor en voor je kritische, heldere en snelle commentaar waardoor de structuur in 
verschillende manuscripten verbeterd werd.  
 
De leden van de manuscriptcommissie, Prof. dr WJHM van den Bosch, Prof. dr RPRM Grol en 
dr FJ van Kemenade dank ik voor het kritisch lezen en beoordelen van het manuscript. 
 
Mijn co-auteurs wil ik bedanken voor al hun inspanningen: ten eerste Prof. dr ALM Verbeek, 
bedankt voor de bijdrage aan het tot stand komen van twee publicaties en het 
opbouwende commentaar. Ing. H de Leeuw, beste Henk, jij hebt een belangrijke bijdrage 
geleverd bij het tot stand komen van dit proefschrift door je kennis van het inlezen van ruwe 
PALGA-data en het presenteren hiervan in een leesbare en bewerkbare vorm in Access-
databases. Onze samenwerking om tot een werkbare regionale evaluatie module te komen 
was bijzonder prettig. Ook met betrekking tot spirituele zaken heb je me heel wat 
bijgebracht. Ik ben zelden iemand tegen gekomen die zo veelzijdig in het leven staat.   
Dr JMM Grefte, beste Annemarie, hartelijk dank voor de samenwerking op de vele gebieden, 
ook buiten dit proefschrift om. Je bent altijd beschikbaar voor uitwisseling van gedachten en 
ideeën en ik waardeer de samenwerking met jou en je gezelligheid zeer! Drs PJJM 
Klinkhamer, beste Paul, als projectleider heb je samen met Ton de Nethcon studie in de 
steigers gezet, een prestatie van groot formaat! Ook jou wil ik bedanken voor het vertrouwen 
en de stimulans die je de afgelopen jaren hebt gegeven. Ik heb veel geleerd van je 
uitgebreide kennis van het Nederlandse Bevolkingsonderzoek Baarmoederhalskanker en 
onze samenwerking, ook in je functie van RCP van de regio Zuid, heb ik bijzonder 
gewaardeerd! Dr M Arbyn, beste Marc, hartelijk dank voor de uitgebreide statistische en 
methodologische kennis en zeer bereidwillige ondersteuning. Je was altijd bereid tijd vrij te 
maken om kritisch naar de trial data te kijken. Jouw bijzonder actieve bijdrage heeft in 
belangrijke mate bijgedragen tot de goede uitvoering van de Nethcon trial. Amidu Raifu wil 
ik danken voor de uitvoering van de statistische analyses van de Nethcon trial.  
 
Mijn (ex)collega’s van het Screening Center Nijmegen wil ik bedanken voor de loyaliteit naar 
elkaar. Dankzij deze houding en heel erg veel humor hebben we ons door goede en slechte 
tijden geslagen. Anja Ligtenberg, bedankt voor jouw eenvoud (hoewel deze wel heel erg 
diep verborgen ligt) en humor. We hebben heel wat afgelachen samen! Vincent Cuijpers, 
jouw kijk op tal van zaken was vaak bijzonder, zo niet uniek. Je handel in de meest 
uiteenlopende zaken was ook vaak reden tot grote hilariteit met als hoogtepunt de 
‘verwerking’ van de beroemde ‘feest-slingers’! Ook aan onze reis naar Vancouver bewaar ik 
goede herinneringen. Maria Melgers, zonder jouw opgewektheid was het leven een stuk 
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saaier geweest. Ik heb er bewondering voor hoe je ons als chauffeuse van de ‘bus’ bij de 
grote en kleine ‘tourtochten’, ondanks de hevige pijn in onze buik en kaken, steeds weer 
geroutineerd thuis wist af te leveren. Marij Kosman, waar moet ik bij jou mee beginnen? De 
meest uiteenlopende onderwerpen, van astrologie, theologie en Paulus tot joy-sticks, van 
Cybele tot Madonna’s, van krachtvoorwerpjes (zoekt en gij zult vinden) tot March-amuletten, 
volgens mij hebben we geen enkel exotisch onderwerp onbesproken gelaten. Wat een geluk 
dat de wereld is bevolkt met ’s herens vreemdste kostgangers! Judith Vedder, dank dat je 
mijn paranimf wilt zijn en nog ‘een keer wilt stralen’. Ik hoop dat je met volle teugen van de 
gelegenheid zult genieten, je hebt er inderdaad (te) lang op moeten wachten. Gelukkig valt 
de ‘schade’ nog reuze mee! Ook met jou heb ik heel wat tranen met tuiten en kramp in de 
buik gelachen. Daarnaast heb je mij echter ook talloze keren ondersteund met je 
scherpzinnige inzichten. Je inspirerende en bruisende stroom van ideeën heeft al heel wat 
mooie samenwerking opgeleverd. Jammer dat je de ‘technische’ uitvoering van je meest 
briljante ideeën zelf nog niet helemaal onder de knie hebt en deze nog steeds moet 
‘uitbesteden’!  
 
Mijn (ex)kamergenoten wil ik bedanken voor het ‘thuiskomen’ op mijn werk. Tiny Heijnen, met 
jou heb ik de ‘Office’ mogen delen, de historische kamer waar de dunnelaag cytologie werd 
geboren. Jou wil ik bedanken omdat je altijd klaar stond én staat om te helpen en te 
luisteren. Jouw sociale vaardigheden zullen weinigen kunnen evenaren! Mijn huidige 
kamergenoot en goede collega Jeroen van der Laak: jouw intelligentie en scherpzinnigheid 
doen mij regelmatig duizelen. Ik ben er dus trots op dat ik een kamer met je mocht delen. 
Bedankt voor de samenwerking in de afgelopen jaren, voor je transparantie en de nuttige 
besprekingen van de actuele politieke barometer. Ik zie zonder enige twijfel in de toekomst 
een belangrijke eervolle vermelding of ‘pluim’ voor jou in het verschiet. Ik ben in ieder geval 
voor! 
 
Een speciaal woord van dank wil ik richten aan twee van mijn collega’s van het RCP-buro 
die ik nog niet heb genoemd: Rietje Salet, heel erg bedankt voor de samenwerking op de 
vele verschillende gebieden. Je kennis van cytologie is indrukwekkend en ik hoop nog lang 
samen te kunnen werken. Annelies Mulders, jij bent de ‘RCP-buro-rots’ in de branding. Jouw 
stabiliteit is onmisbaar bij het af en toe hectische overleg. Je gezelligheid en vrolijkheid maar 
zeker ook je secretariële steun is het fundament van het ‘Buro’!  
 
Mijn collega’s en ex-collega’s van het laboratorium cytologie en blok 1 (Shona, Manita, 
Gonnie, Noor, Marthe, Rietje H., Danny, Brenda, Marleen, Marc, Anne, Lia, Peter, Uta, Monika, 
Ineke, Sabine, Rina, Elly) wil ik allen bedanken voor de samenwerking en gezelligheid. Met 
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name de lunches in vroegere tijden vergden een strakke organisatie maar desondanks 
mondde dit bijna altijd uit in een geslaagd bijeenzijn!  
 
Marcel Beukeboom, bedankt voor de regelmaat waarmee jij de sleur van mijn 
werkzaamheden op ‘de 4e’ hebt onderbroken voor een gezellig praatje, muziekje en 
uitwisseling van belangrijke en minder belangrijke wederwaardigheden! 
 
Mijn lieve zus Annette, we hebben samen veel meegemaakt en ik ben er trots op dat je mijn 
paranimf wilt zijn! William, jij hebt laten zien dat je mijn zus meer dan waard bent! We moeten 
alleen nog eens samen onderzoeken hoe klaverjassen voor alle vier spelers leuk kan 
worden…. 
 
Een laatste, maar niet minste, woord van dank aan allen die mijn pad hebben gekruist en 
besloten deze samen een eindje op te lopen. Alle ‘verre’ vrienden en ‘nabije’ buren: 
bedankt voor jullie gezelligheid, feestjes, ‘gewone’ borrels, de soms diep-, maar meestal on-
zinnige gesprekken maar vooral het vertrouwen in elkaar. Zonder jullie zou het maar een 
saaie boel zijn geweest!  
 
Tenslotte kom ik dan aan bij de mensen die de belangrijkste hoofdstukken in mijn leven 
hebben geschreven en bij wie vergeleken de afronding van dit proefschrift niet meer is dan 
een aardige voetnoot. Mijn vader en mijn moeder: bedankt voor al jullie liefde. Wij hebben 
elkaar helaas veel te kort gekend maar ik hoop dat jullie toch onopgemerkt aanwezig zullen 
zijn. Lieve Rosan, bedankt voor al onze jaren samen! Jij ben degene die mij kent zoals verder 
niemand mij kent en dat feit op zich mag best een prestatie genoemd worden! ‘Ik kan het 
nog steeds niet geloven…’! Mijn kinderen, zonder jullie was mijn leven maar half zo 
waardevol! Dank voor wie jullie zijn en voor alles wat jullie mij, zonder het zelf te weten, 
hebben gegeven! Isabel, je bent mijn heerlijke, nuchtere no-nonsense dochter met je eigen 
ambities. Carmen, jouw gevoeligheid, enthousiasme en levendigheid verwarmen dagelijks 
mijn hart en Arthur, ik heb zelden een zo vriendelijke en aardige man meegemaakt zoals jij! 
Blijf wie je bent. Aan jullie draag ik dit proefschrift op…. 
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Curriculum Vitae 
 
Bert Siebers werd geboren op 23 januari 1963 als zoon van Henk Siebers en Jenny Hasselo te 
Almelo alwaar hij zijn jeugd doorbracht. In 1982 behaalde hij zijn VWO-diploma aan de 
Almelose Rijksscholengemeenschap Erasmus. De opleiding HLO werd in 1982 gestart in 
Hengelo en Enschede maar in 1983 verliet hij zijn Twentse vaderland en vervolgde zijn 
opleiding in Nijmegen. In 1986 werd het diploma HLO cyto-histologie behaald, waarna hij zijn 
dienstplicht vervulde bij de Terreinmeetkundige Dienst van de Veldartillerie van de Koninklijke 
Landmacht. In 1987 startte hij zijn carrière als cytologisch analist op het laboratorium voor 
cytopathologie van de afdeling Pathologie van het UMC St Radboud. In 1989 begon hij aan 
de Katholieke Universiteit Nijmegen met de doctoraalstudie Gezondheidswetenschappen, 
afstudeerrichting Toxicologie, begonnen waarvoor hij in 1992 afstudeerde. Van 1992 tot 1996 
was hij werkzaam bij het Screening Center Nijmegen en van 1996 tot heden keerde hij terug 
in de schoot van de afdeling Pathologie van het UMC St Radboud. Zijn functie ontwikkelde 
zich van cytologisch analist via ‘Coördinator BVO‘ naar ‘Beleidsmedewerker 
BVO/Coördinator informatisering en automatisering medisch inhoudelijke en administratieve 
zaken’ en uiteindelijk tot ‘Junior onderzoeker/Stafmedewerker Pathologie’ waarbij werd 
gewerkt aan diverse onderzoeksprojecten. In deze tijd werd de fundering voor dit  
proefschrift gelegd. 
 
Hij is sinds 1993 getrouwd met Rosan Kelly en samen hebben zij 3 kinderen gekregen: Isabel 
(1996), Carmen (1997) en Arthur (1999).  
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